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Abstract 
 
A novel model of mitochondrial bioenergetic regulation has been proposed whereby 
microtubules may directly influence the permeability of ADP into the mitochondria to stimulate 
the production of ATP. Specifically, tubulin, the structural unit of microtubules, physically 
inserts into the voltage gated dependent anion channel (VDAC) embedded in planar lipid 
membranes which was speculated to prevent ADP/ATP cycling. Such regulation could be 
profound given ADP/ATP cycling kinetics determine the rate of oxidative phosphorylation and 
reactive oxygen species (ROS) emission – key mitochondrial functions that are critical to muscle 
cells. VDAC is also believed to be central to the formation of the mitochondrial permeability 
transition pore (mPTP) which releases pro-apoptotic factors that trigger cell death. To date, a 
direct measure of a tubulin-VDAC interaction has yet to be demonstrated in cardiac and skeletal 
muscles, particularly in relation to mitochondrial bioenergetics. 
The primary objective of this thesis was to explore the tubulin-VDAC model of 
mitochondrial bioenergetic regulation in cardiac and skeletal muscles. This was achieved by 
employing pharmacological and genetic models of microtubule disorganization in an attempt to 
alter tubulin-VDAC interactions in relation to mitochondrial dysfunction. The results 
demonstrate that in-vitro paclitaxel treatment in extensor digitorum longus (EDL) muscle 
increases both a- and bII-tubulin-VDAC2 interaction while impairing some mitochondrial 
functions in partial support of the tubulin-VDAC model. The remaining data challenges this 
model. Specifically, cardiac muscle demonstrated a host of bioenergetic impairments in-vitro 
independent of a change in tubulin-VDAC interaction, while in-vivo treatment with paclitaxel, 
and vinblastine resulted in creatine independent mitochondrial impairments. Second, in-vivo 
paclitaxel administration surprisingly increased hind-limb torque and bII-tubulin-VDAC2 
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interaction in soleus while eliciting minor inhibitions of ADP-dependent bioenergetic functions. 
In contrast, in-vivo administration of vinblastine caused muscle weakness and mitochondrial 
dysfunction in both soleus and white gastrocnemius, but did not change tubulin-VDAC2 
interactions. Lastly, EDL muscles isolated from D2.mdx mouse model of disorganized 
microtubules and muscle weakness did not show altered tubulin-VDAC interactions despite the 
presence of mitochondrial dysfunctions. Overall, this thesis is the first to identify a direct a- and 
bII-tubulin interaction with VDAC2 in cardiac and skeletal muscle. While the data presented are 
not always in support of this model it raises new questions that challenges the regulation of this 
physical interaction in ADP diffusion regulation.  
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Introduction 
 
Muscle is a very plastic tissue, able to adapt to various physiological conditions. This 
plasticity is partially due to the proper functioning of the mitochondria. Commonly known as the 
power house of the cell, mitochondria are primarily responsible for maintaining cell survival 
through the production of adenosine triphosphate (ATP), influencing cellular redox state through 
reactive oxygen species generation, or triggering cell death through the initiation of apoptosis. 
These cellular fates are governed, in part, by the ability of adenosine diphosphate (ADP) to 
permeate the outer-mitochondrial membrane (OMM) allowing its phosphorylation into a high 
energy ATP molecule, the energy ‘currency’ of the cell. ADP drives membrane potential-
dependent oxidative phosphorylation which in turn determines the balance of reactive oxygen 
species (ROS) emission. ADP is able to cross the OMM through a channel protein embedded in 
the OMM known as the voltage dependent anion channel (VDAC). The process of ADP 
diffusion through the OMM was initially believed to be quite simple due to the abundance of 
pore proteins embedded in the OMM. A considerable amount of research has now highlighted 
the complexity of this process which may be regulated through various mechanisms.  
In 1995, a new model was proposed which suggested that a cytoskeletal component could 
regulate mitochondrial ADP permeability (136). Through transmission electron microscopy, it 
was later discovered that tubulin, the dimeric component of microtubules, existed in close 
association with the mitochondria (20, 127). Since then, researchers have uncovered that the C-
terminal tail (CTT) of tubulin physically inserts itself into VDAC, where phosphorylation, post-
translational modifications or changes to mitochondrial membrane lipid composition, can 
influence tubulin-VDAC binding (125, 145). To date, the majority of this work has been 
completed using reconstructed planar lipid membranes. While this methodology is a great 
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physiological tool aiding the molecular understanding of this interaction, it places these proteins 
in isolation and therefore not mimicking the interactions between tubulin and VDAC that may 
occur under in-vivo conditions. Other groups examined this model using approaches that either 
removed tubulin by treating samples with trypsin, a non-specific protease, resulting in increased 
ADP-stimulated respiration or added tubulin to isolated mitochondrial preparations decreasing 
respiration, both highlighting the importance of tubulin regulation ADP permeability (40, 127). 
This introduces some limitations the understanding of the tubulin-VDAC model given the degree 
of mitochondrial-microtubule interactions are not preserved in these approaches nor was tubulin 
targeted specifically with general proteases.  
To mitigate these limitations, the work completed in this thesis utilized in-vitro and in-
vivo methodologies that better retained microtubule networks and mitochondrial morphology. In 
addition, pharmaceutical and genetic models of altered microtubule architectures were employed 
in an attempt to further reveal the contribution of the tubulin-VDAC model to mitochondrial 
bioenergetics in muscle. The pharmaceutical approach of applying microtubule stabilizers 
(paclitaxel) and destabilizers (vinblastine) to single fibres in-vitro or administered in-vivo will 
promote polymerization or depolymerisation of microtubules respectively. Interestingly, these 
microtubule targeted compounds are commonly used chemotherapies, which creates an 
intriguing opportunity to apply the tubulin-VDAC model of bioenergetic regulation to 
understand how microtubule-targeting chemotherapy may disrupt normal muscle metabolism. 
Concomitantly, this work will aid in determining the degree to which microtubule organization 
fundamentally regulates ADP-dependent mitochondrial bioenergetics in muscle.  Considerations 
of muscle type and the effects of in-vitro vs in-vivo administration were considered in the 
experimental design (Chapters 4-7). 
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To further examine the contribution of the tubulin-VDAC model to mitochondrial 
bioenergetic regulation in muscle, this thesis utilized a model that is known to have a 
disorganized microtubule architecture. Duchenne muscular dystrophy is an X-linked disease 
characterized by the lack of dystrophin in the sarcolemma (5, 18). Dystrophin is required to 
anchor the intracellular and extracellular structural components of the cell, which includes 
microtubules (111). The disorganization of microtubules in the mouse (mdx) model of Duchenne 
muscular dystrophy is speculated to contribute to the intracellular impairments seen with this 
disease (111). Our lab has previously shown sever mitochondrial and whole muscle dysfunction 
in cardiac and skeletal muscles from a more severe mouse model of Duchenne muscular 
dystrophy (D2.mdx) (51, 52). What remains unknown is the contribution of an altered tubulin-
VDAC interaction to these impairments in ADP-dependent mitochondrial bioenergetics.  
These pharmacological and genetic models of altered microtubule organization represent 
new approaches to study the fundamental role of the tubulin-VDAC model and its contribution to 
mitochondrial bioenergetics in muscle, and may represent novel mechanisms to explain how 
disrupted muscle metabolism occurs in response to microtubule-targeting chemotherapy and in 
Duchenne muscular dystrophy.  The main aims of this thesis are to 1) determine whether a-
tubulin and bII-tubulin interact with VDAC2 in cardiac and skeletal muscles in rodent models 2) 
determine whether alterations in microtubule organization changes the amount of tubulin-VDAC 
interactions in-vivo and in-vitro, 3) determine whether mitochondrial bioenergetic changes are 
related to tubulin-VDAC model and lastly 4) relate mitochondrial bioenergetic changes to whole 
muscle functional capacity.  
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2. Literature Review 
 
2.1 Overview of mitochondrial bioenergetics 
 
2.1.1 Oxidative phosphorylation  
 
Originally believed to be rod-shaped structures, mitochondria are composed of an outer 
mitochondrial membrane (OMM) containing specialized proteins and channels that regulate the 
transport of metabolites into the mitochondria and an inner mitochondrial membrane (IMM) 
where adenosine triphosphate (ATP) synthesis occurs. Between the OMM and the IMM is the 
inter mitochondrial membrane space (IMS) and in the center of the mitochondria is the matrix 
where metabolites are further reduced into reducing equivalents used as substrates for ATP 
synthesis. This was first proposed as the chemiosmotic theory, written by Dr. Peter Mitchell who 
elucidated the process of oxidative phosphorylation (87). Up until that point, researchers had 
already determined ATP to be the energy currency of the cell but the mechanism was unknown. 
The production of ATP is completed through a series of redox reactions through the 
mitochondrial respiratory chain (OXPHOS) proteins embedded in the IMM (97) (Figure 2-1). 
The mitochondrial respiratory chain is composed of 5 complexes: complex I (NADH-UQ 
oxidoreductase), complex II (succinate dehydrogenase), complex III (UQH2-cyt c 
oxidoreductase), complex IV (cytochrome c oxidase) and complex V (ATP synthase). The foods 
we consume (carbohydrates/sugars or fats) are taken up by the cell and broken down through 
glycolysis and b-oxidation to produce the high energy reducing equivalents NADH and FADH2. 
These reducing equivalent then interact with complex I (NADH) or complex II (FADH2) 
pumping protons through into the inter membrane space while simultaneously donating electrons 
that are passed through complexes I-IV to make H2O at complex IV. The donation of electrons 
across the IMM creates a negative charge in the matrix of the mitochondria while the process of 
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pumping protons through to the inter mitochondrial membrane space creates the proton motive 
force. Protons that accumulate in the IMS create potential energy that is utilized by the motor of 
complex V allowing the phosphorylation of an ADP molecule to produce ATP.  
     ADP + Pi -----> ATP 
 The transfer of electrons and proton motive force are predominately maintained by the 
concentration of adenosine diphosphate (ADP). ADP and Pi are the primary determinants of 
ATP synthase permeability to protons such that their kinetic concentrations dictate oxidative 
phosphorylation where a linear relationship exists between the amount of ADP provided and 
ATP produced (75). In a state of reduced [ADP], the proton motive force or membrane potential 
is increased slowing down the rate of ATP production and in turn, slows down the rate of 
electron transport. This can result in electrons slipping off complexes I and III, prematurely 
interacting with oxygen to produce superoxide (122). Also known as a reactive oxygen anion 
(O2-), superoxide is highly reactive, capable of damaging proteins and cell membranes, 
ultimately leading to cell death. Understanding how ADP/ATP is transported through the 
mitochondria is crucial to understand how various metabolic states promote cell death or 
survival. The voltage dependent anion channel (VDAC) embedded in the OMM and adenine 
nucleotide translocase (ANT) embedded in the IMM are the two proteins responsible for the 
diffusion of ADP/ATP through the mitochondria and will be further discussed below (Section 
2.2) 
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Figure 2-1. Schematic depiction of the mitochondrial electron transport chain. Embedded in 
the inner mitochondrial membrane (IMM) are complex I (NADH-UQ oxidoreductase), complex 
II (succinate dehydrogenase), Ubiquinone (Q), complex III (UQH2-cyt c oxidoreductase), and 
complex IV (cytochrome c oxidase) where protons (H+) are pumped through to the 
intermembrane space (IMS) and electrons (e-) travel through the complexes. At complex V (ATP 
synthase), protons are pumped back into the mitochondrial matrix to make ATP.  
  
NADH
FADH2
H+ H+
H+
Cyt c
H2O½O2 + 2H+
IMS
Matrix
ADP ATP
NAD
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Complex I Complex II Complex III Complex IV Complex V
Q
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2.1.2 Mitochondrial reactive oxygen species production and emission 
 
 A natural by-product of oxidative phosphorylation is the generation of reactive oxygen 
species (ROS) in the form of superoxide (O2-), a membrane impermeable, unstable, highly 
reactive free radical capable of reducing proteins, rendering them dysfunctional (1). A major 
source of free radical production occurs in the mitochondria where there are 11 reported sites of 
O2- emission (172). In the absence of ADP, reducing equivalents continue to supply complexes 
with protons and electrons but do not complete oxidative phosphorylation. This results in an 
accumulation of protons in the IMS, decreasing the proton motive force, increasing the chances 
of an electron slip which in turn produces O2-. Fortunately, mitochondria are equipped with 
endogenous superoxide dismutases to quickly scavenge O2- free radicals, such as manganese 
superoxide dismutase (MnSOD), copper-zinc superoxide dismutase (CuZnSOD), both located 
within the mitochondrial matrix. These dismutases function to donate protons to O2- to produce 
hydrogen peroxide (H2O2). While H2O2 is a type of ROS, it is a stable non-radical oxidant, able 
to permeate through lipid membranes and is an integral signaling molecule responsible for 
maintaining intracellular redox balance (30, 59). This is of particular interest as most 
experimental methods of measuring O2- production can be done indirectly through the 
measurement of H2O2 emission, providing an overall redox status of the cell. When the amount 
of ROS produced exceeds the antioxidant capacity, the cell is considered to be in a state of 
oxidative stress. This can occur under pathological conditions where the rate ROS emission no 
longer functions for signaling purposes but can now damage intracellular proteins and organelle 
membranes leading to cell death. This is coupled with an decreased capacity for endogenous 
antioxidant systems (catalase, glutathione, thioredoxin) to buffer the increased ROS generation 
(59).  
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2.1.3 Energy transfer through cytosolic and mitochondrial creatine kinase 
 
Cells in high energy demanding tissue such as the liver, brain, heart and skeletal muscles 
do not contain a reserve of ATP waiting on demand to be utilized. If depleted, this would result 
in a massive accumulation of metabolites and protons that would negatively impact the 
metabolic equilibrium. In order to provide and maintain an adequate energy balance, 
phosphagens are used to buffer intracellular energy. More specifically, creatine (Cr), and 
phosphocreatine (PCr) work with creatine kinase (CK) acting as an intracellular energy buffering 
system (Figure 1-3). This “system” is strategically placed in energy consuming locations within 
the cell to efficiently transport energy to its utilization sites and buffers the resulting metabolites 
to produce energy as needed. This is known as the creatine kinase system (165). There are 
various CK isoforms expressed in different quantities and locations depending on the tissue type 
and needs (166). In cardiac and skeletal muscle, the two predominate isoforms are cytosolic CK 
(ctCK) and mitochondrial CK (mtCK). mtCK is an octameric protein found embedded in 
between the IMM and OMM, attached to cardiolipin and indirectly attached to ANT on the IMM 
(72, 165) spanning the IMS, interacting with VDAC on the OMM (72, 140, 165). Together they 
catalyze the transfer of phosphates in the following reaction: 
              MgADP + PCr + H+ ßà MgATP + Cr                         (165) 
This is known as the more efficient method to transport energy through the mitochondrial 
membranes. Alternatively, ADP can passively diffuse through both VDAC and ANT to stimulate 
ATP production in a more inefficient manner. In the absence or inhibition of CK, ADP diffusion 
still occurs just at a significantly lower rate, reducing functional capacity which is exemplified 
by a recorded reduce sea urchin sperm flagellar motility further outlined below (155) (Figure 2-
3).  
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Figure 2-2. Creatine independent and dependent pathways of ADP/ATP transport through 
the mitochondria. Creatine independent pathway: Production of ATP at Complex V can directly 
diffuse through ANT and VDAC to the cytosol where ATP is utilized by various ATPases, 
generating ADP that can then diffuse back through VDAC and ANT providing ADP to complex 
V to maintain the production of ATP. Creatine dependent pathway: ATP produced at complex V 
is shuttled through ANT to the IMS where mtCK catalyzes the transfer of ATP’s high energy 
phosphate to a Cr molecule creating PCr). PCr is then shuttled out through VDAC to ctCK where 
the high energy phosphate is transferred to an ADP molecule making ATP which can then be 
utilized by ATPases. The resulting Cr is shuttled back through VDAC to mtCK where the high 
energy phosphate transfer cycle occurs again (51, 52, 141). 
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2.1.4 Energy transfer through the mitochondrial interactosome 
 
 There is evidence that mitochondrial respiratory control, in cardiac cells, is regulated by 
the mitochondrial interactosome consisting of; ctCK located in the cytosol, outside of the 
mitochondria, VDAC embedded in the OMM with tubulin on the cytosolic side, mtCK anchored 
in the IMS, ANT embedded in the IMM and the proteins of the electron transport chain 
(OXPHOS), also embedded in the IMM (153). These mitochondrial interactosomes are believed 
to be situated in specific locations throughout the cell were energy is utilized forming 
intracellular energy units (ICEU) (134). While the majority of the work exploring ICEU’s were 
completed in cardiac tissue, the same principles can be applied to skeletal muscles as 
mitochondria, mtCK and tubulin all appear to co-localize with muscle contractile units in a fiber 
type and tubulin isoform dependent manner (161). 
 The mitochondrial interactosome describes a model whereby reducing equivalents 
provide protons to the OXPHOS proteins generating free energy to drive motor of complex V, 
producing ATP which is then shuttled out into the IMS through ANT. The high energy 
phosphate on ATP is then transferred to a Cr molecule by CK, allowing the resulting ADP to 
cycle back through ANT to be re-phosphorylated in the matrix. The resulting PCr molecule is 
then shuttled out through VDAC on the OMM, interacting with ctCK catalyzing the transfer of 
the high energy phosphate from PCr onto an ADP yielding an ATP molecule that can then be 
used to provide energy to neighbouring ATPases. ADP and Cr is then quickly shuttled back into 
the IMS through VDAC where the entire cycle begins again (Figure 2-3).  
As mentioned above this method of phosphate shuttling has been shown to be a more 
efficient way of transferring ATP through the double membranes of the mitochondria when 
compared to the diffusion of ATP and ADP alone. For this system to work effectively, 
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mitochondrial membrane potential needs to be maintained as prolonged VDAC closure will 
prevent ADP permeability, increasing membrane potential, which in turn increases the potential 
for ROS emission which can ultimately lead to mitochondrial dysfunction. Alternatively, if 
VDAC is maintained in an open confirmation, membrane potential will eventually dissipate also 
leading to mitochondrial dysfunction. Tubulin has been shown to be involved in the maintenance 
of membrane potential and therefore ADP permeability through the reversible closure of VDAC 
but the complete elucidation of how this occurs is currently unknown. 
2.2 Proteins involved in ADP/ATP diffusion 
 
2.2.1 Adenine Nucleotide Translocase (ANT) 
 
 ANT is a specialized protein embedded in the IMM responsible for the export of newly 
synthesized ATP and import of ADP from the cytoplasm to complex V. The kinetics of 
ATP/ADP cycling between mitochondria and cytoplasm are therefore determined, in part, by 
ANT permeability to these nucleotides on the inner mitochondrial membrane.  In addition to its 
role in energy production, ANT is believed to contribute to mitochondrial proton leak or 
uncoupling where ANT1 knockout mice display a significant reduction in proton conductance in 
addition to a significant decrease in oxygen consumption (17). Although the mechanism of 
ANT’s contribution to uncoupling remains unknown, a host of literature presents its importance 
for energy exchange. ANT is one of the most abundant proteins in mitochondria. Inhibition of 
ANT with carboxyatractyloside inhibits ATP transport by binding to the channel and blocking 
ATP/ADP diffusion in mitochondria isolated from cardiac tissue, outlining the importance of 
ANT in ADP supply (91).  
There are 4 ANT isoforms all expressed in most tissue types (with the exception of 
ANT4) with a specific tissue distribution. ANT1 is most abundant in heart and skeletal muscles 
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(77), ANT2 is expressed in most tissue types with a potent expression in cardiac tissue and lower 
expression in skeletal muscle, ANT3 is ubiquitously expressed and ANT4 is exclusively 
expressed in testis (17, 79). ANT1 is expressed in both cardiac and skeletal muscle tissues where 
knockout studies reveal mitochondrial myopathy, highlighting its importance for proper 
mitochondrial function. As such, the remainder of this thesis will focus on the ANT1 isoform. In 
addition to its role in survival, ANT is believed to be involved in the initiation of cell death 
pathways which will be discussed further below.  
2.2.2 Voltage Gated Dependent Anion Channel (VDAC) 
 
The primary role of VDAC is to mobilize ADP from the cytosol into the IMM while 
transporting ATP from the IMM to the cytosol. There are three VDAC isoforms (VDAC1-3) 
where VDAC1 is expressed on both sarcolemma and OMM and VDAC2 and 3 are 
predominately found on the OMM. VDAC1 and 2 have a distinct distribution pattern on the 
OMM, where they are often found in groups or clusters while VDAC3 is uniformly distributed 
throughout the OMM. The VDAC proteins have a 75% sequence similarity (25, 95), structurally 
organized in barrels of 19 amphipathic b-strands and a N-terminal moiety, containing an a-helix 
segment (85), where protein-protein interactions are believed to occur (95). To further determine 
specific roles for the VDAC isoforms, knockout studies were completed. VDAC1 knockout 
induces changes to mitochondrial enzymes causing modifications to mitochondrial kinetics, 
compacted the mitochondrial cristae and enlarged the mitochondria (85, 95). VDAC3 knockout 
did not appear to cause dramatic impairments in mitochondrial function but it did increase male 
infertility, suggesting its involvement in reproductive success (85, 95). Interestingly, VDAC2 
knockout resulted in embryonic death, highlighting its importance for survival (25). To an extent, 
the VDAC proteins appear to play redundant roles as VDAC1 knockout resulted with 
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dysfunctional mitochondria, unable to clear dysfunctional segments of the mitochondrial 
reticulum, while complete ablation of VDAC2 diminishes any redundancies with VDAC1 and 3, 
inhibiting the production of energy production and organelle survival (85). In addition, VDAC2 
appears to have unique features when compared to the other two isoforms including an extension 
of 11 amino acids – believed to be on the a-helical portion of the N-terminus protruding outside 
of the pore – and it also has 9 cysteines, making it more susceptible to SH-oxidation when 
compared to the other VDAC isoforms. These factors have highlighted the uniqueness and 
importance of VDAC2 and is the VDAC isoform that will be focused for the remainder of this 
thesis.  
One of the first elucidations of VDAC function was through the incorporation of VDAC 
into reconstructed planar lipid membranes where VDAC is isolated from mitochondria and 
added to synthetic membranes (139). It has been determined that – as the name suggests – the 
open or closed state of VDAC is dependent on the OMM membrane potential. Through these 
methodologies, researchers have been able to apply specific voltages to the OMM to manipulate 
the state of VDAC closure. At negative membrane potentials VDAC is mostly opened with a 
pore diameter of ~2-4nm allowing the transport of large molecules (~4-6kDa) through the OMM 
(85, 95, 123, 139). At positive membrane potentials, the VDAC pore is in a closed confirmation 
reducing the diameter to ~1.7-1.8nm, approximately half its size, no longer allowing the 
transport of most metabolites and proteins including nucleotides (123). The opened and closed 
state of VDAC was believed to be the only mechanism regulating ATP diffusion through VDAC, 
but even in the closed state, the channel can still be ~1.7nm opened which, in theory should 
allow metabolites and ATP through. It is not only the structural change in diameter that prevents 
ATP permeability, but the change in membrane potential that makes VDAC ion selective. As the 
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charge switches from negative to positive it creates an electrostatic barrier where in addition to a 
change in pore diameter, the channel becomes cation/anion selective (99, 123). At negative 
OMM potentials VDAC becomes anion selective and at positive OMM potentials VDAC 
becomes cation selective (85, 95, 123). In addition to the change in membrane potential and pore 
diameter, interactions with desmin, vimentin, tubulin and plectin appear to modulate 
mitochondrial function (132). Specifically, the cytoskeleton protein tubulin appears make a 
significant contribution to ADP permeability through VDAC, regulating bioenergetic processes. 
2.2.3 Microtubules 
 
Microtubules are hollow rod-like structures that span the length and width of cells (93, 
100). They are composed of a- and b- tubulin dimers originating at microtubule organizing 
centers (MTOC) (100, 114). Through the hydrolysis of a GTP molecule, each tubulin dimer is 
bound to a successive one forming long protofilaments. The attachment of 3-4 protofilaments 
make up a mature microtubule. Microtubules are primarily known for their role in mitotic 
spindle formation during cell division and also known to provide an intracellular route for 
protein movement as well as providing structure and organization for the other intracellular 
organelle (46, 54). In striated muscle, microtubules originate from perinuclear golgi complexes 
growing from the plus end of the microtubule along the length of the fiber with the assistance 
from microtubule associated proteins (MAP) and end binding (EB) family proteins (93, 100). 
Unfortunately, in order to fully elucidate the role of microtubules, it would require 
methodologies capable of observing the spontaneous dynamic stability that microtubules are 
constantly under. Currently, fluorescently labeled tubulin molecules are below the level of 
resolution of most microscopes, making it particularly difficult to capture true in-vivo functions 
(163). 
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In skeletal muscle, microtubules contribute to providing the cell with structure, in 
addition to the thick and thin filaments that comprise the cytoskeleton. This structure is essential 
to maintain proper intracellular function through organelle placement and protein trafficking. 
Specifically, in skeletal muscle, microtubules are crucial to the maintenance of glucose 
metabolism as it provides a route for GLUT4 vesical translocation to the sarcolemma to allow 
for glucose diffusion into the cell (118). The dynamic stability of microtubules have also been 
speculated to contribute to force production where a shift towards stability or de-stability alters 
the ability of a cardiomyocytes to produce force (121). Although microtubules have been 
historically known only for their role in cell division, recent literature has highlighted its 
importance in overall metabolism. 
Within the a- and b- class of tubulin isoforms, there are 8 different isotypes of a-tubulin 
and 10 different isotypes of b-tubulin each able of undergoing different post-translational 
modifications (PTM) including; acetylation, palmitoylation, phosphorylation, polyglutamylation, 
detyrosination, and polyglycylation, effectively changing each respective tubulin isoform type 
and function (46, 84, 93). In addition, g-, h-, x-, e-, and d-tubulin isoforms also exist with a 
complete set of isotypes with their functions currently unknown (84). To further complicate the 
current understanding, tubulin isoform and isotype expression is varied amongst different tissue 
types and organisms presenting further difficulties in understanding their function (21, 84).  
In skeletal muscle, in a more oxidative tissue such as the soleus, a-tubulin organization is 
composed of dense bundles that interlock around the nucleus forming long lines between nuclei 
while a more glycolytic tissue such as tensor fascial latae (TFL) display more individual 
microtubules not as densely organized as the soleus (16, 113). This fiber type specific 
organization of tubulin does not appear to be plastic as fiber types can be. Denervation of the 
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soleus and EDL muscles in Wistar rats results in a similar orthogonal microtubule organization 
in both tissues (113, 114) but when electrically stimulated in a manner to induce a change in 
fiber type, the EDL is able to mimic the dense microtubule organization seen in soleus but the 
soleus is unable to mirror the EDL’s organization (114). This suggests that microtubule 
organization in each muscle fiber type may be specific to support the physiological demands of 
that tissue. Understanding microtubule organization is crucial in understanding microtubule and 
whole cell function as disruptions in microtubule dynamics has been shown to lead to cardiac 
and skeletal muscle dysfunction (78, 142). Microtubules are an integral component of all cells, 
interacting with cell membranes, golgi complex, endoplasmic reticulum and mitochondria (16, 
20, 100, 111, 113, 114) where destabilization has been shown to reduce mitochondrial distance 
traveled and speed (54). 
2.3 Tubulin regulation of VDAC permeability 
 
Saetersdal and colleagues in 1990 were the first to report a close association of b-tubulin 
and mitochondria in isolated cardiomyocytes (131). Immunohistochemistry images reviled a 
dense microtubule network spread throughout the entire cell when it was originally believed that 
microtubules were only localized to the perinuclear region. Further investigation with the use of 
electron microscopy and immunogold labelling determined that microtubule organization 
appeared to be highly co-localized with mitochondria. In 1995, Saks and colleagues speculated 
the involvement of a cytoskeletal protein during oxidative phosphorylation (136). The 
comparison between isolated mitochondria to permeabilized muscle fiber bundles (PmFB) 
yielded significantly reduced oxygen consumption rates (136, 162). In isolated mitochondrial 
preparations, the tissue is homogenized and subjected to differential centrifugation, successfully 
disturbing all intracellular networks and potential protein interactions to isolate the mitochondrial 
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organelles. Comparatively, utilizing a PmFB preparation requires significantly less tissue, while 
also retaining most intracellular compartments – including the cytoskeleton – allowing for a 
more accurate depiction of what in-vivo conditions may be like (162). With the use of PmFB, 
researchers were able to determine that a cytoskeletal component, specifically tubulin, was able 
to limit the ability of ADP to diffuse into the mitochondria to stimulate oxygen consumption 
(127, 131, 136) (Figure 2-2).  
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Figure 2-3. Schematic depiction of how the tubulin-VDAC interaction. It is hypothesized that 
when VDAC is in an opened conformation, ADP and ATP diffusion is permitted through the 
outer mitochondrial membrane (OMM) where ADP/ATP exchange can then occur through ANT 
embedded on the inner mitochondrial membrane (IMM). The closed confirmation of VDAC has 
been suggested to prevent any diffusion of ADP/ATP through the OMM. Schematic adapted 
from Rostovtseva et al., 2018 (127). 
 
2.3.1 Reconstructed planar lipid membranes 
 
 The current model presents tubulin as a major regulator of ADP permeability through 
VDAC. Unfortunately, the exact mechanism of how this occurs in-vivo is currently unknown. 
Research completed to date has utilized reconstructed planar lipid membrane methodologies 
revealing the majority of what is known about the tubulin-VDAC interaction. These works show 
that it is solely the C-terminal tail of tubulin that is physically inserted into VDAC blocking its 
permeability (145). In addition, post-translational modifications (PTM), specifically 
detyrosination, increases the amount of tubulin-VDAC binding in a planar lipid membrane 
model (145). Phosphorylation of VDAC (146) and the manipulation of the OMM phospholipid 
content has also shown to alter this interaction (125). While this method of assessing tubulin-
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VDAC interactions has proven to be extremely valuable in elucidating some mechanistic 
approaches of understanding this interaction, it is predominately completed in an isolated system. 
In these studies, VDAC and tubulin proteins are isolated from different tissues, where the 
isoform and isotypes are rarely specified (Table 2-1). In addition, it is possible that in the 
presence of other tubulin dimers, and protofilaments, microtubules may form which may alter 
the affinity of tubulin-VDAC binding.  
2.3.2 In-vitro tissue analysis of tubulin and VDAC interactions 
 
Studies in various human cancer cell lines have determined that tubulin is in an integral 
component of mitochondria. Electron microscopy images of mitochondria reveal traces of both 
a- and b-tubulin around the mitochondria (20). In addition, immunoprecipitation experiments 
isolating VDAC from the mitochondrial fraction yielded positive results when probed for tubulin 
(20). Analysis in striated muscle revealed that the addition of tubulin to isolated mitochondria 
decreases oxygen consumption while the removal of bII-tubulin increases oxygen consumption, 
strongly suggesting that tubulin is able to restrict the permeability of ADP by blocking VDAC 
(40, 127). The blocking action of tubulin on VDAC also corroborated with changes in membrane 
potential where at negative potentials the VDAC pore was open and with the addition of tubulin, 
membrane potentials became positive, effectively closing VDAC (127). This interaction was 
further supported by immunohistochemical images overlaying bII-tubulin with VDAC in 
cardiac, soleus and white gastrocnemius (WG) muscles harvested from rodents, displaying a 
close proximity of bII-tubulin with VDAC (161). These works strongly suggest that tubulin does 
in fact interact with VDAC but a direct protein-protein interaction had yet to be measured. In 
2018, Rostovsteva and colleages were the first to identify a direct protein-protein interaction 
between bIII-tubulin with VDAC in a human neuroblastoma cell line (126) concluding that 
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perhaps the abundance of a tubulin isotype expressed in each respective tissue mediates the 
tubulin-VDAC interaction. To date, the direct interaction between tubulin and VDAC in cardiac 
and skeletal muscle has not been explored. 
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Table 2-1. Current literature measuring tubulin-VDAC interactions.  
 
 
2.4 Mitochondrial-mediated apoptosis 
 
Mitochondria are known as the “powerhouse of the cell” functioning to provide energy 
and promote survival. Concomitantly, mitochondria are also a major regulator of cell death 
where pathological conditions (cardiovascular disease, cancer, muscular dystrophies) present 
hostile intracellular environments where the cell’s susceptibility to death is increased through 
swelling, dysfunction and permeabilization of mitochondria. This leads to the release of pro-
apoptotic factors, initiating the cascade of mitochondrial derived cell death. A general overview 
of apoptosis is described below to provide further insight in understanding how VDAC may be 
involved in the initiation of apoptosis. 
2.4.1 Apoptosis 
 
 Apoptosis, necrosis, mitotic catastrophe and autophagy are the main mechanism that lead 
to cell death (73). Focusing on apoptosis, it is defined by morphological changes including: cell 
Author Isoform/Isotype Tissue Methodology 
Gonzales-Granillo et 
al., 2012 
bII-tubulin Cardiomyocytes Trypsin 
Carre et al., 2001 a- and b-tubulin SK-N-SH, IMR-34 
and A549 cells 
Transmission Electron 
microscopy, co-
immunoprecipitation 
Maldonado et al., 2010 Tubulin HepG2, A549 and 
UM-SCC-1 cells 
Confocal microscopy – 
immunohistochemistry 
Sheldon et al., 2015 PTM of a- and 
b-tubulin 
--- Reconstructed planar 
lipid membrane 
Rostovteva et al., 2008 CTT --- Reconstructed planar 
lipid membrane 
Gurnev et al., 2011 Tubulin --- Reconstructed planar 
lipid membrane 
Varikmaa et al., 2014 bII-tubulin Soleus and white 
gastrocnemius 
Confocal microscopy- 
co-localization 
Rostovteva et al., 2018 bIII-tubulin SK-N-SH Proximity ligation assay 
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shrinkage, chromatin condensation, nuclear fragmentation and blebbing while functionally 
preventing ATP production, increasing ROS production and dissipating the mitochondrial 
membrane potential. There are two pathways in which apoptosis is stimulated 1) extrinsic 
pathway; mediated through the binding of a ligand to a cell membrane receptor which then 
stimulates a cascade of apoptotic events and 2) intrinsic pathway; mediated through increased 
mitochondrial permeability leading to the subsequent release of pro-apoptotic factors. Both 
pathways result in activating caspases which then cleave proteins causing the morphological and 
functional changes that occur during apoptosis. As VDAC is the most abundant protein on the 
OMM, responsible for the regulation of mitochondrial permeability, it is also believed to play a 
role in mediating mitochondrial induced cell death. 
2.4.2 Mitochondrial permeability transition pore formation 
 
 Another mechanism of increased mitochondrial permeability is through the formation of 
the mitochondrial permeability transition pore (mPTP). Under pro-apoptotic stimulation this 
multi-complex protein channel forms a pore allowing water and solutes ~1.5kDa through, 
swelling the mitochondria and dissipating membrane potential (73, 128). Formation of the 
channel is stimulated by an increased calcium influx, pro-apoptotic protein binding (BcL-2 
family) and some chemotherapies (73). Through the generation of cyclophilin D null mice, 
Baines and colleagues (2005) determined that cyclophilin D is a key regulator of the mPTP 
formation as null mice were resistant to in-vivo and in-vitro induction of mPTP (10, 27). The 
pore is speculated to be composed of VDAC, ANT, mtCK, HK and/or Bax (9, 73, 128). The 
exact components of the pore are highly debateable as under different experimental condition 
and in different tissues the presence of each protein appears to be optional (9, 73).  
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 mPTP formation can be induced through elevated Ca2+ and ROS emission. Under 
conditions of elevated intracellular stress, cyclopilin D localizes from the matrix of the 
mitochondria to the IMM where it is believed to bind to ANT. Elevated intracellular calcium is 
then taken up into the mitochondria where it is speculated to bind to ANT – cycloplinin and 
induce a conformational change resulting in an IMM pore formation (10, 45). This then initiates 
the unrestricted flow of molecules through the mitochondria, such as the release of cytochrome c 
oxidase and other pro-apoptotic factors, initiating apoptosis. mPTP induction is also believed to 
be through elevated ROS production. Multiple measures of isolated rat cardiomyocytes subjected 
to ischemia-reperfusion injury to induce mPTP found elevated ROS production prior to changes 
in cytosolic calcium release and up until a loss in cell viability suggesting that ROS production 
precedes and may play more of a role in the induction mPTP (68).  
2.4.3 The role of VDAC in mPTP formation 
 
Under major speculation is VDAC as an integral component of the mPTP (9). VDAC 
was first speculated as an essential component of mPTP as isolation of cyclophilin D retained an 
ANT and VDAC interaction (31). In addition, reconstructed proteoliposomes embedded with 
VDAC, ANT and cyclophilin D demonstrated the characteristic mPTP opening and release of 
fluorescein with calcium stimulation (31). Closer observations presented doubt as the closed 
state of VDAC still appeared to be permeable to calcium (151). In addition, antibody and 
pharmacological inhibition of VDAC and mPTP has been questioned (9, 128). While there is a 
significant amount of evidence questioning the involvement of VDAC in mPTP formation, there 
has yet to be a physiological examination of VDAC knockout. Studies exploring knockout or 
knockdown of VDAC1 or 3 results with the other isoforms compensating for the subsequent 
knockout except VDAC2 where genetic manipulation does not sustain life (25, 85). To by-pass 
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this problem, Baines and colleagues (2007) isolated fibroblasts from VDAC1/3 knockout mice 
and then went on to knockdown VDAC2 to gain further insight of VDAC contribution to mPTP 
(11). Here they still discovered the release of cytochrome c oxidase, occurring quicker than in 
the presence of VDAC suggesting the formation of mPTP even in the absence of all VDAC 
isoforms. These authors suggest that the presence of VDAC may limit the induction of apoptosis 
through mPTP formation. While this work is very thorough, it does not discount that alternative 
mechanisms may be occurring in-vivo and in different tissues.  
2.4.4 Bcl-2 family of proteins and hexokinase involvement in VDAC permeability 
 
 The Bcl-2 family of proteins contain members involved in the prevention of apoptosis 
(Bcl-2 and Bcl-XL) and initiation of apoptosis (Bax, Bak, Bid and Bad) with the latter speculated 
to promote apoptosis through an interaction with VDAC (73, 128, 158). Specifically, planar lipid 
bilayer membranes embedded with VDAC displayed significantly increased VDAC activity with 
the addition of Bax/Bak, creating a channel 4-10fold larger than the open conformation of 
VDAC alone (147). A full delineation of Bax/Bak function is still up for debate as some labs 
have shown Bax/Bak form a pore independently on the OMM or others have shown that the 
mere swelling of the mitochondria is enough to cause breaks in the OMM allowing the release of 
cytochrome c oxidase and other pro-apoptotic factors, allowing the initiation of apoptosis (158). 
A limitation in this current model is the lack of specificity of VDAC isoforms used in 
experiments. It is generally believed that VDAC1 is more involved in the apoptotic activities of 
the cell (85, 95) but isoform specification is rarely defined (128, 147, 158). 
 Hexokinase is a rate limiting enzyme responsible for the commitment of glucose to 
glycolysis or the pentose pathway. Alternatively, research has shown that hexokinase is also 
involved in the suppression of apoptosis through an interaction with VDAC on the OMM. 
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Overexpression of hexokinase II inhibited cytochrome c oxidase release through competitive 
binding with Bax in HeLa cells (103). In addition, it has been speculated that the presence Bax is 
not necessary to prevent apoptosis (80). Lastly, others have also deduced that the VDAC closure 
caused by hexokinase binding increased mitochondrial swelling and membrane rupture, creating 
holes in the membrane allowing the release of cytochrome c oxidase to initiate apoptosis (73, 
128, 158). Similarly to the BcL-2 family, a complete consensus has not been made regarding the 
role of hexokinase – considering both hexokinase isoforms – and VDAC permeability. It is 
interesting to note that both hexokinase and VDAC play a major role in cell survival by 
providing the cell with fuel for ATP production and energy transport respectively, while also 
contributing to the mediation of cell death through cytochrome c oxidase release.  
2.5 Diseases and conditions of disorganized microtubules 
 
2.5.1 Overview of cancer and chemotherapy  
 
The world health organization has reported 9.6 million cancer cases in 2018 with this 
prevalence only expected to increase. In 2010, this placed an economic burden of 1.16 trillion 
dollars and can only be assumed to be larger now (57, 109). As these numbers continue to rise, 
lifestyle behaviours continue to worsen. Although there are some genetic influences in the 
development of cancer, the foods consumed and amount of physical activity can significantly 
increase an individual’s chances of developing a tumor (57). The common goals in place for 
individuals diagnosed with cancer is to; 1) resect the tumor and “cure” the cancer, 2) prolong life 
and 3) improve their quality of remaining life. In addition to the side effects caused by the tumor, 
almost all treatment options involve the administration of cytotoxic compounds that not only 
target tumor cells, but all of the cells in the body causing new or exacerbating side effects seen 
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with this disease. Part of this thesis will explore how a specific class of chemotherapy alters 
cardiac and skeletal muscle mitochondrial bioenergetic function. 
 One of the major complications for individuals receiving cancer treatment and even after 
surviving treatment is the development of fatigue. Fatigue can manifest as psychological, 
physical or both and have debilitating effects on quality of life. A study completed on women 
diagnosed with breast cancer reported reduced strength and endurance, flexibility, and grip 
strength following unilateral treatment (48) resulting with reduced quality of life. A major 
strength to this study was the comparison between the treated and untreated arms or upper bodies 
that allowed for an internal control. A common limitation in this particular type of cancer 
literature is being unable to determine whether an individual is experiencing the symptoms due 
to the tumor itself or due to the treatment they’ve received. Jacobsen and colleagues (1999) 
attempted to overcome this limitation by determining levels of fatigue following various 
treatment cycles. Through questionnaires and home assessments, there was a significant increase 
in severity of symptoms and distress throughout treatment cycles (cycles 1-4) (56). The most 
commonly reported symptoms were sleep problems, muscle weakness, emotional upset and 
mouth sores (56). Of particular interest is the resulting muscle weakness that occurs from 
chemotherapy treatment. Developing a better understanding of how these chemotherapeutic 
drugs effects muscles may uncover why muscle weakness is a major symptom and aid in the 
development of better treatment strategies.  
2.5.2 Overview of the different types of chemotherapies  
 
2.5.2.1 Basic overview of the cell cycle 
 
Originally, the term chemotherapy was classically known as a drug to treat a disease. 
More recently, it has been specifically used in the context of cancer treatment. There are many 
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classes of chemotherapies all with the common goal of preventing tumor cell division. As such, 
these chemotherapies are designed to prevent cell division. Both cancerous and non–cancerous 
cells undergo a process known as mitosis in order to divide and maintain life. This process 
occurs in 5 phases and can be thought of as a cycle where each cell produces 2 new cells that 
eventually go through the cycle producing even more cells (Figure 2-4). This process begins in 
the G0 or resting phase where non-dividing/dormant cells wait for an external stimulation to 
initiate division. Upon stimulation, the cell enters the G1-phase where it begins to duplicate 
intracellular proteins and grows in size so that it is capable of splitting into two cells which is 
quickly followed by the S-phase where DNA is copied making new DNA for the new cell. The 
G2-phase is known as the regulating check point where proteins double check that the DNA was 
copied correctly leading to the last step known as the M-phase, where microtubules form into 
mitotic spindles allowing the physical split of one cell into two (2, 83). Understanding the cell 
cycle is crucial as some chemotherapy drugs are developed to targeted a specific phase of the cell 
cycle to inhibit tumor growth (Figure 2-4). 
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Figure 2-4. Representative schematic of the mitotic cell cycle. Dormant mitotic cells are 
found in the G0-phase awaiting external or internal stimulus to begin dividing. In the G1-phase, 
the cell grows while intracellular proteins are duplicated in preparation for division, quickly 
followed by the S-phase where new copy genetic materials are made. The G2-phase is a check-
point to ensure no errors were made during duplication while mitotic spindle formation begins. 
Lastly, during the M-phase microtubules fully form mitotic spindles and divide the cell into two 
new cells. These newly divided cells can directly re-enter the cell cycle or remain dormant in the 
G0-phase. Chemotherapies are often designed to target specific phases of the cell cycle, all with 
the goal of inhibiting cell division. 
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2.5.2.2 Alkylating agents 
 
 This class of chemotherapy drugs inhibits tumor cell growth by attaching alkyl groups to 
the quinine base of DNA, introducing errors to the DNA during all phases of the cell cycle 
ultimately causing the cell to die (24). A major side effect of this therapy is the development of 
leukemia as the damage to the DNA occurs to both rapidly dividing cancerous and non-
cancerous cells. Common alkylating agents are nitrogen mustards, nitrosoureas and alkyl 
sulfonates. 
2.5.2.3 Antimetabolites 
 
 Through competitive inhibition, antimetabolites interfere with the replication of DNA 
and RNA during the S-phase of the cell cycle (58). This is especially advantageous in killing 
cancer cells as they divide at a much faster rate than normal cells.  
2.5.2.4 Anti-tumor antibiotics 
 
 Anti-tumor antibiotics inhibit tumor cells from replicating by interfering with the 
enzymes involved in DNA replication and RNA production. These drugs physically insert 
themselves between the strands of DNA inhibiting replication. A subclass of anti-tumor 
antibiotics called topoisomerase inhibitors are also able to inhibit DNA replication by inhibiting 
topoisomerase II, preventing the separation of DNA for replication. One of the most common 
and successful anti-tumor antibiotics are anthracyclines, capable of sequestering to the nucleus 
causing DNA/RNA damage while also increasing ROS production. A common side effect with 
the use of anthracyclines is cardiotoxicity which limits the amount that each patient can receive.  
2.5.2.5 Targeted therapies 
 
 As the knowledge of tumor cell metabolism increase, so do the advancement of treatment 
strategies. Targeted therapies are designed to mostly target tumor cells while leaving the majority 
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of healthy cells intact. These types of therapies are often used in conjunction with classic 
chemotherapies. One such type of therapy is hormone therapy aimed to alter the action or 
production of male and female hormones to successfully slow the growth of breast, prostate and 
uterine cancers dependent on hormones for growth. Another type of targeted therapy is immune 
therapy designed to either stimulate the body’s natural immune response to target and fight 
tumor cells or are exogenously administered as antibiotics to target tumor cells. Lastly, in 2010 
the first cancer vaccine was developed (Provenge®) to treat prostate cancer similarly to 
endogenous immune therapy shown to significantly extend life by 50% compared to control (22). 
2.5.3 Microtubule targeted chemotherapy 
 
The remainder of this thesis will specifically focus on mitotic inhibitors. These drugs are 
plant alkaloids often derived from natural products that have extreme cytotoxic effects. They 
specifically target the M phase of the cell cycle to prevent mitosis. Mitotic inhibitors, or 
microtubule targeted compounds are often used to treat lung and breast cancers, myelomas, 
lymphomas and leukemia. As mentioned above, a major consequence of these drugs is that they 
are not tumor cell specific, therefore they are successful at targeting and killing tumor cells but 
they are also successful at killing healthy cells. There are 4 types of microtubule targeted 
compounds designed to inhibit microtubule dynamics 1) Epothilones; inhibiting the transition 
from G2-phase to the M-phase by binding ab-dimers stabilizing microtubules causing cell cycle 
arrest 2) Estramustine; a combination of estrogen and nitrogen mustards designed for the 
treatment of prostate cancer. This class of mitotic inhibitor is not often used 3) Taxanes; function 
by stabilizing ab-dimers during the M-phase of the cell cycle preventing cell division ultimately 
causing cell death and lastly 4) Vinca alkaloids; prevent b-tubulin polymerization during the M-
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phase of the cell cycle (129). This thesis will specifically focus on the taxane paclitaxel and the 
vinca alkaloid vinblastine. 
2.5.3.1 Paclitaxel 
 
 Taxol, originally discovered by botanist Arthur Barclay and further isolated by Mansukn 
Wani and Monroe Wall, was found to have highly toxic properties specifically useful for killing 
cancer cells. Taxol is extracted from the bark of pacific yew tree, Taxus brevifolia, but 
unfortunately it is slow growing and, in the 1980’s, was quickly becoming extinct as bark 
removal ultimately kills the tree. The synthetic form of taxol, paclitaxel, was then derived and is 
what is currently used for the treatment of some cancers (169). Paclitaxel inhibits the dynamic 
stability of microtubules by binding to ab-dimers, preventing depolymerisation and encouraging 
polymerization. Specifically, paclitaxel binds to 31 amino acids on the N-terminal tail of b-
tubulin, a site specific to only paclitaxel (130). A 5 minute incubation with paclitaxel in human T 
lymphocytes is sufficient to see the first bundles of polymerized microtubule appear, while 2 
hours has been shown to be where cell cycle arrest begins to occurs (90). A result of microtubule 
stabilization during the G2-M phase of the cell cycle is the subsequent initiation of apoptosis 
activated through various pathways in different mitotic cell types (23, 90, 129, 173).  
 Paclitaxel induced apoptosis in cancer cells appears to occur in a multi-pathway manner 
where activation of certain apoptotic pathway differs depending on tumor type. Canine 
mammary gland tumor cells treated with paclitaxel increased ROS formation paired with 
decreased SOD activity. This was coupled with increased Bax and cytochrome c oxidase 
expression both resulting with increased caspase 3 activation, ensuing apoptosis (117). 
Following a 2-hour incubation with paclitaxel, human T lymphocyte cells displayed increased 
phosphorylation of BcL-2 followed by increased caspase 3 activation during the G2-M phase of 
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the cell cycle, also suggesting the initiation of apoptosis (90). There is an abundance of literature 
with the aim to understand how paclitaxel targets phases of the cell cycle to induce apoptosis and 
tumor cell death but unfortunately, there is limited knowledge on how this occurs in non-mitotic 
cardiac and skeletal muscles. 
2.5.3.2 Vinblastine 
 
There are three main types of vinca alkaloids; vinblastine, vincristine and vendesine 
(moudi et al.,). Vinca alkaloids binds to formed microtubules (~16 binding sites along the length 
of a microtubule) and has shown to inhibiting growth at the plus end of axonemal seeds while 
also promoting destabilization at the minus end (61, 62, 101). This thesis will primarily focus on 
the use of vinblastine to alter microtubule organization. Vinblastine was first discovered as an 
intended therapy for diabetes by Robert Noble and Charles Beer at the University of Western 
Ontario (98). Vinblastine is extracted from the catharanthus roseus plant and is now commonly 
utilized for chemotherapy treatment due to its cytotoxic properties (12, 61, 92).  
 In addition to inhibiting cell division by depolymerizing microtubules, vinblastine has 
shown to have a serious of intracellular effects all contributing to the fatality of the cell. Upon 
mitotic arrest, vinblastine has shown to induce apoptosis through various pathways. In KB-3 
human carcinoma cells, vinblastine treatment was shown to induce apoptosis though a BcL-2 
activated pathway (160) while in human cervical carcinoma, apoptosis was induced through c-
Jun N-terminal protein pathway (JNK) (69). Lastly, mitochondria isolated from A375 and BLM 
melanoma cells treated with vinblastine resulted with the induction of apoptosis measured 
through dissipated mitochondrial membrane potential, cytochrome c oxidase release, and caspase 
3 and 9 activation (143). It is evident that there is a link between altering microtubule 
architecture and initiating apoptosis through mitochondrial and non-mitochondrial induced 
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pathways but the mechanism remains unknown. Moreover, the effects on non-mitotic tissues also 
remain unexplored. 
2.5.4 Potential impairments to muscle function in response to microtubule manipulation 
 
Skeletal muscle is the largest organ in our body primarily responsible for locomotion and 
maintaining metabolism. As most chemotherapeutic therapies, specifically mitotic inhibitors, are 
not cell specific, they not only target and kill tumor cells but also target muscle cells. This 
presents an advantageous model to attempt to understand how microtubules may be involved in 
regulating non-mitotic cardiac and skeletal muscle metabolism and in-turn muscle function. 
Cardiac and skeletal muscle are non-mitotic, raising the question whether microtubule targeted 
drugs play a role in cardiotoxicity and muscle weakness seen following chemotherapy. As 
discussed, the known functions of microtubules in skeletal muscle are protein trafficking and 
organelle and protein movement/placement (54). The role of the tubulin-VDAC interaction has 
not been fully put to question as the model is still “novel”. Current research exploring the effects 
of mitotic inhibitors on skeletal muscle focus more on the neurological effects. Direct 
administration of vinblastine to the sciatic nerve decreases contractility of extensor digitorum 
longus muscle (EDL) following caffeine stimulation due to swelling and fragmentation of the 
nerve (3). The effect at the level of the nerve causes morphological changes to the muscle similar 
to denervation, uniforming the fiber type distribution, reducing the diameter of each fiber and the 
overall muscle’s functional capacity (3, 174). In addition to the neurological insults that have a 
direct effect on muscle function and morphology, mitotic inhibitors are also known to have a 
direct effect on muscle tissue. Unfortunately, the literature on this topic is not well known. 
Whether an inability to transport energy (ATP/ADP) through the mitochondria concomitantly 
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with altered microtubule organization plays a role in the development of cardiotoxicity and 
muscle weakness has yet to be explored. 
2.4.5.1 Human studies utilizing microtubule targeted chemotherapies 
 
 A limiting factor in human cancer research is the inability to delineate the contribution of 
adverse effects from the tumor and the chemotherapy delivered. Correlations can be made based 
on treatment regime and development of side effects to attempt to elucidate their origins. 58% of 
women diagnosed with metastatic breast cancer receiving first line taxane-based chemotherapy 
developed sarcopenia during their treatment regime (144). In addition, 5 hours following a single 
dose of chemotherapy containing vinblastine, a 32-year old male with no prior cardiac risk 
factors suffered an acute myocardial infraction (49). Perhaps, these cardiac and skeletal muscle 
decrements may be due to an impairment in the ability of the muscle to maintain or regulate 
ATP/ADP diffusion which is critical for cell survival as mentioned above. Currently, a 
mechanism explaining these reported side effects is unknown. In the absence of cancer, 
endogenous manipulation of cardiac microtubule architecture through the release of macrophage 
migration inhibitory factor (MIF) induced mitochondrial dysfunction measured by reduced 
respiratory capacity while also reducing cardiac contractility (110). This study suggests that it is 
not just the cytotoxic effect of chemotherapy that contributes to cardiac and skeletal muscle 
dysfunction, but the disorganized microtubules as well.  
2.5.4.2 Rodent studies utilizing microtubule targeted chemotherapies 
 
 Rodent studies allow researchers to delve deeper into research allowing the isolation of 
the effects of tumors from the chemotherapy administered. Indeed, this also allows the 
independent isolation of the effect of microtubule disorganization (using microtubule targeted 
chemotherapies) without the systemic effects of a tumor present. Historically, the use of mitotic 
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inhibitors was known to induce peripheral neuropathy, believed to be the cause of any myopathy 
seen. Konish and colleagues (1984) revealed the appearance of basophilic granular deposits in 
combination with degenerating muscle fibers prior to the development of peripheral neuropathy 
suggesting a direct cytotoxic effect to the muscle (71, 174). Other cellular metabolic impairments 
as a result of microtubule stabilization or destabilization is currently unexplored in skeletal 
muscle. In ventricular cardiomyocytes, contractile amplitude and calcium transients were 
significantly reduced following a 4 hour incubation with 10µM taxol (50). Howarth and 
colleagues (1999) concluded that taxol caused an inhibition on sarcoplasmic reticulum calcium 
release. While this may be true, an unexplored aspect of the reported reduced contractile 
amplitude could also be due to an unmet energy demand. The addition of tubulin to isolated 
mitochondria reduced ADP stimulated respiration therefore limiting the production of ATP to 
fuel metabolic processes such as muscle contraction (127).  
2.5.5 Is microtubule disruption and mitochondrial dysfunction associated with muscle 
dysfunction? 
 
 Currently there is a gap in the literature where microtubule targeted compounds appear to 
induce ROS, stimulate mitochondrial dysfunction and apoptosis through unknown mechanisms 
in cancer and non-cancer models. These impairments are linked with muscle weakness and 
impaired function with an unknown mechanism (Figure 2-5). Alternatively, a new model of 
mitochondrial bioenergetic impairment has been proposed whereby the cytoskeleton – more 
specifically, microtubules – a functional unit of muscle – may regulate mitochondrial 
bioenergetics, the organelle largely responsible for regulating cell death or survival. This thesis 
has been describing the tubulin-VDAC interaction as a novel mechanism but, as mentioned 
above, this model was first proposed in 1990 (131) and is now starting to catch the interest of 
researchers.   
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Figure 2-5. Activation of apoptosis in skeletal muscle by paclitaxel and vinblastine. 
Microtubule targeted chemotherapies paclitaxel and vinblastine are known to induce apoptosis in 
skeletal muscle with an unknown mechanism all resulting with mitochondrial dysfunction, 
cytochrome c oxidase release, caspase activation leading to apoptosis and cell death. Yellow 
arrows represent the pathway studied in this thesis. Schematic adapted from Chiu et al., 2012 
(26). 
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2.5.6 Overview of Duchenne muscular dystrophy 
 
 Duchenne muscular dystrophy (DMD) is another muscle disorder with disorganized 
microtubules and mitochondrial dysfunction, known to exhibit sever muscle weakness and 
dysfunction. Duchenne muscular dystrophy (DMD) is an X-linked disease effecting 1-3600 
males (18, 19). This disease is characterized by weak proximal muscles with early phenotypical 
onset (~5 years old) where the first distinguishable signs is through Gowers’ manoeuver used by 
children to get into a standing position (19). Significant decrements in muscle strength ensues as 
these males age resulting in the need of ambulatory and respiratory assistance by young 
adulthood. The average age of death is ~19 years old with the cause of death often due to 
respiratory failure or cardiac dysfunction (19). 
 DMD results from the partial or full loss of a single protein located in the sarcolemma of 
skeletal muscle named dystrophin (18). As one of the largest proteins in the body, dystrophin is 
responsible for anchoring intracellular structural components of the cell to the extracellular 
space. This provides structural integrity during muscle contraction keeping proteins and 
organelle in place. In the absence of dystrophin, each contraction or movement results in micro-
tears along the sarcolemma, producing a low amount of force and causing host of metabolic 
insults resulting with increased intracellular calcium release and ROS production (5, 170). These 
intracellular impairments often result in muscle loss coupled with fat and fibrotic deposits (52). 
As DMD is a genetic disease, gene therapy appears to be the best route to developing a cure 
(120). In-lieu of a cure, therapeutic strategies aim to treat the side effects that result from the lack 
of dystrophin. 
2.5.6.1 Microtubule disorganization in Duchene muscular dystrophy 
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 Dystrophin is found bound to the sarcoglycan – dystroglycan complex embedded in the 
sarcolemma (Figure 2-5). Prins and colleagues (2009) were one of the first to suggest that 
dystrophin may bind to the cytoskeleton in a similar method to cytolinkers (111). Fluorescence 
microscopy revealed a highly disorganized pattern of a-tubulin in a mouse model of DMD, the 
mdx mouse (111). As mentioned above, a-tubulin is one of the building blocks in the formation 
of microtubules, responsible for maintaining structural integrity, organelle placement and protein 
transport. In addition to increased disorganization, both a- and b-tubulin protein content 
appeared to be increased in the mdx model without any changes in MAP proteins (111). In the 
absence of dystrophin, the nitric oxide pathway, calcium homeostasis and ROS production is 
perturbed (5). Microtubule contribution to these intracellular events is currently unknown.  
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Figure 2-6. Representative schematic of microtubule disorganization in the absence of 
dystrophin in skeletal muscle. Connecting the extracellular space to the intracellular space is 
the dystroglycan-sarcoglycan complex where in WT muscles, dystrophin binds to a-dystrobrevin 
anchoring microtubules in place contributing to the overall structural integrity of the cell. In 
DMD muscle, dystrophin is absent, therefore, microtubules lack an anchor and become unstable 
and disorganized schematic adapted from Fairclough, Wood and Davies., 2013 (34). 
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2.5.6.2 Mitochondrial impairments in Duchene muscular dystrophy 
 
 Mitochondrial have become of particular interest in the DMD pathology as they are a 
major regulator of cell survival. One of the first comprehensive studies analyzing mitochondrial 
bioenergetics in permeabilized muscle fiber bundles (PmFB) from mdx mice determined a 
mitochondrial dysfunction as a result of this disease. These authors reported decreased maximal 
respiration, decreased H2O2 emission coupled with increased ROS scavenging when compared to 
wildtype controls (39).These tissues were also more susceptible to calcium induced cell death 
through induction of the mPTP (39). Of particular interest was the reduced H2O2 emission, as a 
muscle displaying constant regeneration with fat and fibrotic accumulation in addition to 
mitochondrial dysfunction, in theory, should have elevated H2O2 emission. Utilizing a more 
severe DMD mouse model – the D2.mdx – work from the Perry lab at York University has 
determined impaired H2O2 emission during impaired oxidative phosphorylation in cardiac, 
respiratory and skeletal muscles (51, 52). These mitochondrial bioenergetic impairments are 
strongly linked with the ability of ADP to be transported into the mitochondria to stimulate 
oxidative phosphorylation and produce ATP. Mitochondrial dysfunction is also associated with 
decrements in muscle function. D2.mdx mice display significantly reduced muscle strength 
measured through cage hang time, grip strength and hind-limb force production in addition to a 
decreased functional capacity measured through voluntary wheel running (52). A common factor 
linking whole muscle dysfunction and mitochondrial bioenergetic impairment is the  
 As microtubules are known to bind both mitochondria and the sarcolemma, the D2.mdx 
mouse model provides a novel model to further understand the tubulin-VDAC model. The 
disorganized microtubule architecture in the D2.mdx mouse sets up an endogenous model that 
does not introduce any cytotoxic compounds or external manipulation allowing the passive 
	 41	
observation of how the tubulin-VDAC model may result in mitochondrial and muscle functional 
impairments.  
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3 Objectives and hypothesis 
 
3.1 Overview of thesis 
 
 The overall purpose of this thesis was to determine whether a-tubulin and bII-tubulin 
interact with VDAC2 in cardiac and skeletal muscles from rats and mice. This thesis explores 
pharmaceutical manipulated and genetic models of altered muscle microtubule organization to 
determine tubulin-VDAC interactions in muscle, and whether this alters ADP-stimulated 
respiration which is dependent in part on VDAC permeability.  
3.2 Objective and hypothesis for study 1 (Chapter 4) 
 
 The current literature has identified tubulin as a novel regulator of VDAC permeability of 
ADP/ATP cycling, driving mitochondrial bioenergetics. To date, the direct measurement of 
tubulin interacting with VDAC has yet to be completed particularly in muscle. In addition, it 
remains unknown whether perturbations to the microtubule architecture alters this interaction 
and in doing so, alters ADP-dependent mitochondrial bioenergetics. The purpose of study 1 was 
to determine whether a-tubulin and bII-tubulin interact with VDAC2 in EDL single fibers. We 
then aimed to determine whether this interaction is altered following microtubule 
stabilization/destabilization following separate in-vitro paclitaxel and vinblastine incubations as 
an approach to alter microtubule organization in muscle. Lastly, we aimed to determine which 
ADP-dependent bioenergetic functions are impaired following incubations with these 
microtubule targeted compounds.  
Hypothesis 
1) In untreated EDL muscles, both a-tubulin and bII-tubulin will interact with VDAC2 on 
the mitochondrial outer membrane. 
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2) In-vitro incubations with paclitaxel will cause an increase in microtubule network while 
vinblastine incubations will cause a decrease in microtubule network. 
3) Treatment of muscle fiber bundles with paclitaxel increases a-tubulin and bII-tubulin 
interaction with VDAC2. This increased interaction will limit the ability of ADP to 
diffuse through VDAC, impairing ADP-stimulated respiration and attenuation of H2O2 
emission. 
4) Treatment of muscle fiber bundles with vinblastine will decrease a-tubulin and bII-
tubulin interaction with VDAC2. This decreased interaction will enhance the diffusion of 
ADP through VDAC, increasing ADP-stimulated respiration and increasing the 
sensitivity of ADP to attenuate H2O2 emission.  
5) As VDAC is speculated to be a central component to the mitochondrial permeability 
transition pore (mPTP), paclitaxel and vinblastine treatment will alter calcium retention 
capacity, increasing the cell’s susceptibility to apoptosis induced death. 
 
3.3 Objective and hypothesis for study 2 (Chapter 5) 
 
 Cardiotoxicity remains to be one of the largest contributors to reduced quality of life in 
individuals receiving microtubule targeted chemotherapies. Cardiac mitochondrial dysfunction is 
believed to play a role in the development of this pathology but an exact mechanism remains 
unknown. The main objective of study 2 was to explore the contribution of the tubulin-VDAC 
interaction to the development of mitochondrial dysfunction through in-vitro and in-vivo 
methodologies. First, we aimed to determine the extent of mitochondrial bioenergetic 
impairments caused by 2-days of in-vivo paclitaxel and vinblastine injections. To determine 
whether the a-tubulin and bII-tubulin interaction is involved in bioenergetic impairments 
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observed in-vivo, in-vitro incubations experiments were utilized to determine protein-protein 
interactions and then related to mitochondrial bioenergetics. Lastly, to determine whether 
findings in cardiac tissue are similar to other oxidative tissue, the soleus PmFB was incubated in-
vitro with both paclitaxel and vinblastine to determine whether the changes in mitochondrial 
bioenergetics were similar to cardiac tissue.  
Hypotheses: 
1) In-vivo injections with paclitaxel and vinblastine over 2-days in Wistar rats will alter 
ADP-dependent mitochondrial bioenergetics in a creatine dependent and independent 
manner. In addition, these cytotoxic drugs will increase the cells susceptibility to death 
through altered calcium retention capacity and activation of apoptosis through caspases 
activation. 
2) Muscle fiber bundles incubated with paclitaxel will limit ADP-stimulated respiration and 
ADP attenuation of H2O2 in response to an increased a-tubulin and bII-tubulin 
interaction with VDAC2. Muscle fiber bundles incubated with vinblastine will increase 
ADP-stimulated respiration and attenuation of H2O2 emission in response to a decreased 
a-tubulin and bII-tubulin interaction with VDAC2 
3) As VDAC is a central component of the mPTP, paclitaxel will decrease while vinblastine 
will increase calcium retention capacity altering the cells susceptibility to apoptosis 
measured through caspase activation.  
4) Soleus muscle fiber bundles incubated with paclitaxel will decrease while vinblastine 
increases ADP-stimulated bioenergetics. Similarly, paclitaxel and vinblastine will 
decrease and increase calcium retention capacity respectively, altering the cells 
susceptibility to apoptosis. 
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3.4 Objective and hypothesis for study 3 (Chapter 6) 
 
 Muscle weakness is a common side effect reported in individuals with cancer. The 
contribution of the tumor or chemotherapy in the development of muscle weakness is unclear. 
Following 2-days of in-vivo treatment in Wistar rats, we aim to determine voluntary and in-
voluntary muscle function capacity as a result of paclitaxel and vinblastine injections. 
Mitochondrial bioenergetic assessments were then completed to determine whether muscle 
functional decrements were associated with altered mitochondrial function. To uncover whether 
the a-tubulin and bII-tubulin interaction with VDAC2 was involved in the mitochondrial 
dysfunction observed, protein-protein interaction analysis was also completed.  
Hypotheses: 
1) Following 2-days of both paclitaxel and vinblastine injections, Wistar rats will have 
reduced voluntary running capacity, grip strength and hind-limb force production.  
2) Soleus and white gastrocnemius muscles will exhibit ADP-dependent mitochondrial 
bioenergetic changes in a creatine dependent and independent manner. 
3) ADP-dependent bioenergetic changes will be related to increased and decreased a-
tubulin and bII-tubulin interaction with VDAC2 in response to paclitaxel and vinblastine 
injections respectively. 
4) Both paclitaxel and vinblastine will increase the cells susceptibility to apoptosis induced 
death through altered calcium retention capacity and caspase activation. 
3.5 Objective and hypothesis for study 4 (Chapter 7) 
 
 An underlying result of Duchenne muscular dystrophy is a disorganized microtubule 
architecture contributing to whole cell impairments seen with this disease. Previously, our lab 
uncovered reduced muscle functional capacity and mitochondrial bioenergetic impairments in 
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the rodent model of Duchenne muscular dystrophy. The objective of this study was to utilize the 
rodent model of Duchenne muscular dystrophy – a genetic model of altered microtubule 
organization – to determine whether the a-tubulin-VDAC2 interaction contributes to 
bioenergetic impairments observed with this disease. 
Hypotheses: 
1) Microtubule organization will be significantly disorganized in the D2.mdx mouse model 
of Duchenne muscular dystrophy. 
2) Disorganized microtubules will result in an altered a-tubulin-VDAC2 interaction in 
D2.mdx mice when compared to wildtype. 
3) Disorganized microtubules in combination with an increased a-tubulin-VDAC2 
interaction contributes to ADP-dependent mitochondrial bioenergetic impairments found 
in the D2.mdx mouse when compared to wildtype.  
3.6 Methodological considerations: The initial design for the above-mentioned studies intended 
to progress from pharmacological manipulations of microtubules using in-vitro and in-vivo 
approaches to a genetic model of disorganized microtubule architecture. The in-vitro model 
analyzed EDL, cardiac, and soleus muscles together to determine changes in tubulin-VDAC 
interaction with microtubule manipulation across an oxidative spectrum of muscles. We then 
aimed to continue with the same tissues to an in-vivo model to determine whether the 
observations in-vitro were also observed in-vivo and in relation to skeletal muscle function. The 
in-vivo study posed some limitation during the selection of tissues to harvest; one leg of tissue 
would not be usable as it would be utilized for in-vivo hind-limb force analyses. This would then 
leave only one EDL muscle to be divided between mitochondrial bioenergetics (fresh tissue 
required), embedded sections, glutathione measures (not included), and frozen assays. The 
resolution was then to select a larger glycolytic tissue capable of meeting all experimental needs, 
which led to our choice of the white gastrocnemius. During the design of the genetic model 
(D2.mdx) we returned to the EDL muscle given both limbs were available for mitochondrial and 
imaging analyses.  
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PhD not included in this thesis.  
 
Co-First Author Published 
 
1. Hughes MC*., Ramos SV*., Turnbull PC., Edgett BA., Huber JS., Polidovitch N., 
Schlattner U., Backx PH., Simpson JA., and Perry CGR. (2019) Impairments in left 
ventricular mitochondrial bioenergetics precede overt cardiac dysfunction and 
remodelling in Duchene muscular dystrophy. Journal of Physiology, (In press) (* denotes 
equal contributions) 
 
2. Hughes MC*., Ramos SV*., Turnbull PC., Rebalka IA., Cao A., Monaco CMF., Varah 
NE., Edgett BA., Huber JS., Tadi P., Schlattner U., Simpson JA., Hawke TJ., and Perry 
CGR. (2019) Mitochondrial H2O2 emission during impaired oxidative phosphorylation is 
associated with early myopathy in Duchenne muscular dystrophy. The Journal of 
Cachexia, Sarcopenia and Muscle (JCSM) (In press) (* denotes equal contributions) 
 
Co-Author Published 
 
1. Rudnicki M., Abdifarkosh G., Nwadozi E., Ramos SV., Makki A., Sepa-Kishi DM., 
Ceddia RB., Perry CGR., Roudier E., and Haas TL. (2018) Endothelial-specific FoxO1 
depletion prevents obesity-related disorders by increasing vascular metabolism and 
growth. eLife, 4;7. pii e39780  
 
2. Song E., Ramos SV., Huang X., Liu Y., Botta A., Sung HK., Turnbull PC., Wheeler 
MB., Berger T., Wilson DJ., Perry CGR., Mak TW., and Sweeney G. (2017). Holo-
lipocalin-2-derived siderophores increase mitochondrial ROS and impair oxidative 
phosphorylation in rat cardiomyocytes. Proceedings of the National Academy of Sciences 
(PNAS), 115(7):1576-1581  
 
3. Monaco CMF., Hughes MC., Ramos SV., Varah NE., Lamberz., Rahman FA., McGlory 
C., Tarnopolsky MA., Krause MP., Laham R., Hawke TJ., and Perry CGR. (2018). 
Altered mitochondrial bioenergetics and ultrastructure in skeletal muscle of young adults 
with type 1 diabetes. Diabetologia, 61(6):1411-1423 
 
4. MacPherson REK., Dragos SM., Ramos SV., Sutton C., Frendo-Cumbo S., Castellani L., 
Watt MJ., Perry CGR., Mutch DM., and Wright DC. (2016). Reduced ATGL-mediated 
lipolysis attenuates beta-adrenergic-induced AMPK signaling, but not the induction of 
PKA-targeted genes, in adipocytes and adipose tissue. American Journal of Physiology, 
Cell Physiology, 311:C269-C276  
 
5. Hughes MC., Ramos SV., Turnbull PC., Nejatbakhsh A., Beachler BL., Tahmasebi H., 
Laham R., Gurd BJ., Quadrilatero J., Kane DA., and Perry CGR. (2015). Mitochondrial 
	 48	
bioenergetics and fiber type assessments in microbiopsy vs. Bergstrom percutaneous 
sampling of human skeletal muscle. Fontiers in Physiology, 6:360  
 
  
	 49	
Chapter 4 
 
Altered skeletal muscle microtubule-mitochondrial VDAC2 binding is related to 
bioenergetic impairments after paclitaxel but not vinblastine chemotherapies. 
 
This chapter is an original published article in the American Journal of Physiology; Cell, Rapid 
Reports. It is included in this thesis in the published format. 
 
Assay development prior to initiation of experiments 
• Optimization of mitochondrial respiration and H2O2 kinetics following the incubation of 
various microtubule targeted compounds  
• Single extensor digitorum longs (EDL) fiber isolation and fixation  
• Immunohistochemical staining of EDL single fibers  
• Optimization and protocol development of the proximity ligation assay 
 
Author contributions: Initial study design was completed by Christopher GR Perry (CGRP), 
Meghan C Hughes (MCH) and the previous undergraduate thesis students. Tissue harvest and 
experimental data collection for this and subsequent chapters were completed by Sofhia V 
Ramos (SVR) and MCH because mitochondrial bioenergetic assays require the use of fresh 
tissues and therefore required the presence of two people to complete assays in a timely manner. 
SVR analyzed data, SVR, MCH and CGRP interpreted results, SVR and CGRP, prepared figures 
and drafted manuscript. All authors edited, revised and approved final version of manuscript. 
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Abstract 
Microtubule-targeting chemotherapies are linked to impaired cellular metabolism which 
may contribute to skeletal muscle dysfunction. However, the mechanisms by which metabolic 
homeostasis is perturbed remains unknown. Tubulin, the fundamental unit of microtubules, has 
been implicated in the regulation of mitochondrial-cytosolic ADP/ATP exchange through its 
interaction with the outer membrane voltage-dependent anion channel (VDAC). Based on this 
model, we predicted that disrupting microtubule architecture with the stabilizer paclitaxel and 
destabilizer vinblastine would impair skeletal muscle mitochondrial bioenergetics. Here we 
provide in-vitro evidence of a direct interaction between both a-tubulin and bII-tubulin with 
VDAC2 in un-treated single extensor digitorum longus fibres. Paclitaxel increased both a- and 
bII-tubulin-VDAC2 interactions whereas vinblastine had no effect. Utilizing a permeabilized 
muscle fiber bundle preparation that retains the cytoskeleton, paclitaxel treatment impaired the 
ability of ADP to attenuate H2O2 emission, resulting in greater H2O2 emission kinetics. Despite 
no effect on tubulin-VDAC2 binding, vinblastine still altered mitochondrial bioenergetics 
through a surprising increase in ADP-stimulated respiration while also impairing ADP-
suppression of H2O2 and increasing mitochondrial susceptibility to calcium-induced formation of 
the pro-apoptotic permeability transition pore. Collectively, these results demonstrate that 
altering microtubule architecture with chemotherapeutics disrupts mitochondrial bioenergetics in 
EDL skeletal muscle. Specifically, microtubule stabilization increases H2O2 emission by 
impairing ADP sensitivity in association with greater tubulin-VDAC binding. In contrast, 
decreasing microtubule abundance triggers a broad impairment of ADP’s governance of 
respiration and H2O2 emission as well as calcium retention capacity albeit through an unknown 
mechanism.  
Keywords: microtubule, mitochondria, chemotherapy, paclitaxel, vinblastine, fatigue  
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Introduction 
Two common classes of chemotherapeutics are the microtubule-targeting taxanes (eg. 
paclitaxel, or taxol) and vinka alkaloids (eg. vinblastine) which are used as treatments for solid-
state tumors in multiple cancers. Many patients receiving these types of chemotherapies report 
symptoms of fatigue (152), and tumor-free rat models injected with these compounds show 
severe hind-limb muscle weakness and impaired cardiac contraction (50, 71). This weakness has 
been associated with the development of peripheral neuropathies induced by chemotherapies, 
where paclitaxel and vinblastine alter neuronal microtubules causing axonal dysfunctions and 
transmission impairments (37, 64). These peripheral nerve dysfunctions have been associated 
with marked mitochondrial respiratory impairments leading to substantial morphological 
changes to skeletal muscle and cellular metabolic stress (37, 47, 71). However, the degree to 
which this also occurs in skeletal muscle fibres remains unknown. Likewise, the mechanism by 
which these drugs impair oxidative phosphorylation is uncertain as is their influence on 
mitochondrial reactive oxygen species emission and calcium-induced permeability transition 
pore (mPTP) formation. Given all three bioenergetic functions are critical determinants of cell 
fate (97), understanding the relationship between altered microtubule dynamics and 
mitochondrial bioenergetics may provide insight into the mechanism by which these compounds 
disturb cellular metabolism in muscle. 
Both paclitaxel and vinblastine disrupt the normal dynamics of microtubules leading to 
cell death following mitotic arrest in tumors (23). An emerging model has proposed that 
microtubules regulate mitochondrial bioenergetics in muscle through direct binding of tubulin to 
the ADP/ATP exchanger voltage dependent anion channel (VDAC) on the outer mitochondrial 
membrane (Figure 1A) (42). The available literature suggests a- and b-tubulin likely binds 
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VDAC in muscle which may impede ADP import, thereby implicating microtubules as 
regulators of ADP-dependent mitochondrial bioenergetics (126, 127, 161). As the model posits 
that any change in tubulin-VDAC binding would alter ADP’s control of bioenergetics (Figure 
1A), an extended prediction is that stressors that manipulate microtubule architecture may alter 
ADP-dependent bioenergetics. If true, this relationship may represent a novel mechanism by 
which microtubule-targeting chemotherapy disrupts cellular energy homeostasis in muscle.  
The purpose of this study was to determine whether paclitaxel and vinblastine alter 
mitochondrial bioenergetics by manipulating tubulin-VDAC2 binding in skeletal muscle. 
VDAC2 is of particular interest as global gene knock down of VDAC1 (abundant on both 
sarcolemma and mitochondrial outer membranes) and VDAC3 (present on the mitochondrial 
outer membrane) isoforms permit proper embryonic and pup development whereas VDAC2 
knock down resulted in embryonic death signifying its importance for survival (112). We 
employed a proximity ligation assay with 12-angstrom resolution (126, 161) to determine the 
extent of isoform-specific tubulin binding to VDAC2. We then determined the effect of these 
compounds on ADP-dependent bioenergetics, namely ADP-stimulated oxidative 
phosphorylation, ADP-attenuation of H2O2 emission as occurs through lowering membrane 
potential, as well as the propensity for mPTP formation as VDAC has been implicated in this 
process.   
Materials and Methods 
Animal Care 
 Male and female Wistar rats (180.9 ± 7.0g) bred at York University (Toronto, Ontario) 
but purchased at Charles River laboratories (Toronto, Ontario). Housing was maintained on a 
12:12-h light dark cycle in pairs. Rats were fed standard rodent chow and had ad libitum access 
	 54	
to food and water. A total of 35 rats, ages 6-8 weeks, were used for the completion of 
bioenergetic (n=24) and immunohistochemical experiments (n=11). All procedures were in 
accordance to the Canadian Care Animal Committee and with approval from the York 
University Animal Care Committee (AUP 2016-19). 
Preparation of permeabilized muscle fiber bundles (PmFB) and mitochondrial bioenergetic 
assays 
 The extensor digitorum longus (EDL) muscle was removed and immediately placed in 
BIOPS buffer on ice for further separation of fibers into intact bundles (2-4 mg wet weight) that 
were incubated at 4◦C with either the microtubule stabilizer, paclitaxel (Tocris, 1097, 
Minneapolis, USA) at 23µM for 2hrs (96) or the microtubule destabilizer vinblastine (Sigma-
Aldrich, V1377, Missouri, USA) at 3µM for 1hr (101). Control bundles were incubated in 
corresponding concentrations of the vehicle DMSO. Following incubations, bundles were 
permeabilized (PmFB) with saponin (75, 104) and washed for 15 minutes at 4◦C. Bundles 
dedicated to H2O2 emission were permeabilized in the presence of 2,5-dinitrochlorobenzene 
(CDNB) to deplete glutathione and allow the detection of H2O2 emission (35). Respiration assays 
were completed using a high-resolution respirometer (Oroboros Instruments Corp., Innsbruck, 
Austria) at 37°C in MiRO5 respiration media supplemented with 20mM creatine (8, 136) and 
5µM blebbistatin to prevent PmFB contraction (89, 106). Creatine was used to saturate 
mitochondrial creatine kinase to promote efficient cytosolic-mitochondrial exchange of creatine 
and phosphocreatine through VDAC, in addition to ADP/ATP, to optimize respiratory conditions 
(42).  
Separate PmFB were used for fluorometric detection of H2O2 emission (QuantaMaster 
40, HORIBA Scientific) with Amplex UltraRed as described previously (89). Briefly, PmFB 
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were placed into a quartz cuvette containing Amplex Ultra Red dissolved in Buffer Z. H2O2 
emission was induced with the addition of 10mM pyruvate and 4mM malate (NADH, complex I) 
followed by a titration of ADP to determine the efficiency of attenuating H2O2 emission. Other 
PmFB were used to determine calcium retention capacity (CRC) utilizing EGTA coated cuvettes, 
loaded with 300µL of Buffer Y supplemented with 1µM calcium green-5N (Invitrogen), 2µM 
thapsigargin, 5mM 2-deoxyglucose, 2U/mL hexokinase, 20mM creatine, 5mM glutamate, 2mM 
malate, 5µM blebbistatin and 40µM EGTA. Briefly, Ca2+ uptake was initiated with 8nmol pulses 
of CaCl2 with subsequent 4nmol pulses until mPTP opening was observed (QuantaMaster 80; 
HORIBA Scientific)(89).  
Immunohistological experiments and image acquisition 
EDL muscle was collagenase-treated, single fibers were isolated and then treated with 
23µM paclitaxel, 3µM vinblastine or DMSO for 2hrs at room temperature. Following drug 
incubations fibers were washed, fixed, blocked and permeabilized in preparation for staining. 
Primary and secondary antibodies used were as follows; a-tubulin (1:1000, Sigma-Aldrich; 
T6199), b-II tubulin (1:250, Abcam; ab28036) (separate fibres), VDAC2 (1:250 santa cruz; 
32059), Alexa Flour 488 (Invitrogen/Thermo-Fisher Scientific, A21121) and Alexa Flour 555 
(Invitrogen/Thermo-Fisher Scientific, AS1431). The proximity ligation procedures were 
completed as previously done (63, 126). Briefly, fibers containing primary antibodies were 
incubated with oligonucleotide secondary probes and then subsequently with detection reagents 
allowing the quantification at a specific wavelength. All fibers were coated with mounting media 
and secured with a cover slip. Minimal background signal during the proximity ligation assay 
was verified by incubating fibres with the probes, ligase and polymerase using each antibody 
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above in isolation (Figure 1B). Control experiments confirmed the specificity of the proximity 
ligation assay used to detect tubulin-VDAC2 interactions (Figure 1B). 
Images were acquired using a Zeiss laser scanning confocal microscope 700 (Carl Zeiss, 
Thornwood, NY). Images were collected with a 40X oil-immersion lens with the pin hole 
adjusted to 1AU capturing 3 fields of view per sample with 8-12 stacks and a z-step of 0.23 µm. 
Image quantitation was completed using Imaris image quantifying software (Bitplane, Zurich, 
Switzerland) using the spot tool to identify protein-protein interactions.  
Analysis and statistics 
Results are reported as mean ± SEM with significance accepted at p< 0.05. PmFB were 
randomized into groups and all analyses were completed in an un-blinded fashion. Outliers were 
omitted in accordance with the ROUT test. The D’Agostino–Pearson omnibus or Shapiro-Wilks 
normality test was first performed to determine whether data resembled a Gaussian distribution. 
Given all data passed normality, differences between the means were then tested (GraphPad 
Prism 7, La Jolla, CA) by one-way ANOVA for proximity ligation assays, two-way ANOVA for 
ADP-stimulated respiration and attenuation of H2O2 emission followed by Fisher’s least squares 
difference post-hoc analyses when a significant F ratio was obtained. A student’s un-paired t-test 
was used to test differences in CRC and all other H2O2 emission data in absence of ADP. 
Results 
Paclitaxel increased both a-tubulin-VDAC2 (p=0.001) and b-II-tubulin-VDAC2 
interactions (p=0.0001) (Figure 1B, C, D) which appeared to be associated with altered 
organization of a-tubulin as has been shown previously (65) but not bII-tubulin (Figure 2). 
Paclitaxel a- (p=0.0002) and bII-tubulin-VDAC2 (p=0.002) interaction was also significantly 
higher when comparing paclitaxel and vinblastine. Vinblastine had no effect on either isoform’s 
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interaction with VDAC2 (Figure 1B, C, D) despite an apparent reduction in a-tubulin content 
(Figure 2).  
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Figure 4-1. a-tubulin-VDAC2 interactions in EDL single fibers increase following 
Paclitaxel stabilization. A. Model of tubulin regulation of VDAC-dependent ADP/ATP 
exchange (adapted from (42)). Confocal microscopy images of single EDL B. Control 
experiments in the presence of either a-tubulin, bII-tubulin or VDAC2 incubated alone or 
together (n=3) C. Proximity ligation assay representative images. D. Graphical depiction of a-
tubulin-VDAC2 protein interaction, (n=8, *p=0.001 vs control). E. Graphical depiction of bII-
tubulin-VDAC2 interaction, (n=8-9, *p=0.0001 vs control). Scale bar,16µm. Results are reported 
as means ± SEM.  
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Figure 4-2. a-tubulin but not bII-tubulin organization is altered following microtubule-
targeted chemotherapy. Confocal microscopy representative images of single EDL fibers 
stained with antibodies recognizing a-tubulin and bII-tubulin following either control (DMSO), 
paclitaxel or vinblastine treatment. Scale bar, 16µm. 
 
We next determined the degree to which ADP-dependent mitochondrial bioenergetics 
were affected by either drug. After stimulating complex I-supported respiration with NADH 
(generated by pyruvate and malate), subsequent titrations of ADP were not affected by paclitaxel 
yet were surprisingly increased by vinblastine (Figure 3A, B). While neither drug affected H2O2 
emission in the absence of ADP (Figure 3C, D), paclitaxel impaired the ability of ADP to 
attenuate H2O2 emission (Figure 3E, p=0.0006, main effect) consistent with greater interactions 
between VDAC2 and both b-II and a-tubulin. Vinblastine, while having no effect on tubulin-
VDAC2 binding, also impaired ADP’s attenuation of H2O2 (Figure 3F, p=0.002, main effect). 
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Similar impairments in the ability of ADP to attenuate H2O2 by both drugs were seen 
when supported by succinate (reverse electron flow to Complex I, data not shown). Pyruvate 
dehydrogenase complex-supported H2O2 was also assessed as a control given it is not regulated 
directly by ADP. No effect of either drug was observed (Figure 3G and H) suggesting that the 
drugs act specifically on ADP’s ability to attenuate H2O2 as noted above. 
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Figure 4-3. ADP-dependent mitochondrial bioenergetics is altered following microtubule-targeted chemotherapy incubations 
in EDL PmFB. Complex I-supported (NADH from 5mM pyruvate/4mM malate) State 3 (+ADP) respiration was tested following 
incubations with (n=6-8) A. paclitaxel and B. vinblastine. Complex I-supported (10mM pyruvate/4mM malate) H2O2 emission in the 
absence (n=6-8) (C, D) and presence of ADP (E, F) was determined following both paclitaxel and vinblastine incubations (n=6-8).  
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ADP-insensitive Pyruvate Dehydrogenase Complex (PDC)-supported (10mM pyruvate) H2O2 
emission was tested with G. paclitaxel and H. vinblastine incubations (n=6-7). **p<0.01, 
***p<0.001 vs control. Results are reported as mean ± SEM. 
 
Given VDAC’s potential role in the formation of the mPTP and mitochondrial induction 
of cell death (75), a calcium-titration ‘stress’ protocol was used to determine CRC as an index of 
the propensity for mPTP induction. Similar concentrations of calcium were required to open the 
mPTP following paclitaxel incubations (Figure 4A) while vinblastine demonstrated a reduced 
CRC suggesting a greater sensitivity to calcium-induced mPTP (Figure 4B, p=0.01). 
Figure 4-4. Calcium retention capacity is altered following vinblastine incubation in EDL 
PmFB. Mitochondrial calcium retention capacity following A. paclitaxel and B. vinblastine. 
*p<0.05 vs control, (n=6-10). Results are reported as mean ± SEM.  
 
Discussion 
 Using a high-resolution proximity ligation assay, we demonstrate that both a- and bII-
tubulin interact with VDAC2 in EDL muscle, confirming previous suggestions in skeletal muscle 
based on confocal fluorescent overlay approaches. This finding aligns with the proposed model 
that tubulin isoforms regulate ADP/ATP exchange through VDAC on the outer mitochondrial 
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membrane in skeletal muscle (161). We then treated muscles with the microtubule-stabilizer 
paclitaxel and destabilizer vinblastine to determine whether altering microtubule architecture 
changed tubulin-VDAC2 interactions and ADP-dependent mitochondrial bioenergetics. Here we 
show that paclitaxel increased a-tubulin-VDAC2 and bII-tubulin-VDAC2 interactions and 
impaired the ability of ADP to attenuate H2O2 emission, which supports the model. In contrast, 
vinblastine did not alter tubulin-VDAC2 interactions but still impaired ADP-dependent 
mitochondrial bioenergetics. These findings suggest that both cytotoxic drugs cause 
mitochondrial dysfunction but potentially through different mechanisms. 
Several lines of evidence suggest that tubulin may impede ADP’s control of 
mitochondrial bioenergetics by directly decreasing VDAC permeability. The organization of bII-
tubulin in proximity to mitochondria in rat skeletal and cardiac muscle suggests its involvement 
in regulating mitochondrial bioenergetics (41) This interaction has also been explored in cancer 
cell lines where transmission electron microscopy experiments identified both a- and b-tubulin 
in close proximity with the mitochondria. Co-immunoprecipitation experiments have also 
identified a-tubulin and VDAC in mitochondrial isolations (20). In addition, trypsin removal of 
bII-tubulin increased ADP-stimulated respiration in cardiomyocytes while the addition of tubulin 
to isolated mitochondria decreased ADP-stimulated respiration, further supporting the role of 
tubulin in VDAC permeability regulation (127, 161). The present findings align with this model 
by demonstrating a direct interaction between VDAC2 and both a- and bII-tubulin in skeletal 
muscle, and that these interactions are increased by altering microtubule architecture with 
paclitaxel in conjunction with impaired ADP-control of H2O2 emission.  
While paclitaxel increased tubulin-VDAC2 interactions and impaired ADP-attenuation of 
H2O2 emission, a similar impairment in ADP-stimulated respiration was not observed. This 
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finding does not align with the proposed model that tubulin regulates ADP’s overall control of 
bioenergetics. The lack of effect of paclitaxel on ADP-stimulated respiration contrasts with 
evidence that the removal or addition of tubulin to permeabilized cardiomyocytes (40) and 
isolated brain mitochondria (126) increases and decreases ADP-stimulated respiration 
respectively. While the results challenge the model of tubulin’s regulation of respiration, the 
differences between studies may be related to the examined tissues and cellular models or sample 
preparations (eg. cardiomyocytes, isolated brain mitochondria, cancer cell culture and 
permeabilized skeletal muscle fibres). A previous report in skeletal muscle demonstrated an 
inverse association between free/non-polymerized tubulin and mitochondrial sensitivity to ADP, 
suggesting free tubulin may regulate VDAC permeability to ADP, although the comparison was 
performed between muscles with differing ADP sensitivities rather than using an approach of 
manipulating free or polymerized tubulin. The present study suggests a refinement to the model 
in EDL whereby altering tubulin-VDAC2 binding in this muscle alters ADP-control of H2O2 
emission specifically. The lack of effect on ADP-control of respiration is perplexing but may be 
due to slight changes in ADP permeability such that H2O2 emission responds with greater 
sensitivity than respiration, at least in muscle. In addition, it has been suggested that VDAC also 
facilitates the export of mitochondrial-derived phosphocreatine in addition to ADP/ATP cycling, 
but this is not fully established (42). Given creatine was present in the assays during respiration 
and H2O2 emission, it is possible that creatine/phosphocreatine cycling may also have been 
modulated by paclitaxel’s effect on tubulin-VDAC2 and may serve as an area for future research. 
Finally, the lack of change in calcium-induced PTP in EDL with paclitaxel contrasts with 
previous work in permeabilized cardiomyocytes which reported increased propensity for mPTP 
formation (74). This may suggest that paclitaxel’s effects on mPTP are fibre-type dependent. 
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 Following vinblastine incubations, we reported a surprising increase in ADP-stimulated 
respiration, as well as an impairment of ADP suppression of H2O2 and increased susceptibility to 
apoptosis. However, there were no changes in tubulin-VDAC2 interactions which suggests off-
target effects on mitochondrial bioenergetics. For example, vinblastine activates apoptosis 
through the c-Jun N-terminal protein pathway (JNK) as reported in human cervical carcinoma 
cells (70), and nocodazole – another microtubule destabilizer – triggers the release of 
cytochrome c oxidase through the formation of the mPTP (74). This is consistent with the 
reduced CRC seen in the present study whereby less calcium is required to trigger mPTP. An 
alternative mechanism to explore is the possibility that lower tubulin content following 
vinblastine treatment disrupts mitochondrial morphology by impairing tethering to microtubules 
through a Miro GTPase regulated docking system (74) which would occur independently of 
VDAC. It is also possible that vinblastine altered VDAC2 interactions with other isoforms of 
tubulin or tubulin interactions with mitochondrial VDAC1 or 3. These VDAC isoforms were not 
examined in the present study given VDAC1 is also on the sarcolemma and would be difficult to 
separate in the proximity ligation assay, whereas VDAC3 is less abundant than VDAC2 (85). 
Collectively, our findings suggest either the tubulin-VDAC model is more complex than 
previously proposed or vinblastine’s effects on cellular stress responses linked to mitochondrial 
dysfunction are independent of tubulin-VDAC binding.   
Conclusion 
These findings demonstrate that microtubule-targeting chemotherapy impairs 
mitochondrial bioenergetics in EDL skeletal muscle. In the case of paclitaxel, we identified 
altered tubulin-VDAC2 interactions as a novel potential mechanism underlying this compound’s 
effect on increasing H2O2 emission through impairing control by ADP. The effects of paclitaxel 
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also support the developing model that mitochondria are subject to regulation by cytoskeletal 
dynamics through microtubule influence on bioenergetic control by ADP, but the dissociation 
between ADP’s control of respiration and H2O2 emission should be a focus for further 
investigation. Moreover, it appears that microtubule disruption by vinblastine is associated with 
impaired mitochondrial bioenergetics through mechanisms distinct from tubulin-VDAC 
interactions. Ultimately, these findings serve as a foundation for exploring the mechanism by 
which these chemotherapeutics contribute to muscle dysfunction and suggest microtubule 
dynamics may be a potential mechanism in this regard.  
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Supplemental figure – not included in published article  
 
Supplemental figure 4-1. H2O2 emission and kinetics following microtubule-targeted 
chemotherapy incubations in EDL PmFB. Complex-II supported (FADH2 from 5mM 
succinate) H2O2 emission was tested in the absence of (A. and B.) and presence of (C. and D.) 
ADP following both paclitaxel and vinblastine incubations (n=7-8). *p<0.05 vs. control. Results 
are reported as mean ± SEM. 
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Chapter 5 
Microtubule targeted chemotherapies impair mitochondrial ADP-sensitivity in rat 
myocardium 
 
This chapter has been written in preparation for submission to the journal of Biochimica et 
Biophysica Acta. It is included in this thesis in the pre-submission format. 
 
Assay development prior to initiation of experiments 
• Optimization of mitochondrial respiration and H2O2 kinetics in cardiac tissue following 
the incubation of various microtubule targeted compounds  
• Isolated cardiomyocyte immunohistochemical staining and optimization for proximity 
ligation assay  
 
Author contributions: Initial study design was completed by Christopher GR Perry (CGRP), 
Meghan C Hughes (MCH) and the previous undergraduate thesis students. Tissue harvest and 
experimental data collection for this and subsequent chapters were completed by Sofhia V 
Ramos (SVR) and MCH because mitochondrial bioenergetic assays require the use of fresh 
tissues and therefore required the presence of two people to complete assays in a timely manner. 
ES harvested hearts and isolated cardiomyocytes used for imaging. SVR analyzed data, SVR, 
MCH and CGRP interpreted results, SVR and CGRP, prepared figures and drafted manuscript. 
All authors edited, revised and approved final version of manuscript. 
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Abstract 
 Microtubule targeted chemotherapies have been known to induce mitochondrial 
dysfunction in muscle which may be linked to the development of cardiotoxicity reported in 
cancer patients. Unfortunately, mechanisms underlying mitochondrial dysfunctions have yet to 
be determined. An intriguing model presents the regulation of ADP permeability through an 
interaction between the monomeric component of microtubules, tubulin, and the voltage 
dependent anion channel (VDAC) in regulation of ADP permeability and therefore 
mitochondrial bioenergetic function. To explore this further, we aim to determine the effect of 
microtubule stabilization and destabilization on cardiac muscle mitochondrial bioenergetic 
function and its relation to the proposed tubulin-VDAC model utilizing in-vivo and in-vitro 
methods. Utilizing permeabilized muscle fiber bundle preparation, this work demonstrates 
impairments to ADP-depended respiration and attenuation of H2O2 emission in both in-vivo and 
in-vitro models’ independent of a change in a- and bII-tubulin interaction in-vitro. These results 
may not be transferable to all oxidative tissues as only minor ADP-dependent mitochondrial 
bioenergetic impairments were observed following acute in-vitro treatment with microtubule 
targeted chemotherapies in soleus muscle. This work is the first to identify the onset of cardiac 
mitochondrial dysfunction in response to a 2-day treatment with microtubule targeted 
chemotherapies. While the tubulin-VDAC2 model was not fully supported, it does not discount 
the possibility of other tubulin and VDAC isoforms contributing to the mitochondrial 
dysfunctions observed.  
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Introduction 
Microtubule targeted chemotherapies such as taxanes (eg. Paclitaxel) and vinka alkaloids (eg. 
Vinblastine) are commonly used therapies for treating breast, ovary and lung cancers (37, 119). 
These compounds prevent tumor cell growth by stabilizing or destabilizing microtubules, 
preventing spindle formation and further cell division. As chemotherapy is not cell specific, non-
mitotic heart tissue is also exposed to the effects of microtubule stabilization or destabilization, 
losing its microtubule dynamics. Currently, there is a host of literature exploring the effect of 
microtubule targeted chemotherapy in the development of peripheral neuropathy but the effects 
on cardiac muscle and its contribution to cardiotoxicity remain largely unknown. 
The mechanisms by which disorganized microtubules may contribute to cardiotoxicity with 
these chemotherapies remain incompletely characterized. The underlying role of microtubule 
dysregulation becomes more perplexing when considering that paclitaxel and vinblastine have 
also been linked to mitochondrial dysfunction in muscle (50, 71, 116). While microtubules serve 
diverse roles in cellular dynamics, the manner by which microtubule effects mitochondrial 
bioenergetics becomes an intriguing question as microtubules have been found to physically bind 
the outer mitochondrial membrane. This is mediated through an interaction between the voltage 
gated dependent anion channel (VDAC) and the dimeric component of microtubules, tubulin (40, 
127). It has been speculated that tubulin directly mediates ADP permeability through its 
interaction with VDAC but it is currently unknown under what cellular conditions this 
interaction occurs. 
The addition of tubulin to isolated mitochondria and removal of tubulin from cardiomyocytes 
by trypsin has revealed a decrease and increase and ADP stimulated respiration providing 
evidence that tubulin regulates ADP-dependent mitochondrial bioenergetics(40, 127). The 
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implications of this model are profound given ADP is required to drive oxidative 
phosphorylation (ie. ATP synthesis). In so doing, ADP attenuates membrane potential which 
decreases premature slip onto oxygen and subsequent reactive oxygen species generation emitted 
from mitochondria in the form of H2O2. Impairments in the ability of the mitochondria to 
produce or maintain adequate amounts of ATP has been linked to several diseases (39, 89, 149). 
As such, the possibility that microtubules may directly influence ADP import and ATP export 
from mitochondria positions this component of the cytoskeleton as a potential mediator of 
mitochondrial dysfunction in conditions of altered microtubule architecture. The degree to which 
such a microtubule-mitochondrial axis underlies metabolic dysfunction remains ill defined, 
particularly in muscle disorders. This model becomes particularly intriguing for models of 
cardiac dysfunction given much of the research on tubulin-VDAC regulation has been performed 
in cardiomyocytes (20, 127, 136, 161).  
 Limited work has been completed on elucidating the importance of microtubules in 
mitochondrial bioenergetic and functional regulation. Ventricular cardiomyocytes display 
reduced calcium transients and contractile amplitude in response to an acute taxol treatment (50). 
In addition, both microtubule stabilization and destabilization with paclitaxel and nocodozole 
respectively, have been shown to depolarize membrane potential and induced mitochondrial 
permeability transition pore (mPTP) formation, an indicator of the initiation of apoptosis (74). 
Central to these events is VDAC, where it is believed to play a central role in the maintenance of 
membrane potential and initiation of mPTP (10, 81, 128). Interestingly, microtubules also appear 
to play a pivotal role in these mitochondrial bioenergetic impairments as paclitaxel and 
nocodozole administration to isolated mitochondria did not change membrane potential, 
highlighting the importance of microtubules to mitochondrial bioenergetic function. What 
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remains unknown is whether the link between alterations in microtubule architecture and 
mitochondrial bioenergetic impairments lies within the proposed tubulin-VDAC model. 
Microtubule stabilization increases the network density of microtubules while destabilization 
reduces it which may be impeding proper intracellular function (23, 65). In the heart, 
microtubule stabilization has been shown to limit contractile function which may lead to adverse 
cardiac events (65, 138, 159). Developing a better understanding of how the disorganization of 
microtubules alters the tubulin-VDAC interaction may provide further insight to understanding 
the cardio-toxic side effects seen with microtubule targeted chemotherapies. 
 The purpose of the current investigation is two-fold; first, we aim to determine the effects 
of paclitaxel and vinblastine chemotherapies administered in-vivo and in-vitro on cardiac muscle 
mitochondrial bioenergetics, specifically ADP-dependent respiration and attenuation of H2O2 
emission as well as the cells susceptibility to death through the formation of the mPTP in cardiac 
muscle. We then explored whether such alterations in mitochondrial bioenergetics are related to 
altered tubulin-VDAC2 as previously proposed (40, 127). We hypothesized that microtubule 
stabilization will impair ADP-sensitivity through increased tubulin-VDAC2 interactions while 
microtubule destabilization enhances ADP-sensitivity through decreased tubulin-VDAC2 
interactions. Through impaired ADP sensitivity, we also hypothesize that H2O2 emission and 
susceptibility to calcium-induced apoptosis will be impaired in response to both microtubule 
stabilizing and destabilizing drugs. 
Methods 
Laboratory animal care and handling 
30 male Wistar rats, 4-6 weeks old (302.6 ± 7.3g) were purchased from Charles River 
Laboratories (Toronto, Ontario) and utilized for the completion of in-vivo experiments. 2 
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consecutive days prior to tissue harvest, 10 rats/group were randomly selected to receive either 
intravenous (tail vein) paclitaxel injections (1mg/kg body weight), subcutaneous (abdominal) 
vinblastine injections (1mg/kg body weight) or equal volumes of subcutaneous saline injections. 
For the completion of in-vitro experiments 36 male and female Wistar rats (30 rats utilized for 
mitochondrial bioenergetic analyses while 6 rats were utilized for cardiomyocyte isolations used 
for confocal microscopy described below) were bred at York University (Toronto, Ontario) but 
purchased at Charles River Laboratories (Toronto, Ontario) were used. These animals were 
utilized in conjunction with a previously published study that focused on extensor digitorum 
longus muscle (116). All experiments were performed at 6-8 weeks of age (184.3 ± 5.8 g). All 
animals were maintained on a 12:12-h light-dark cycle, fed standard rodent chow with ad libitum 
access to food and water. All procedures were in accordance to the Canadian Care Animal 
Committee and with approval from the York University Animal Care Committee (AUP 2016-
19).  
Preparation of permeabilized muscle fiber bundles (PmFB)  
 Rats were anesthetized with isoflurane at a rate of 5% and maintained at 3-5% for the 
duration of the tissue harvest. Following 2 days of injections, heart left ventricle was removed 
and immediately placed in ice cold BIOPS buffer containing (in mM): 50 MES Hydrate, 7.23 
K2EGTA, 2.77 CaK2EGTA, 20 imidazole, 0.5 dithiothreitol, 20 taurine, 5.77 ATP, 15 PCr, and 
6.56 MgCl2·6 H2O (pH 7.1), in preparation for further dissection. Rats used for in vitro tissue 
treatments were sacrificed followed by removal of both heart left ventricle and soleus muscle. 
Using antimagnetic needle-tipped forceps under magnification (Zeiss 2000, Germany), tissues 
were trimmed of fat and connective tissue and separated into muscle bundles (1-3mg wet 
weight). Bundles allocated to in-vitro experiments were incubated with either microtubule 
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stabilizer paclitaxel (Torcris, 1097, Minneapolis, USA) at 23µM for 2hrs (96, 116) the 
microtubule destabilizer vinblastine (Sigma, V1377, Ontario, CA) at a 3µM for 1hr (101, 116) or 
corresponding concentrations of vehicle DMSO, all dissolved in BIOPS buffer. Following in 
vitro drug incubation or in-vivo treatments, muscle membranes were permeabilized with 40µg/ml 
saponin dissolved in BIOPS for 30 minutes at 4°C followed by 15 minutes of gentle shaking to 
wash out the cytosol to permit substrate diffusion to the mitochondria during experiments. Fibers 
were then washed with MIR05 buffer containing (in mM): 0.5 EGTA, 10 KH2PO4, 3 MgCl2·6 
H2O, 60 K-lactobionate, 20 Hepes, 20 Taurine, 110 sucrose and 1 mg/ml fatty acid free BSA (pH 
7.1) for respiration experiments, buffer Z containing (in mM): 105 K-MES, 30 KCl, 10 KH2PO4, 
5 MgCl2·6 H2O, 1 EGTA and 5mg/ml BSA (pH 7.1) for H2O2 emission experiments, or buffer Y 
containing (in mM): 250 sucrose, 10 tris-HCl, 20 tris-base, 10 KH2PO4 and 0.5mg/mL BSA for 
calcium retention capacity experiments.  
In-vivo and in-vitro mitochondrial bioenergetic assays 
All mitochondrial bioenergetic assays were performed as described previously (52, 89, 
116). A high-resolution respirometer (Oxygraph 2k, Oroboros Instruments Corp. Innsbruck, 
Austria) was used to determine oxygen consumption set to a temperature of 37°C and maintained 
at a constant stirring rate of 750rpm. In-vivo experiments were completed in 1) the presence of 
20mM creatine to saturate mitochondrial creatine kinase (miCK) which stimulates the transport 
of high energy phosphates as phosphocreatine (PCr) through the outer mitochondrial membrane 
or 2) the absence of creatine to assess the contribution of passive ADP/ATP diffusion according 
to previous models (86, 140, 165, 166). All in-vitro experiments were completed in the presence 
of 20mM creatine. In both in-vivo and in-vitro conditions, respiration was stimulated with the 
addition of NADH from 5mM pyruvate/ 4mM malate followed by a titration of ADP to stimulate 
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state 3 respiration. Physiological (25µM), submaximal (500µM) and saturating (5000µM) ADP 
concentrations were used for in-vivo tissue experiments with the addition of 50µM, 100µM and 
250µM ADP for the in-vitro tissue experiments to capture a wider range of physiological and 
submaximal ADP concentrations. 10mM glutamate was then added generate NADH and 
stimulate complex I-supported respiration in both in-vivo and in-vitro experiments. All 
experiments were completed with the addition of 10µM cytochrome c oxidase to ensure the 
integrity of the mitochondrial membrane was maintained during all experimental procedures. 
Experiments with <15% increase in respiration following addition of 10µM cytochrome c 
oxidase were accepted. Wet bundle weights were established prior to respiration experiments. 
 H2O2 emission experiments were completed using a high-resolution spectrofluorometer 
(QuantaMaster 40, HORIBA Scientific, Edision NJ, USA). During permeabilization, PmFB were 
co-incubated with 100µM CDNB to scavenge endogenous glutathione allowing the generation of 
H2O2 at the pyruvate dehydrogenase complex (35). Washed PmFB were placed into a quartz 
cuvette containing 1mL of Buffer Z with the addition of 10 µM Amplex Ultra Red, 0.5 U/ml 
horseradish peroxidase, 1 mM EGTA, 40 U/ml Cu/Zn-SOD1,5 µM BLEB and 20mM creatine or 
in the absence of creatine for in-vivo experiments. H2O2 emission was stimulated with the 
addition of 10mM pyruvate and 4mM malate followed by a titration of 25µM, 500µM  and 
5000µM ADP for in-vivo experiments and 15µM, 50µM, 100µM, 250µM and 500µM ADP for 
in-vitro experiments to drive oxidative phosphorylation thereby reducing H2O2 emission. Given 
the hypothesis focuses on the potential for tubulin to alter the influence of VDAC on ADP’s 
control of bioenergetics, an ADP-independent H2O2 emission experiment was performed in-vitro 
by stimulating pyruvate dehydrogenase complex (PDC)-supported H2O2 emission by adding 
10mM pyruvate, 4mM malate and 0.5µM rotenone to prevent complex I-induced H2O2 emission. 
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 Susceptibility to calcium-induced apoptosis was measured through the formation of the 
mitochondrial permeability transition pore (mPTP). PmFB were placed into quartz cuvettes filled 
with buffer Y containing 1 µM Calcium Green-5N (Invitrogen), 2 µM thapsigargin, 5 mM 2-
deoxyglucose, 2 U/mL hexokinase, 20mM creatine, 5 µM BLEB and 40 µM EGTA and placed 
into a high-resolution spectrofluorometer (QuantaMaster 80, HORIBA Scientific, Edision NJ, 
USA). Background fluorescence was determined with the addition of 5mM glutamate and 2mM 
malate. An initial 8 nmol pulse followed by subsequent 4 nmol pulses of CaCl2 stimulates 
mitochondrial calcium uptake until the mPTP opens. Maximum fluorescence was established 
with the addition of two 1mM pulses of CaCl2 (89, 116). Upon completion of experiments, 
PmFB were collected following both H2O2 emission and CRC experiments, lyophilized, and 
weighed for dry weights normalization of data. All bioenergetic experiments were conducted at 
37°C with continuous stirring. 
Western blotting and caspase activity assays 
Frozen heart tissue collected from in-vivo injection rats were chipped and homogenized 
in 1.5ml tubes with an electric Teflon pestel submerged in homogenization buffer containing 
(mM): 40 Hepes, 120 NaCl, 1 EDTA, 10 NaHP2O7·10H2O pyrophosphate, 10 
β-glycerophosphate, 10 NaF and 0.3% CHAPS detergent (pH 7.1 adjusted using KOH). A BCA 
assay was used to determine protein concentration (Life Technologies, Carlsbad, CA, USA). 
Samples were prepared, ran through SDS-PAGE followed by a transfer onto a low-fluorescence 
polyvinylidene difluoride membrane. Following transfer, membranes were blocked with LI-COR 
Odyssey Blocking Buffer (LI-COR, Lincoln NE, USA) for 1 hour at room temperature prior to 
an over-night incubation with each respective primary antibody at 4°C. The following primary 
antibodies were used for the completion of Western blot experiments: electron transport chain 
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proteins (OXPHOS cocktail, ab110413, Abcam, Cambridge, UK, 1:250), VDAC2 (32059, 
Santa-Cruz, 1:1000), adenine nucleotide translocase 1 (ANT1) (ab180715, Abcam, 1:1000), 
mitochondrial creatine kinase (mtCK) (a generous gift from Dr. Uwe Schlattner, Grenoble, 
France, 1:1000), a-tubulin (T6199, Sigma-Aldrich, 1:1000) and b-II tubulin (ab28036, Abcam, 
1:100). The next day, membranes were washed in TBST and incubated with the corresponding 
infrared fluorescent secondary antibody (LI-COR, Lincoln NE, USA) for 1 hour at room 
temperature. Membranes were imaged with an infrared imager (LI-COR CLx; LI-COR) and 
quantified with Image J software (ImageJ, http://imagej.nih.gov/ij/). Membranes were then 
stained for total protein using Amido Black total protein stain (A8181, Sigma, St Louis, MO, 
USA) for normalization. 
Caspase 3, 8 and 9 activities were determined as described previously (32, 52). Briefly, 
heart tissue was chipped and homogenized in buffer containing (mM): 250 Sucrose, 50 Tris, 1 
DTT, 1 EDTA, 5 MgCl2 and 10% glycerol. Homogenates underwent a series of differential 
centrifugation to isolate the lysosome and proteasome fractions. The enzymatic activity of 
caspase 3, 8 and 9 were measured using the BioTek Cytation 3 fluorometric plate reader 
(BioTek, Winooski, VT, USA) with the following substrates: caspase 3, AC-DEVD-AMC 
(ALX-260-031-M001, Enzo Life Sciences, Farmingdale, NY, USA), caspase 8, AC-IETD-AMC 
(ALX-260-042-M001, Enzo Life Sciences, Farmingdale, NY, USA) and caspase 9, AC-LEHD-
AMC (ALX-260-080-M001, Enzo Life Sciences, Farmingdale, NY, USA). Caspase activity was 
normalized to protein content measured through BCA assay (Life Technologies, Carlsbad, CA, 
USA). 
In-vitro cardiomyocyte isolation and drug treatment 
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A separate cohort of rats (n=6) were sacrificed for cardiomyocyte isolation and 
immunohistochemical experiments utilizing previously published methods (108, 148). In brief, 
rats were first injected with heparin (100U/100g body weight) and then anesthetized by 
ketamine/xylaxine mixture 10 minutes later. The hearts were quickly excised and submerged in 
ice cold myocyte isolation B1 buffer containing (mM): 113 NaCl, 4.7 KCl, 0.6 KH2PO4, 0.6 
Na2HPO4, 1.2 MgSO4•7H2O, 10 Hepes, 4.6 NaHCO3, 5.5 glucose, 10 2,3-butanedione 
monoxime and 30 taurine to cease the heart from pumping. The cannulated heart (controlled 
within 2 minutes after isolation) was perfused with oxygenated B1 for 6 minutes and 
subsequently perfused with B1 supplemented with Liberase Research Grade (Roche) at 0.2g/mL 
at 37°C for up to 6 minutes. The development of a pale coloring and softer texture indicated that 
the left ventricle was ready to be isolated followed by a rinse with B1 buffer twice. Left ventricle 
was quickly minced into small pieces in stopping buffer (B1 supplemented with 0.02g/mL BSA 
and 200 µM CaCl2) at 37°C for 10 minutes with pipetting every 2 minutes. Following filtration 
of the cell suspension through a 200µM cell strainer, cardiomyocytes were collected by 
centrifugation for 1 minute at 42 x g. Once isolated cardiomyocytes were adhered to laminin 
(10µg/ml, Invitrogen) coated coverslips for 1 hour in M199 medium (Gibco Life technologies), 
supplemented with 100mg/L L-glutamine, 25mM Hepes, 50U/L penicillin-streptomycin (P/S), 
Hanks’ salt, 0.02% BSA and 50mM 2.3-butanedione monoxime. After adherence, 
cardiomyocytes were incubated with either paclitaxel, vinblastine or control (DMSO) at the 
concentrations and volumes listed above for 2hrs in an incubator. Following drug incubations 
fibers were washed 3 times with PBS++ and subsequently fixed with neutral formalin for 10 
minutes at room temperature followed by 3x5min washes with PBS++ (148) for further 
processing.  
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Proximity ligation assay 
The proximity ligation assay was used to determine protein-protein interactions between 
a-tubulin-VDAC2 and bII-tubulin-VDAC2. Isolated cardiomyocytes adhered to a coverslip were 
permeabilized with 0.1% triton X100 for 15min followed by blocking for 1hr in 5% BSA PBS++. 
Cells were co-stained with a-tubulin (1:1000 sigma; T6199) or bII tubulin (1:250 Abcam; 
ab28036) for 4hrs at room temperature followed by VDAC2 (1:250 Santa Cruz; 32059) 
overnight at 4°C. Following primary antibody incubations, cardiomyocytes were washed and 
incubated with Duolink® in-situ PLA anti-goat minus (sigma; DUO92006) and anti-mouse plus 
(DUO92001) probes for 1hour at 37°C. Cardiomyocytes were then washed and incubated with 
the Duolink® in-situ detection reagents red (sigma; DUO92008) to allow for the detection of 
each protein-protein interaction. Negative control experiments have been completed and 
published to determine the antibody specificity of the assay (116). Coverslips were coated with 
mounting media and carefully placed on a microscope slide. 
Image capture and quantitation  
Images were acquired using a Zeiss laser scanning confocal microscope 700 (Carl Zeiss, 
Thornwood, NY). Control experiments completed to determine the specificity of the proximity 
ligation assay were completed in previously published manuscript (116). Images were captured 
with a 40X oil objective with the pin hole was adjusted to 1AU capturing 8-12 stacks with a z-
step of 0.23 µm. Image quantitation was completed using Imaris image quantifying software 
(Bitplane, Zurich, Switzerland) where images were reconstructed into 3D allowing the use of the 
spot tool to identify protein-protein interaction yielding the number of spots per image. 
Analysis and statistics 
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Results are reported as mean ± SEM with significance accepted at P< 0.05. Outliers were 
omitted in accordance with the ROUT test, and the D’Agostino-Pearson omnibus or Shapiro-
Wilks normality test was performed to determine whether the data followed a normal 
distribution. As all data passed normality, a one-way ANOVA was completed for proximity 
ligation assays and complex I and II stimulated respiration. A two-way ANOVA was completed 
for ADP-stimulated respiration and ADP-attenuation of H2O2 emission followed by Fisher’s 
least squares difference post-hoc analysis when a significant F ratio was obtained. To test 
differences in CRC, caspase activity and protein densitometry and other H2O2 emission data in 
the absence of ADP, a student’s un-paired t-test was used. All analysis was completed using 
Prism 8 (GraphPad Prism 8, La Jolla, CA). 
 
Results 
 Regulation of ADP kinetics is impaired following 2 days of paclitaxel and vinblastine injections 
In the presence of 20mM creatine, ADP-stimulated respiration (p=0.56, Figure 5-1A) and 
further isolation of complex I with the addition of glutamate (p=0.63, Supplemental figure 5-1A) 
were unchanged when compared to saline. In the absence of creatine, ADP-stimulated respiration 
was significantly reduced compared to saline (main effect, p=0.01, Figure 5-1D) and was further 
impaired during the addition of glutamate to further isolate complex I (p=0.003 vs saline and 
p=0.03 vs. paclitaxel, Supplemental figure 5-1D). Pyruvate/malate-stimulated H2O2 emission 
(p=0.13, Figure 1B) and ADP-attenuation of H2O2 emission (p=0.08, Figure 5-1C) in the 
presence of 20mM creatine were similar to saline. In the absence of creatine, pyruvate/malate 
stimulated H2O2 emission was unchanged compared to control (p=0.55, Figure 5-1E) while 
ADP-attenuation of H2O2 emission was significantly higher following both paclitaxel and 
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vinblastine injections when compared to saline (main effect, p=0.003, Figure 5-1F). These 
bioenergetic impairments were independent of any change in protein content of mitochondria 
measured by the complexes of the electron transport chain (p=0.88), VDAC2 (p=0.85), ANT 
(p=0.41), mtCK (p=0.20), a-tubulin (p=0.50), and bII-tubulin (p=0.58) (Supplemental Figure 5-
3A-G). Calcium retention capacity, used to determine the propensity for mPTP opening, was not 
altered following both in-vivo injections (p=0.71) and in-vitro incubations with paclitaxel 
(p=0.84) and vinblastine (p=0.65) (Supplemental Figure 5-4A-B). Furthermore, caspase 
activation was not evident as caspase 3 (p=0.79), caspase 8 (p=0.60) and caspase 9 (p=0.31) 
activity were similar between groups (Supplemental Figure 5-4D-F).  
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Figure 5-1. Mitochondrial bioenergetics in left ventricle PmFB following a two-day in-vivo 
treatment with either paclitaxel or vinblastine. State 3 respiration supported by complex I 
(NADH from pyruvate/malate) (n=8-10) in the A. presence and D. absence of creatine. Complex 
I-stimulated H2O2 emission (n=7-10) in the B. presence and E. absence of creatine followed by 
an ADP titration (n=7-10) in the C. presence and F. absence of creatine. Results are reported as 
mean ± SEM. (*p£0.05 saline vs. paclitaxel, #p<0.05 saline vs. vinblastine, &p<0.05 paclitaxel 
vs. vinblastine). 
 
Acute in-vitro incubations with paclitaxel and vinblastine impair mitochondrial ADP-dependent 
kinetics and reduces H2O2 emission 
 
All in-vitro experiments were completed in the presence of 20mM creatine. PmFB treated 
with paclitaxel and vinblastine both displayed a main effect for reduced ADP-stimulated 
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respiration (paclitaxel; p=0.001, Figure 5-2A), (vinblastine; p=0.001, Figure 5-2D). Further 
stimulation of complex I with glutamate trended lower when compared to control (p=0.06, 
Supplemental figure 5-2A) following paclitaxel incubations with no differences following 
vinblastine incubations (p=0.24, Supplemental figure 5-2B). Pyruvate/malate stimulated H2O2 
emission trended to be lower following paclitaxel incubation (p=0.08, Figure 5-2B) and was 
significantly lower following vinblastine incubations (p=0.002, Figure 5-2E). The ability of ADP 
to drive oxidative phosphorylation and reduce H2O2 emission was also significantly impaired 
following both paclitaxel (main effect; p=0.0001, Figure 5-2C) and vinblastine (main effect, 
p=0.0001, Figure 5-2F) incubations. Pyruvate/malate stimulated H2O2 emission at complex I are 
both modulated by the presence of ADP. To determine whether these microtubule targeted 
chemotherapies target the mitochondria in a non-ADP dependent manner we also explored the 
emission potential of the pyruvate dehydrogenase complex (PDC). Here we uncovered no 
differences following paclitaxel incubation (p=0.59, Supplemental figure 5-2A), but significantly 
decreased H2O2 emission following vinblastine incubation (p=0.003, Supplemental figure 5-2B). 
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Figure 5-2. Mitochondrial bioenergetics in heart left ventricle PmFB following in-vitro 
incubations in the presence of 20mM creatine. State 3 respiration supported by complex I 
(NADH from pyruvate/malate) following A. paclitaxel (n=8) and D. vinblastine (n=6-7) 
Incubations. Complex I-stimulated H2O2 emission following B. paclitaxel (n=6-7) and E. 
vinblastine (n=5-6) incubations, followed by an ADP titration C. paclitaxel (n=6-8) and F. 
vinblastine (n=5-6). Results are reported as mean ± SEM. (*p£0.01 vs. control, #p<0.05 vs. 
control). 
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Impairments in ADP kinetics are independent of tubulin-VDAC interaction 
Acute paclitaxel and vinblastine incubations on isolated cardiomyocytes had no effect on 
a-tubulin- (p=0.44, Figure 5-3B) and bII-tubulin-VDAC2 (p=0.90, Figure 5-3C) interaction with 
VDAC2. 
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Figure 5-3. Tubulin-VDAC2 interaction in left ventricle isolated cardiomyocytes. A. 
Representative confocal image of a- and bII-tubulin-VDAC2 interaction following paclitaxel 
and vinblastine incubations. Graphical depiction of B. a-tubulin-VDAC2 interaction (n=5) and 
C. bII-tubulin-VDAC2 interaction (n=5-6). Results are expressed as mean ± SEM.  
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ADP specific impairments from microtubule targeted chemotherapies may not be specific to all 
highly-oxidative tissues 
To determine whether the mitochondrial bioenergetic impairments found in cardiac tissue 
was determined by the tissue’s oxidative capacity, the soleus muscle was also acutely treated 
with both paclitaxel and vinblastine in-vitro with all bioenergetic assays completed in the 
presence of 20mM creatine. ADP-stimulated respiration was similar to control following 
paclitaxel incubations (p=0.24, Figure 5-4A) while following vinblastine incubations, respiration 
was significantly reduced (main effect; p=0.02, Figure 5-4B). Pyruvate/malate stimulated H2O2 
emission and attenuation by ADP was unaltered following both paclitaxel (H2O2 emission; 
p=0.15, ADP kinetics; p=0.99, Figure 5-4C and E) and vinblastine (H2O2 emission; p=0.84, ADP 
kinetics, p=0.98, Figure 5-4D and F) incubations when compared to control. Lastly, calcium 
retention capacity was lower, but not significant compared to control following paclitaxel 
(p=0.08, Figure 4G) and vinblastine (p=0.09, Figure 5-4H) incubations.
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Figure 5-4. Mitochondrial bioenergetics in soleus PmFB following in-vitro incubations in the presence of 20mM 
creatine. State 3 respiration supported by complex I (NADH from pyruvate/malate) following A. paclitaxel (n=7-8) and B. vinblastine 
(n=7-8) incubations. Complex I-stimulated H2O2 emission following C. paclitaxel (n=5-8) and D. vinblastine (n=4-7) followed by an 
ADP titration E. paclitaxel (n=6-8) and F. vinblastine (n=7). Calcium retention capacity following G. paclitaxel (n=4-5) and H. 
vinblastine (n=4) incubations. Results are reported as mean ± SEM. (#p<0.05 vs. control).
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Discussion 
 The mechanisms underlying cardiotoxicity following chemotherapy remain poorly 
understood. Using in-vivo treatments, the present investigation revealed mitochondrial 
bioenergetic impairments in cardiac tissue in response to two microtubule targeted 
chemotherapies, paclitaxel and vinblastine. To further elucidate a mechanism, in-vitro 
methodologies were employed identifying mitochondrial bioenergetic impairments under both 
conditions independent of any change in mitochondrial associated protein content and tubulin-
VDAC2 interactions. These impairments are specific to cardiac tissue because when completed 
in the highly oxidative soleus skeletal muscle PmFB, the majority of the ADP-dependent 
mitochondrial impairments in cardiac tissue were absent. These findings suggest that 
microtubule targeted chemotherapies may have a direct effect on the mitochondria, limiting the 
ability of ADP to produce energy and attenuate H2O2 emission. 
Short term in-vivo microtubule targeted chemotherapy impairs ADP-dependent mitochondrial 
bioenergetics through creatine independent pathways 
To adequately capture mitochondrial bioenergetic function in-vitro, we have attempted to 
mimic in-vivo conditions by maintaining the cells ultrastructure with PmFB, supplementing our 
respiration and H2O2 media with the necessary metabolites and maintaining adequate O2 
concentrations (104). This allows for further manipulation of the system to obtain even more 
information; in this scenario, it allowed for further examination of ADP transport through the 
mitochondria. Cytosolic-mitochondrial exchange of ADP/ATP occurs in part through passive 
diffusion of ADP and ATP via VDAC and the adenine nucleotide translocator (ANT) on the 
outer and inner mitochondrial membranes respectively. This process is thought to represent 20% 
of the total energy transport that occurs in the mitochondria (4, 133). Another mechanism to 
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exchange ADP and ATP through the mitochondrial membranes is facilitated through the 
transport of high energy phosphates donated from PCr, and transferred to ADP and ATP (133, 
165). This is facilitated through cytosolic and mitochondrial creatine kinase (cCK and miCK, 
respectively) providing a faster route for energy exchange contributing to 80% of the energy 
exchange that occurs through the mitochondrial membrane (4, 44, 75, 165, 167). These 
methodologies allow us to create a creatine dependent (utilizing cCK and miCK) condition with 
the addition of 20mM creatine into our respiration and H2O2 media saturating cCK and miCK 
and creatine independent (passive diffusion) conditions with the absence of creatine. With this, 
we can further extrapolate the contribution of each energy exchange system following 
microtubule stabilization or destabilization.  
In the current study, under in-vivo conditions impairments in ADP kinetics were found 
only in the no creatine condition. Reduced ADP-stimulated respiration and an inability of ADP 
to attenuate H2O2 emission following both microtubule stabilization and destabilization were 
also observed. It was very peculiar that only one energy transport pathway was impaired 
following the injection of cytotoxic drugs, while also being the less dominate and inefficient 
pathway. There is a vast amount of literature outlining the importance of creatine and miCK for 
the adequate supply of energy to the cell which may also be the reason why we impairments in 
the creatine independent pathway was observed. Perhaps the cell is attempting to preserve its 
more efficient pathway by “sacrificing” its inefficient pathway. In addition, paclitaxel and 
vinblastine in-vivo injections were completed daily over 2 days which may not be enough time to 
elicit the extreme morphological and pathophysiological changes seen previously (23, 50). In 
addition, the current report may be only capturing the initial bioenergetic impairments that occur 
with microtubule manipulation. Although Gilliam and colleagues (2013) discovered whole body 
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deficits coupled with impaired mitochondrial bioenergetics at 24-72 hours following a single 
injection of doxorubicin in rats (38), the mechanism remains unknown given this compound is 
thought to target nuclear processes. In this current report, paclitaxel and vinblastine specifically 
target microtubules which may require more time for its molecular mechanism to ensue, 
especially in a non-mitotic cell. 
Acute in-vivo microtubule targeted chemotherapy incubations impair mitochondrial 
bioenergetics 
In-vitro incubation of cardiac tissue with paclitaxel and nocodazole, a microtubule 
destabilizer – similar to vinblastine-, has been previously shown to depolarize mitochondrial 
membrane potential and open the mitochondrial permeability transition pore (mPTP), which is 
believed to be responsible for the release of cytochrome c oxidase, activating pro-apoptotic 
pathways (74, 128). These authors have concluded that disrupting the microtubule organization 
in cardiac tissue alters mitochondrial function, but the regulation of ADP transport was not 
investigated. In addition, cardiomyocytes treated with trypsin in an attempt to remove bII-tubulin 
resulted with increased respiratory capacity indicating that the removal of bII-tubulin relieved its 
inhibition on VDAC increasing the permeability of ADP (40). Similarly, the addition of tubulin 
to isolated mitochondria decreased respiration suggesting that tubulin limited ADP diffusion 
through VDAC (127). These and other studies (42, 136, 145, 161) strongly suggest that 
microtubules, specifically tubulin, may be involved in the regulation of ADP permeability 
through VDAC. More recently, our laboratory revealed a direct interaction between a- and bII-
tubulin and VDAC2 in single extensor digitorum longus muscles (EDL) which was linked to 
impaired ADP kinetics. To further deduce the mechanism underlying the bioenergetic 
impairments seen in-vivo, we completed bioenergetic assays using an in-vitro model, acutely 
  93	
incubating heart tissue with paclitaxel and separately vinblastine to observe the bioenergetic 
changes that may be occurring. Here we also observed similar impairments in ADP-dependent 
respiration and attenuation of H2O2 emission with both paclitaxel and vinblastine incubations. To 
determine whether these impairments were mediated by a change in tubulin-VDAC interaction 
we used employed the proximity ligation assay capable of detecting protein-protein interactions 
(<30nm resolution) in isolated cardiomyocytes following incubations with paclitaxel and 
vinblastine. There was no change in both a- and bII-tubulin-VDAC2 interaction, suggesting that 
an alternate mechanism may be at play. 
As mentioned above, there is a strong line of evidence suggesting that the tubulin-VDAC 
interaction governs the permeability of ADP through VDAC and therefore regulates 
mitochondrial respiratory capacity (40, 127, 161). Although the current study did not see a 
change in tubulin-VDAC interaction, tubulin binding to VDAC may still play an important 
physiological role when bound to VDAC. Perhaps in cardiomyocytes, a change in number of 
tubulin-VDAC2 binding may not be indicative of any small morphological changes that may be 
occurring with microtubule stabilization and destabilization undetectable with confocal 
microscopy. VDAC2 is the essential isoform required to sustain life (25), but this does not 
discount the contribution that other VDAC and tubulin isoforms may have. Specifically, each 
tissue, whether it be smooth, cardiac or skeletal muscle, may express different quantities of 
different tubulin isoforms which has been previously shown to be a contributing factor when 
analyzing tubulin-VDAC interactions (126). Further work is needed to distinguish the potential 
for various tubulin and VDAC isoform interactions and its contribution to mitochondrial 
bioenergetics. 
Bioenergetic responses to microtubule targeted chemotherapy may be tissue specific 
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 Cardiac and skeletal muscles fibers are non-mitotic but may still be susceptible to the 
effects of microtubule stabilization and destabilization given the important role of this 
cytoskeletal component in a variety of cell functions. Several similarities exist between cardiac 
and the soleus muscles; 1) they are both highly oxidative tissues reliant on stored fuels, 
specifically fat, to generate energy, 2) they both have a high mitochondria content necessary to 
generate large amounts of energy and lastly 3) although cardiac muscle contraction is an 
involuntary occurrence that does not stop, the soleus muscle is a postural muscle that is 
constantly activated making it unique and resilient, similarly to cardiac muscle. Due to these 
reasons, this report explored whether the same bioenergetic impairments were present in soleus 
muscle following an acute in-vitro incubation with paclitaxel and vinblastine. Surprisingly, the 
majority of ADP dependent bioenergetic impairments seen in cardiac muscle was absent in 
soleus. Vinblastine had specific effects on respiration whereby respiration was significantly 
reduced while there were no differences in attenuation of H2O2 emission compared to control. In 
addition, calcium retention capacity was lower in the soleus while in-vivo and in-vitro 
microtubule disorganization had no effect in cardiac muscle. These data suggest that although 
these two tissues have some similarities, the bioenergetic impairments that ensue in response to 
microtubule disorganization may be mediated through different pathways that requires further 
investigation  
Conclusion 
 In summary, impairments to ADP stimulated respiration and attenuation of H2O2 were 
identified in both in-vivo and in-vitro models, in a creatine independent manner following 
paclitaxel administration independent of any change in a- and bII-tubulin-VDAC2 interaction. 
These finding are not ubiquitous for all oxidative tissues as soleus muscles incubated with both 
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paclitaxel and vinblastine in-vitro did not display all ADP-dependent bioenergetic impairments 
but rather a reduced calcium retention capacity suggesting an increased susceptibility to 
apoptosis. Further work exploring the various tubulin and VDAC isoforms and interactions may 
reveal whether another combination regulates ADP-dependent mitochondrial bioenergetics in 
various muscle tissues. Nonetheless, the present work is the first to identify that only 2 days of 
in-vivo treatment with paclitaxel induces cardiac mitochondrial dysfunction. The more potent 
effects seen of both paclitaxel and vinblastine during in-vitro treatments might suggest that more 
concentrated tissue uptake renders both compounds as mito-toxic in cardiac tissue. 
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Supplemental figures – to be included in journal submission 
 
Supplemental figure 5-1. Complex I- stimulated respiration in left ventricle PmFB 
following a two-day in-vivo treatment with either paclitaxel or vinblastine. State 3 
respiration supported by complex I (NADH from pyruvate/malate + glutamate) following A. 
paclitaxel and B. vinblastine incubations (n=7-10). State 3 respiration supported by complex I 
(NADH from pyruvate/malate + glutamate) in the C. presence and D. absence of creatine (n=7-
10). Results are reported as mean ± SEM. (*p£0.05 saline vs. paclitaxel, &p<0.05 paclitaxel vs. 
vinblastine 
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Supplemental Figure 5-2. Pyruvate dehydrogenase complex (PDC) H2O2 emission from 
heart left ventricle PmFB. H2O2 emission from pyruvate dehydrogenase complex (ADP-
independent) was tested following A. paclitaxel (n=7-8) and B. vinblastine (n=6) incubations. 
Results are reported as mean ± SEM. (#p<0.05 vs. control). 
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Supplemental figure 5-3. A. Representative Western blot of mitochondrial and microtubule proteins. B. Integrative 
densitometry of the proteins of the electron transport chain (complex I-V) (n=5-6), C. voltage dependent anion channel (VDAC) 2 
(n=7-9), D. Adenine nucleotide translocase (ANT)1 (n=7-9), E. mitochondrial creatine kinase (mtCK) (n=5-6), F. a-tubulin (n=7-9), 
and G. bII-tubulin (n=7-9). Results are reported as mean ± SEM.
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Supplemental figure 5-4. Measurements of susceptibility to apoptosis induce cell death in 
heart left ventricle tissue. Calcium retention capacity following A. in-vivo saline, paclitaxel and 
vinblastine injections (n=9-10), B. in-vitro paclitaxel (n=4-7) and C. vinblastine (n=4-6) 
incubations. D. Caspase 3 (n=8-10), E. caspase 8 (n=8-10) and F. caspase 9 (n=8-10) activity 
following in-vivo saline, paclitaxel and vinblastine injections.  
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Chapter 6 
Divergent muscle function and mitochondrial bioenergetic responses to microtubule 
targeted chemotherapy in oxidative and glycolytic skeletal muscles 
Sofhia V. Ramos., Meghan C. Hughes, Trevor Teich., Patrick C Turnbull and Christopher G.R. 
Perry 
Muscle Health Research Center, School of Kinesiology and Health Science, York University, 
4700 Keele Street, Toronto, ON, Canada M3J 1P3 
 
This chapter is in preparation for submission. A journal has yet to be confirmed. 
 
Experimental development prior to initiation of experiments 
• Whole body in-vivo muscle functional tests: voluntary running and grip strength 
• In-vivo muscle force analysis 
• Frozen tissue embedding, sectioning and staining 
• Re-optimization of proximity ligation assays for sectioned muscle 
 
Author contributions: Initial study design and experimental protocols developed by SVR and 
CGRP. SVR, MCH and CGRP contributed to the conception and design of this study. SVR, TT 
MCH and PCT performed experiments. SVR analyzed data. SVR and CGRP interpreted results. 
SVR., and CGRP drafted manuscripts and prepared figures. 
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Abstract 
Microtubule targeted chemotherapies have been implicated in the development of muscle 
weakness. These drugs target and kill mitotic cancer cells through the prevention of mitotic 
spindle formation, preventing cell division thereby killing tumor cells. This, unfortunately, also 
alters the microtubule arrangement in skeletal muscle and may contribute to muscle weakness 
seen with chemotherapy treatment. Emerging evidence suggests that the monomeric subunit of 
microtubules, tubulin, bind and regulate the permeability of ADP/ATP in the mitochondria 
through an interaction with the voltage gated dependent anion channel (VDAC). To further test 
this model, we determined the effect of 2-days of injecting microtubule stabilizing (paclitaxel) 
and destabilizing (vinblastine) chemotherapies on mitochondrial bioenergetics in relation to the 
tubulin-VDAC model and whole muscle function in soleus and white gastrocnemius (WG) 
muscles. Whole body and muscle functional analysis revealed decreased voluntary running 
following vinblastine injections and a surprising increase in torque frequency following 
paclitaxel injections. These changes in muscle function were related to increased bII-tubulin-
VDAC2 interaction only following microtubule stabilization with paclitaxel in embedded soleus 
muscle. However, ADP-dependent respiration and H2O2 emission were unaltered, suggesting the 
changes in tubulin-VDAC interaction and muscle function were independent of mitochondrial 
bioenergetic responses to these compounds. In contrast, WG displayed decreased respiration and 
H2O2 kinetics in response to paclitaxel treatment suggesting that these microtubule targeted 
compounds affect oxidative and glycolytic tissues differently. These results suggest that altering 
mitochondrial bioenergetic responses to altered microtubule architecture may not be linked 
solely through the previously proposed tubulin-VDAC model, and that microtubule-targeting 
chemotherapies may affect muscle mitochondria through alternative mechanisms.   
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Introduction 
 The mechanisms by which chemotherapies cause muscle weakness remain poorly 
understood. As there are many forms of chemotherapies, it stands that each type may trigger 
unique mechanisms of muscle dysfunction. One type of chemotherapy known as mitotic 
inhibitors can either stabilize microtubules, locking them in a polymerized state or destabilize 
microtubules by preventing polymerization; this in turn, prevents the tumor cell from dividing 
and ultimately lead to cell death (23, 130). While these chemotherapies are effective at slowing 
or killing cancer cells, they also target other cells in the body such as skeletal muscle.  
 Individuals receiving chemotherapy endure a series of side-effects including mouth sores, 
nausea, vomiting, diarrhea, sleeplessness, and peripheral neuropathies (37, 119, 129, 171). Of 
particular interest is the muscle weakness that patients experience. Research on male and female 
cancer patients reported that muscle mass is directly related to strength and fatigue during 
treatment (67). This is coupled with reduced muscle size measured through DEXA and 
reductions in single fiber cross sectional area (157). Cellular analysis of a single dose of 
vinblastine resulted a host of morphological changes to gastrocnemius and soleus muscles 
including de-arranged intermyofibular networks and deposits of vacuoles and concentric laminar 
structures, all without any changes to the peripheral nerve in a rodent model (71). The effect that 
these morphological changes – in response to chemotherapy treatment – have on muscle 
intracellular function is currently unknown. It seems possible that an altered microtubule 
intracellular morphology may be a contributing factor towards the development of altered muscle 
function as shown as by increased muscle stiffness following microtubule stabilization in flexor 
digitorum brevis (FDB) muscles (65).  
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 More recently, work presented by three labs, Saks and colleagues (136), Rostovsteva and 
colleagues (127) and Carre and colleagues (20), have suggested a novel model whereby 
microtubules regulate ADP permeability into the mitochondrial through an interaction with the 
voltage dependent anion channel (VDAC) on the outer mitochondrial membrane (136). 
Specifically, the monomeric component of microtubules known as tubulin, is believed to 
physically insert its C-terminal tail into the VDAC channel preventing the diffusion of 
ADP/ATP. The current understanding of this model has been primarily driven by studies 
utilizing reconstructed planar lipid membranes in bedded with VDAC where the addition of 
tubulin, changes to mitochondrial membrane lipid composition, phosphorylation and 
detyrosination of tubulin can alter this interaction (125, 127, 145, 146). Studies in permeabilized 
muscle fiber bundles – where microtubule organization remains in-tact – reveal increased ADP-
dependent respiration with the removal of bII-tubulin from cardiomyocytes and decreased 
respiration with the addition of tubulin to isolated mitochondria (40, 127). Together, these 
studies support the model of tubulin regulation of VDAC permeability. Unfortunately, these 
studies are inconsistent in reporting tubulin and VDAC isoforms, in addition to mirroring in-vivo 
conditions. 
 Previous work from our laboratory has identified a direct protein-protein interaction 
between both a- and bII-tubulin and VDAC2 in EDL muscle (116). When reviewing the current 
literature these two tubulin isoforms appeared to be the most relevant to skeletal muscles while 
knockout studies of VDAC2 result in embryonic death highlighting its important contribution to 
sustaining energy and survival (25, 85) influencing the decision to explore these isoforms. 
Perturbing the microtubule architecture with microtubule targeted chemotherapy paclitaxel 
increased the amount of a- and bII-tubulin-VDAC2 interaction while impairing H2O2 kinetics 
  104	
(115). What remains unknown is whether in-vivo administration of microtubule targeted 
chemotherapies also impair ADP-dependent mitochondrial bioenergetics in a tubulin-VDAC 
dependent manner, which may then be related to muscle weakness commonly seen with 
chemotherapy treatments.  
 The purpose of this investigation was to determine whether short-term treatments with 
microtubule stabilizer, paclitaxel, and destabilizer, vinblastine, cause mitochondrial dysfunction 
in relation to altered tubulin-VDAC interactions, and whether this relationship was associated 
with muscle weakness. We hypothesize that microtubule targeted chemotherapy will cause 
muscle weakness, related to impaired mitochondrial bioenergetics, linked to increased a- and 
bII-tubulin-VDAC2 interaction following paclitaxel treatment vs decreased interactions 
following vinblastine.  
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Methods 
Animal Handling 
 30 male Wistar rats (6-8 weeks old) ordered from Charles Rivers Laboratory (Toronto, 
Ontario, CA) were used for the completion of this project. Rats were housed in pairs and 
acclimatized for 5 days prior to the initiation of experiments where they were then singly housed 
with a running wheel. Housing was maintained on a 12:12 light-dark cycle with ad-libitum 
access to food and water. All procedures were approved and in accordance with Canadian Care 
Animal Committee and the York University Animal Care Committee (AUP; 2016-19). 
Muscle function 
Voluntary wheel running  
 Following acclimatization rats were randomly selected into either saline, paclitaxel or 
vinblastine injection groups. Voluntary wheel running was recorded daily for 5 days prior to 
initiation and during injection days to determine activity before and following microtubule 
targeted chemotherapy treatment. Each rat was place in a specialized cage with 24-hour access to 
a running wheel (Harvard Apparatus) where running distance was recorded at the same time each 
day. Each wheel contained a magnet and a sensor which was connected to an electric counter. 
Revolutions were recorded and multiplied by the known distance of the wheel (108cm) to obtain 
distance traveled. Once the distance was recorded, the electronic counter was reset to 0. 
Voluntary running log was maintained before and during microtubule targeted chemotherapy 
injections. 
Fore-limb grip strength 
On the last day of pre-injection voluntary running, grip strength was measured using a 
force transducer (Mark 10 Digital Force Guage, Copiague, NY) with an attached metal grid 
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secured to the edge of a table. Held by the tail, rats were brought to the grid, allowing their front 
paws to grip while being lightly pulled away until their grasp was broken. Rats repeated 3 reps of 
grip pulls recording the maximum peak tension of the 3 trials (88). Data was omitted from non-
compliant rats. Fore-limb grip strength was measured the day before and after 2-days of 
microtubule targeted chemotherapy injections.  
In-vivo hind-limb force production 
 1-day prior to and following 2-days of saline, paclitaxel or vinblastine injections, in-vivo 
plantar flexor muscle torque was measured. Rats were anesthetized with isoflurane (5%) and 
maintained at 3-4% for the duration of the experiment. Rats were placed on a heated platform 
(37°C) where the fur from the left hind limb was shaved off with rodent clippers and the entire 
hind limb was sterilized with 3 washes of iodine. The left paw was secured to an Aurora 
scientific 305C-FP foot plate attached to the shaft of a servomotor. The left knee was raised to a 
90° angle and clamped in place limiting any upper-limb movement. Percutaneous needle 
electrodes were sterilized and optimally placed under the skin applying electrical stimulus using 
an Aurora Scientific 701C electrical stimulator. Amperage, needle placement and muscle length 
was optimized with a series of twitch contractions. Maximum torque was derived from a series 
of isometric contractions at various stimulation frequencies (25-250Hz) (150). Plantar flexor 
muscle torque was determined the day prior to initiation of microtubule targeted chemotherapy 
injections and on the day of tissue harvest. 
Administration of microtubule targeted chemotherapy and tissue harvest 
 Following acclimatization rats were randomly selected into either saline, paclitaxel or 
vinblastine injection groups. Rats received a dose of 1mg/kg body weight and equal volumes of 
saline for controls based on previous literature and recommendations from the university 
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veterinarian (14, 55, 101). Saline and vinblastine treated rats received intraperitoneal injections 
while paclitaxel treated rats received intravenous injections as paclitaxel has been shown to 
cause atrophy and lesions at injection sites (14, 55). Rats received their respective injections at 
the same time for two consecutive days. The day after injections, rats were anesthetized with 
isoflurane where the white gastrocnemius (WG) plantaris, soleus, extensor digitorum longus 
(EDL), tibalis anterior, diaphragm and heart muscles were removed and prepared for subsequent 
experiments. The soleus and WG muscles were removed, placed on ice and quickly divided for 
bioenergetic experiments, OCT embedding and snap frozen for frozen assays. 
Mitochondrial bioenergetic assays 
Preparation of permeabilized muscle fiber bundles (PmFB) 
 Soleus and WG muscles allocated for mitochondrial bioenergetic experiments were 
trimmed of fat and connective tissue and submerged into ice cold BIOPS buffer containing 
(mM): 50 MES, 7.23 K2EGTA, 2.77 CaK2EGTA, 20 Imidazole, 0.5 Dithiothreitol (DTT), 20 
Taurine, 5.77 ATP, 15 phosphocreatine and 6.56 MgCl2•6H2O (pH 7.1) (51, 75, 89, 104). 
Muscle fiber bundles (1-3mg wet weight) were prepared in 16mm dishes filled with BIOPS 
buffer using antimagnetic needle tipped forceps under magnification (Zeiss, 2000, Germany) 
maintained at 4°C. Bundles were then placed in centrifuge tubes containing 40ug/ml saponin 
dissolved in BIOPS buffer to selectively permeabilize the cholesterol rich sarcolemma, washing 
the cytosol, allowing substrates to enter the cell and stimulate the mitochondria. Fibers allocated 
for pyruvate stimulated H2O2 emission were permeabilized in the presence of 100µM 2,4-
dinitrochlorobenzene (CDNB), depleting endogenous glutathione allowing the generation of 
H2O2 from complex I of the electron transport chain (35, 51). Permeabilized muscle fiber 
bundles (PmFB) allocated for respiration experiments were washed with MIR05 buffer 
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containing (mM): 0.5 EGTA, 10 KH2PO4, 3 MgCL2•6 H2O, 60 K-lactobionate, 20 hepes, 20 
taurine, 110 sucrose and 1 mg/ml fatty acid free BSA (pH 7.1), and PmFB allocated for H2O2 
emission experiments were washed with Buffer Z containing (mM): 105 K-MES, 30 KCl, 10 
K2PO4, 5 MgCl2•6 H2O, 1 EGTA and 5 mg/ml BSA (pH 7.1) for 15 minutes at 4°C. PmFB 
allocated for calcium retention capacity assays were washed for 10 minutes in Buffer Y 
containing (mM): 250 sucrose, 10 tris-HCl, 20 tris Base, 10 KH2PO4, and 0.5mg/ml BSA 
followed by another 10 minutes with 10µM blebbistatin dissolved in Buffer Y at 4°C. Wet 
weights were obtained for PmFB selected for respiration experiments while PmFB selected for 
H2O2 and calcium retention capacity were removed from the cuvette, dried and lyophilized to 
obtain dry weight for normalization.  
Mitochondrial respiration 
 PmFB were placed into a high-resolution respirometer, Oroboros Oxygraph-2k (Oroboros 
Instruments, Corp. Innsbruck, Austria) containing 2mls of either MIR05 buffer with or without 
20mM creatine to maximally stimulated mitochondrial creatine kinase (8, 44, 136), maintained at 
37°C with a stir speed of 750rpm. All experiments began with a starting [O2] of ~350µM, and 
were completed before the chamber reached 150µM [O2]. State 3 respiration was achieved with 
the addition of 5mM pyruvate and 4mM malate to stimulate complex I through NADH, followed 
by a titration of ADP at physiological (25µM), submaximal (300µM and 500µM) and maximal 
(5mM and 10mM) [ADP] in soleus PmFB and physiological (25µM), submaximal (500µM) and 
maximal (5mM) [ADP] in the WG PmFB (75, 116). Complex I and II were further isolated with 
the addition of 5mM glutamate and 20mM Succinate respectively. Mitochondrial membrane 
integrity was determined with the addition of 10µM cytochrome c oxidase with all responses 
maintained below 15%.  
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H2O2 emission 
 PmFB were submerged into 1ml of buffer Z containing 10µM Amplex UltraRed, 
0.5U/ml horse radish peroxidase, 40U/ml Cu/Zn-SOD1 and 5µM BLEB in a quartz cuvette 
maintained at 37°C with constant stirring. H2O2 emission was detected fluorometrically 
(QuantaMaster 40, HORIBA Scientific, Edison, NJ, USA) with the addition of 10mM pyruvate 
and 4mM malate. To determine the ability of ADP to reduce H2O2 emission by driving ATP 
production, a titration of ADP was added at physiological (25µM), submaximal (500µM) and 
maximal (5mM) [ADP] for both soleus and WG PmFB.  
Calcium retention capacity 
 To determine the cells susceptibility to induce mitochondrial permeability transition pore 
(mPTP) opening, PmFB were placed into quartz cuvettes containing 300µL of buffer Y 
containing 1 µM Calcium Green-5N (Invitrogen), 2 µM tharpsigargin, 5 mM 2-deoxyglucose, 2 
U/mL hexokinase, 20mM creatine, 5 µM BLEB and 40 µM EGTA, placed in a high-resolution 
fluorometer (QuantaMaster 80, HORIBA Scientific, Edison, NJ, USA). Background 
fluorescence was obtained with the addition of 5mM glutamate and 2mM malate followed by an 
initial 8nm CaCl2 pulse with subsequent 4nm CaCl2 pulses until mPTP opening was evident. 
Maximum florescence was achieved following the addition of two 0.5mM pulses of CaCl2 
saturating the fluorophore.  
Immunohistochemistry 
 Soleus muscle allocated for histology was cleaned and cut of fat and connective tissue on 
ice and placed in O.C.T embedding compound (Tissue Tek) so that fibers lay longitudinally to 
obtain muscle cross-sections. Embedded soleus muscle was then submerged into liquid nitrogen 
cooled 2-methlybutane and stored at -80°C. Prior to slicing the muscle sections, frozen 
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embedded soleus muscle was brought up to and maintained between -19°C - 21°C. Soleus 
muscle was sliced in triplicate 10µm thick slices/slide on three separate slides. Slides containing 
muscle sections were stored at -20°C.  
 Soleus muscle sections were fixed with 4% paraformaldehyde and permeabilized with 
0.5% triton-X100 dissolved in PBS followed by blocking for 1 hour with 5% BSA dissolved in 
PBS at room temperature. Primary antibodies for a-tubulin (Sigma-Aldrich; T6199; 1:1000) and 
bII-tubulin (Abcam: ab28036; 1:250) were incubated on separate slides for 4 hours at room 
temperature followed by an overnight incubation on all slides with voltage dependent anion 
channel (VDAC) 2 primary antibody (Santa-Cruz; 32059, 1:250) at 4°C. The following day 
muscle sections were prepared for the proximity ligation assay as described previously with a 
few modifications (15, 116). Briefly, sections were washed with the buffer provided in the assay 
kit and incubated with probes matching the primary antibodies for 1.5 hours followed 
incubations with detection reagents red (Sigma-Aldrrich; DUO92008). Muscle sections were 
coated with 5µL of mounting medium and sealed with a coverslip.  
Image acquisition 
 Confocal microscopy images were acquired using a Zeiss laser scanning confocal 
microscope 700 (Carl Zeiss, Thornwood, NY). Images were captured using a 40x oil objective 
with the pin hole adjusted to 1AU with a z-step of 0.23µm capturing 10-15 slices. Three separate 
images per muscle section per slide were imaged. Analysis was completed using Imaris image 
quantifying software (Bitplane, Zurich, Switzerland) where images were reconstructed into 3D 
and using the spot tool, each individual spot (protein-protein interaction) was counted yielding 
number of spots.  
Western blotting and caspase activity assay 
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 Western blot procedures were completed as described previously (51, 176). Briefly, 
frozen soleus and WG muscles were chipped and homogenized. Protein content was determined 
using a BCA protein assay kit (Life Technologies, Carlsbad, CA, USA). Samples were prepared 
and proteins were separated on a 12% gel followed by a transfer onto a low-fluorescence 
polyvinylidene difluoride membrane. Following blocking, membranes were incubated overnight 
at 4°C with the following primary antibodies: electron transport chain proteins (OXPHOS 
cocktail, ab110413, Abcam, Cambridge, UK, 1:250), VDAC2 (32059, Santa-Cruz, 1:1000), 
adenine nucleotide translocase 1 (ANT1) (ab180715, Abcam, 1:1000), mitochondrial creatine 
kinase (mtCK) (a generous gift from Dr. Uwe Schlattner, Grenoble, France, 1:1000), a-tubulin 
(T6199, Sigma-Aldrich, 1:1000) and b-II tubulin (ab28036, Abcam, 1:100). The following day 
membranes were washed and incubated with their corresponding infrared fluorescent secondary 
antibody (LI-COR, Lincoln NE, USA), imaged with a LI-COR infrared imager and analyzed 
with ImageJ software (ImageJ, http://imagej.nih.gov/ij/).  
 Mitochondrial derived caspases 3 and 9, and cytosolic caspase 8 was determined as 
described previously (32, 52). Proteosomal fractions were isolated from soleus and WG 
homogenates to determine the enzymatic activity of caspase 3 AC-DEVD-AMC (ALX-260-031-
M001, Enzo Life Sciences, Farmingdale, NY, USA), caspase 8, AC-IETD-AMC (ALX-260-042-
M001, Enzo Life Sciences, Farmingdale, NY, USA) and caspase 9, AC-LEHD-AMC (ALX-260-
080-M001, Enzo Life Sciences, Farmingdale, NY, USA). Caspase activity was normalized to 
protein content. 
Analysis and Statistics 
 Outliers were omitted with the ROUT test and normal distribution was tested with 
the D’Agostino-Pearson omnibus or Sharpiro-Wilks test. A one-way ANOVA was completed for 
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H2O2 emission in the absence of ADP, proximity ligation assay analysis, calcium retention 
capacity, caspase activity assays and all Western blot analysis except for the proteins of the 
electron transport chain (OXPHOS). A two-way ANOVA was completed for ADP-stimulated 
respiration, ADP attenuation of H2O2 emission and the Western blot for the proteins of the 
electron transport chain (OXPHOS). The Fisher’s least squares difference post-hoc analysis was 
completed when a significant F ratio was obtained. All data analysis was completed using Prism 
8 (Graphpad prism 8, La Jolla, CA) and results are reported as mean ± SEM with significance 
accepted at P<0.05. 
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Results 
Whole body effects of paclitaxel and vinblastine injections 
 Body weight did not change following 2 days of either control (saline), paclitaxel, or 
vinblastine injections (Table 1). To determine whether microtubule stabilization with paclitaxel 
or destabilization with vinblastine would have muscle specific changes, each muscle was 
carefully harvested and weighed before processing. We found significantly higher in diaphragm 
muscle weight following paclitaxel injections (saline; 0.44 ± 0.06g vs. paclitaxel; 0.60 ± 0.03g, 
p=0.02, Table 1) and significantly lower weight following vinblastine injections in the 
gastrocnemius (saline; 1.55 ± 0.07g vs. vinblastine; 1.33 ± 0.11g p=0.0004 and vs. paclitaxel; 
1.57 ± 0.06g, p=0.0002) and heart muscles (saline; 1.09 ± 0.05g vs. vinblastine; 0.95 ± 0.03g, 
p=0.02 and vs. paclitaxel; 1.11 ± 0.05g, p=0.009, Table 1).  
Table 6-1. Body and tissue weights before and after 2-days microtubule targeted 
chemotherapy injection. Results are expressed as means ± SEM. $p<0.05 vs. saline, #p<0.05 
vs. paclitaxel and &p<0.05 vs. vinblastine 
 
 
 
  
 Saline Paclitaxel Vinblastine 
Body Weight (g) 
Pre – injection  301.1 ± 14.1 308.8 ± 14.5 305.0 ± 11.3 
Post – injection 305.0 ± 13.7 306.4 ± 14.1 296.7 ± 12.0 
Tissue Weight (g) 
Soleus 0.17 ± 0.01 0.16 ± 0.01 0.14 ± 0.01 
Plantaris 0.27 ± 0.02 0.26 ± 0.02 0.24 ± 0.02 
Gastrocnemius 1.55 ± 0.07 1.57 ± 0.06 1.33 ± 0.11$# 
Tibalis Anterior (TA) 0.60 ± 0.04 0.58 ± 0.03 0.53 ± 0.03 
Extensor digitorum longus 
(EDL) 
0.15 ± 0.01 0.14 ± 0.01 0.14 ± 0.01 
Diaphragm 0.44 ± 0.06 0.60 ± 0.03$ 0.49 ± 0.04 
Heart 1.09 ± 0.05 1.11 ± 0.05 0.95 ± 0.03$# 
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 Rats were randomly placed into either saline, paclitaxel or vinblastine groups in an un-
blinded manner. Following saline injections there were no significant differences in voluntary 
running distance (pre- 3.13  ±  0.61, post- 2.25  ±  0.45 km, p=0.13, Figure 6-1 A). Interestingly, 
following both paclitaxel (pre- 4.87  ± 0.58, post- 2.16  ±  0.42 km, p=0.0004, Figure 6-1 B) and 
vinblastine (pre- 4.88  ±  1.21, post- 0.7  ±  0.36 km, p=0.0001 Figure 6-1 C) injections, there 
was a significant decrease in voluntary running distance. Whole body strength was asses through 
fore-limb grip strength with no differences following saline injections (pre-15.93  ±  1.56, post- 
16.51  ±  2.02, p=0.40, Figure 6-1 D). Following paclitaxel injections there was a significant 
decrease in forelimb force production (pre- 15.26  ±  1.22, post- 11.89  ±  1.02, p=0.02, Figure 6-
1 E). Lastly, following vinblastine injections there were no differences in forelimb grip strength 
(pre- 15.98  ±  1.61, post- 13.42  ±  1.67, p=0.14, Figure 6-1 F).  
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Figure 6-1. Whole body assessments of muscle function. 5-Day voluntary cage wheel running 
distance (n=10 measured over 5 days) measured pre- and post- A. saline, B. paclitaxel and C. 
vinblastine injections.  Maximal forelimb grip strength measured pre- and post- D. saline E. 
paclitaxel and F. Vinblastine injections (n=10). Results are represented as means ± SEM. 
#p<0.05 saline vs. paclitaxel, $p<0.05 saline vs. vinblastine and &p<0.05 paclitaxel vs. 
vinblastine. 
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In-vivo hind-limb muscle force was tested to determine whether altering microtubule 
organization would affect the muscles ability to generate force. Percutaneous needle electrodes 
stimulated plantar flexion at the ankle generating a torque reported as (nM/mg body weight). 
Following 2-days of saline (p=0.27), paclitaxel (p=0.55) and vinblastine (p=0.51) injection there 
were no differences in maximum torque (Figure 6-1A, D and G). Following paclitaxel injections, 
torque frequency was significantly increased compared to pre-injection frequencies (main effect, 
p=0.01, Figure 6-1E) whereas vinblastine injected rats resulted with a lower torque frequency 
curve following injections (p=0.056) (Figure 6-1H) with no differences in saline injected rats 
(p=0.12, Figure 6-1B). 
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Figure 6-2. Functional and in-vivo assessment of activity and muscle strength. In-vivo hind-
limb maximal torque and torque frequency prior to and following 2 days of saline (n=10) (A – 
C), paclitaxel (n=9-10) (D – F) and vinblastine (n=10) (G – I) injections. Results are represented 
as means ± SEM. *p<0.05, #p<0.05 saline vs. paclitaxel, $p<0.05 saline vs. vinblastine and 
&p<0.05 paclitaxel vs. vinblastine. 
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Mitochondrial bioenergetic impairments may be associated with changes in tubulin-VDAC 
interaction in soleus muscles 
 
 Our laboratory has previously shown an altered microtubule organization in response to 
both paclitaxel and vinblastine in-vitro incubations (116). A proximity ligation assay was used to 
determine whether 2-days of paclitaxel or vinblastine injections alters the tubulin-VDAC 
interaction where we found no changes in a-tubulin-VDAC2 interaction (p=0.06) while 
paclitaxel significantly increased bII-tubulin-VDAC2 interaction (saline vs. paclitaxel; p=0.004 
and vs. vinblastine; p=0.009, Figure 6-3B and C).  
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Figure 6-3. Protein-protein interaction between tubulin-VDAC2 in soleus muscle. A. 
Representative images of a-tubulin-VDAC2 and bII-tubulin-VDAC2 interaction in soleus 
muscle sections following 2-days of saline, paclitaxel or vinblastine in-vivo injections. Graphical 
depiction of B. a-tubulin-VDAC2 (n=9) and C. bII-tubulin-VDAC2 (n=8-9) interactions 
following 2-days of saline, paclitaxel or vinblastine injections. Results are represented as means 
± SEM. #p<0.05 saline vs. paclitaxel and &p<0.05 paclitaxel vs. vinblastine. Scale bar, 20µm. 
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 Complex I-stimulated respiration in the presence of 20mM creatine was similar at all 
[ADP] between saline, paclitaxel and vinblastine injected rats (p=0.58, Figure 6-4A). Similarly, 
there were no differences in maximal complex I-stimulated H2O2 emission between groups 
(p=0.92, Figure 6-4B) with a main effect found following vinblastine injections resulting with a 
decreased ability of ADP to attenuate H2O2 emission (+10 to 51%, p=0.009, Figure 6-4C). In the 
absence of creatine, a main effect was found for complex I-stimulated respiration where both 
paclitaxel (+4 to 37%, p=0.001) and vinblastine (+2 to 41%, p=0.03) injections increased 
respiration compared to saline treatment (Figure 6-4D). Both paclitaxel and vinblastine yielded 
divergent responses in H2O2 emission in the absence of creatine with paclitaxel increasing 
(+53%, p=0.06) and vinblastine significantly decreasing (-34%, p=0.01) H2O2 emission 
following 2-days of injections (Figure 6-4E). A main effect was uncovered displaying impaired 
ADP sensitivity following vinblastine injections compared to saline (+50-56%, p<0.0001) and 
paclitaxel (+18-54%, p=0.006) injections (Figure 6-4F).  
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Figure 6-4. Soleus PmFB mitochondrial bioenergetics. In the presence of 20mM creatine; A. 
Complex I-supported respiration stimulated with pyruvate (5mM) and malate (4mM) at 
physiological (25µM) submaximal (300 and 500µM) and maximal (5mM and 10mM) ADP 
concentrations (n=8-10). B. Complex I-stimulated H2O2 emission stimulated in the presence of 
pyruvate (10mM) and malate (4mM) (n=7-10) C. H2O2 emission at a given ADP concentration 
expressed as a percent of maximal H2O2 emission. In the absence of creatine; D. Complex I-
supported respiration stimulated with pyruvate (5mM) and malate (4mM) at physiological 
(25µM) submaximal (300 and 500µM) and maximal (5mM and 10mM) ADP concentrations 
(n=8-10). E. Complex I-stimulated H2O2 emission stimulated in the presence of pyruvate 
(10mM) and malate (4mM) (n=8-10) F. H2O2 emission at a given ADP concentration expressed 
as a percent of maximal H2O2 emission. Results are represented as means ± SEM. #p<0.05 saline 
vs. paclitaxel, $p<0.05 saline vs. vinblastine and &p<0.05 paclitaxel vs. vinblastine. 
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Paclitaxel injections impairs the ability of ADP to attenuate H2O2 emission in WG muscle 
 
 In the presence of 20mM creatine, complex I-stimulated respiration (p=0.92, Figure 6-
5A) and maximal H2O2 emission (p=0.19, Figure 5-6B) was similar between saline, paclitaxel 
and vinblastine injected groups. No change was observed in ADP sensitivity between groups 
(p=0.27, Figure 6-5C). In the absence of creatine, a main effect was observed for reduced 
complex I-stimulated respiration following paclitaxel injections compared to both saline (-12 to -
31%, p=0.02) and vinblastine (-20 to -34%, p=0.001) injection groups (Figure 6-5D). Maximal 
H2O2 emission (p=0.21, Figure 6-5E), and ADP sensitivity (p=0.83, Figure 6-5F) was similar 
between saline paclitaxel and vinblastine injection groups. 
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Figure 6-5. White gastrocnemius PmFB mitochondrial bioenergetics. In the presence of 
20mM creatine; A. Complex I-supported respiration stimulated with pyruvate (5mM) and malate 
(4mM) at physiological (25µM) submaximal (500µM) and maximal (5mM and 10mM) ADP 
concentrations (n=8-10). B. Complex I-stimulated H2O2 emission stimulated in the presence of 
pyruvate (10mM) and malate (4mM) (n=7-10) C. H2O2 emission at a given ADP concentration 
expressed as a percent of maximal H2O2 emission (n=8-10). In the absence of creatine; D. 
Complex I-supported respiration stimulated with pyruvate (5mM) and malate (4mM) at 
physiological (25µM) submaximal (500µM) and maximal (5mM, 10mM and 17.5mM) ADP 
concentrations (n=9-10). E. Complex I-stimulated H2O2 emission stimulated in the presence of 
pyruvate (10mM) and malate (4mM) (n=8-10) F. H2O2 emission at a given ADP concentration 
expressed as a percent of maximal H2O2 emission. Results are represented as means ± SEM. 
#p<0.05 saline vs. paclitaxel, and &p<0.05 paclitaxel vs. vinblastine. 
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Decreased susceptibility to apoptotic cell death in WG muscle following vinblastine injections 
with divergent responses in soleus muscle. 
 
 The susceptibility of the mitochondrial permeability transition pore formation was tested 
through the calcium retention capacity assay yielding significantly increased ability to retain 
calcium following vinblastine injections (+144%, p=0.01) compared to control and paclitaxel 
(Figure 6-6D). In addition, this increase is associated with decreased mitochondrial activated 
caspase 3 (-26% vs. saline, p=0.02 and -24% vs. paclitaxel, p=0.03, Figure 6-6E), and caspase 9 
(-31% vs. saline, p=0.01 and -35% vs. paclitaxel, p=0.002, Figure 6-6G) compared to both saline 
and paclitaxel treated groups. Similarly, caspase 8 activity was significantly decreased following 
vinblastine injections when compared to both saline and paclitaxel treatment groups (-34% vs. 
saline, p=0.005 and -25% vs. paclitaxel, p=0.04, Figure 6-6F).  
 Calcium retention capacity in soleus muscle was significantly increased following both 
paclitaxel (+90%, p=0.01) and vinblastine (+79%, p=0.03) injections when compared to the 
saline treated group (Figure 6-6A). Interestingly, paclitaxel elicited an increase in caspase 3 
activity (+29%, p=0.01) while vinblastine trended to increase as well (p=0.06, Figure 6-6B). No 
change in caspase 8 activity was observed following both paclitaxel and vinblastine treatment 
(p=0.13, Figure 6-6C).  
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Figure 6-6. Measures of susceptibility to cell death. A. Calcium retention capacity (n=9) B. 
caspase 3 (n=3-8) and C. caspase 8 (n=2-7) activity in soleus muscles following 2-days of saline, 
paclitaxel or vinblastine injections. D. Calcium retention capacity (n=8-9), E. caspase 3 (n=7-
10), F. caspase 8 (n=7=10) and G. caspase 9 (n=7-10) activity in white gastrocnemius. Muscles 
following 2-days of saline, paclitaxel or vinblastine injections. Results are represented as means 
± SEM. #p<0.05 saline vs. paclitaxel, $p<0.05 saline vs. vinblastine and &p<0.05 paclitaxel vs. 
vinblastine. 
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Mitochondrial bioenergetic responses to acute non-specific hind-limb muscle contraction 
 
The hind-limb in-vivo stimulation protocol provided a preliminary opportunity to 
determine the effects of contraction on mitochondrial bioenergetics following paclitaxel and 
vinblastine treatment. As shown in supplemental figure 6-1, contraction following paclitaxel 
treatment increased ADP-stimulated respiration in the presence (+9 to24%, p=0.001) and 
absence (+9 to +29%, p=0.01) of creatine while impairing ADP attenuation of H2O2 emission 
(+69 to 133%, p=0.0002) in the absence of creatine in soleus muscles. In addition, vinblastine 
treatment also displayed impaired ADP attenuation of H2O2 emission in the absence of creatine 
(+98 to 157%, p<0.0001) following acute non-specific hind-limb contraction in soleus PmFBs. 
In the WG muscle, paclitaxel and vinblastine did not alter ADP-stimulated respiration in the 
presence or absence of creatine. In the presence of creatine, paclitaxel significantly increased the 
ability of ADP to attenuate H2O2 emission (-23 to -33%, p=0.04) with no effect in the absence of 
creatine. Vinblastine treatment following acute non-specific muscle contracted decreased the 
ability of ADP to attenuate H2O2 emission when compared to paclitaxel (-16 to -24%, p=0.008). 
Lastly, implementation of this stimulation protocol had no effect on calcium retention capacity 
following paclitaxel (p=0.14) and vinblastine (p=0.64) treatment (Supplemental figure 6-3).  
Discussion and conclusions 
 
In this report, we have demonstrated that 2-days of in-vivo microtubule targeted 
chemotherapies produced divergent drug effects on both oxidative soleus and glycolytic WG 
muscles. Vinblastine, a microtubule destabilizer, significantly lowers voluntary running capacity 
while also reducing the amount of force produced from the hind-limb muscles. Paclitaxel, a 
microtubule stabilizer significantly increases in-vivo hind-limb muscle force production without 
altering whole body strength or voluntary running capacity. These functional measures are 
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associated with altered mitochondrial bioenergetics in oxidative soleus and glycolytic WG, in 
response to microtubule manipulation. In the soleus, we found that vinblastine impairs ADP 
sensitivity in a creatine dependent and independent manner, regardless of no change in the 
tubulin-VDAC2 interaction. Interestingly, paclitaxel did not appear to have a damaging effect in 
the soleus but instead increased ADP-stimulated respiration, in a creatine independent manner. In 
addition, there were trends for increased maximal H2O2 emission despite no effect on ADP 
sensitivity/ability to attenuate H2O2. To further understand how microtubule manipulation may 
be effecting different muscle fiber types we also looked at the WG muscle. We found no changes 
in respiration or H2O2 emission following vinblastine treatment. Following paclitaxel treatment, 
we uncovered increased submaximal H2O2 emission in the presence of creatine and reduced 
ADP-stimulated respiration in the absence of creatine. This work has uncovered the effect of 
microtubule targeted chemotherapy in a non-mitotic cell type where bioenergetic impairments 
may be related to muscle weakness commonly seen during and following chemotherapy.  
Paclitaxel increases both a- and bII-tubulin – VDAC interaction without impairing 
mitochondrial bioenergetics 
 
The literature strongly suggests that ADP/ATP flux regulation is mediated through an 
interaction between tubulin and VDAC on the outer mitochondrial membrane. In reconstructed 
plannar phospholipid membranes, nano-molar concentration of dimeric tubulin is sufficient 
enough to elicit VDAC closure (127). The mitochondrial lipid membrane composition is also 
involved in the tubulin – VDAC interaction as membranes of giant unilamellar vesicles enriched 
with dioleoyphosphatidylethanolamine (DOPE) increases the affinity of tubulin binding with 
VDAC (125). Phosphorylation of VDAC by glycogen synthase kinase-3b and protein kinase A 
(146) significantly increases tubulin binding to VDAC while detyrosination of an a-tubulin tail 
also promotes VDAC binding (145). There appears to be so many conditions that promote 
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tubulin-VDAC binding which presents a level of difficultly when trying to understand the 
contribution of this interaction to muscle energy exchange. We have previously shown, in an in-
vitro model, that stabilization of microtubules with paclitaxel promotes both a- and bII-tubulin 
interaction with VDAC2 limiting the ability of ADP to attenuate H2O2 emission in the extensor 
digitorum longus muscle (116). In the current report, we aimed to determine whether this 
interaction would increase with in-vivo administration of paclitaxel and to what extent would this 
effect skeletal muscle function. Although we report an increased interaction of bII-tubulin-
VDAC, this did not result in detrimental effects to mitochondrial bioenergetics in the soleus 
muscle. In fact, we report a main effect for increased oxygen consumption during creatine 
independent ADP-stimulated respiration in soleus muscles. Microtubule density is known to 
differ amongst different fiber types which may elicit different effects in different tissues (16). 
This data suggest that the tubulin-VDAC model may be dependent on the fiber type of the 
muscle.  
In another highly oxidative tissue, unpublished work from our lab revealed creatine 
independent mitochondrial bioenergetic impairments in cardiac muscle following in-vivo 
injections of paclitaxel (unpublished). Further investigation through in-vitro paclitaxel 
incubations uncovered impaired oxygen consumption and an inability of ADP to reduce H2O2 
emission. Interestingly, these in-vivo and in-vitro cardiac mitochondrial bioenergetic 
impairments were present without any change in both a- and bII-tubulin – VDAC2 interaction 
(unpublished). Similarly to the present manuscript, in-vitro incubations of paclitaxel in the soleus 
muscle did not alter ADP-dependent bioenergetics which – comparing the oxidative heart and 
soleus – would suggest that 1) the exploration of other tubulin and VDAC isoforms need to be 
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examined for protein-protein interactions (126) and 2) paclitaxel may be impairing mitochondrial 
and muscle function through an alternative mechanism in different tissue types. 
As VDAC is involved in the formation of the mPTP, we also explored whether calcium 
induced apoptosis was increased following paclitaxel injections. Surprisingly we found an 
increased calcium retention capacity in both soleus and WG in response to vinblastine which 
suggests that a given calcium stress is less able to induce mitochondrial permeability transition 
pore formation – a key event that permits pro-apoptotic stimuli to exit the mitochondria and 
trigger apoptosis. Indeed, in WG this greater calcium retention capacity was associated with less 
mitochondrial-linked caspase 3 activation suggesting calcium stress was inducing less apoptosis 
after vinblastine treatment. While speculative, this is not necessarily a positive outcome as 
vinblastine may prevent normal muscle turnover – a possibility that is consistent with reduced 
hind-limb torque. However, in soleus both paclitaxel and vinblastine increased calcium retention 
capacity and caspase 3 activities while βII tubulin-VDAC2 interactions were increased only 
following paclitaxel treatment, suggesting that the tubulin-VDAC model may not be the only 
mechanism triggering apoptosis in this oxidative muscle.  
 Boudriau and colleagues (1993) determined that oxidative muscles contain 1.7-fold 
higher a-tubulin content compared to glycolytic muscles (16). In addition, confocal microscopy 
analyzing the distribution of bII-tubulin and VDAC revealed a close proximity between these 
two proteins in WG (161) which sparked our interested in exploring the effect of altering 
microtubule organization in a glycolytic tissue. Surprisingly, we uncovered increased 
submaximal H2O2 emission with no impairments to ADP sensitivity in the presence of creatine. 
In addition, paclitaxel significantly reduced ADP-stimulated respiration when compared to the 
saline treated group in the absence of creatine. Drawing on the assumption that glycolytic 
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muscles would respond similarly, this decline in respiration may be due to an increased a- and 
bII-tubulin – VDAC2 interaction seen in the EDL muscle (116) limiting the ability of ADP to 
diffuse through the mitochondria. A limitation to the current manuscript was the inability to 
measure the a- and bII-tubulin – VDAC2 interaction in the WG but we can speculate that 
following paclitaxel injection this interaction would increase similarly to the glycolytic EDL due 
to the similarities in fiber type composition (33, 116). Similarly to the EDL, we report no 
changes in susceptibility to cell death through calcium and caspase activation.  
Vinblastine impairs soleus mitochondrial ADP-dependent mitochondrial bioenergetics 
independent of the tubulin – VDAC2 interaction 
 
 Destabilization of microtubules with the use of vinblastine has been previously shown to 
have debilitating side effects in rodent models. Konishi and colleagues (1984) report significant 
morphological changes to the skeletal muscle which was linked to impaired functional capacity 
(71). In addition, a microtubule destabilizing compound very similar to vinblastine named 
nocodozole has been shown to induce the mPTP, signaling the initiation of apoptosis in 
cardiomyocytes with in-vitro (10µM) conditions (74). Unfortunately, there is not much literature 
to draw on to further our understanding of how microtubule destabilization with vinblastine 
effects skeletal muscle mitochondrial bioenergetics, highlighting the importance of this work. In 
the presence of creatine we uncovered impaired ADP sensitivity regardless of changes in 
maximal and submaximal H2O2 emission. This was further exacerbated in the absence of creatine 
where vinblastine significantly reduced ADP-stimulated respiration, maximal H2O2 emission and 
ADP sensitivity. These effects were seen with no changes in the a- and bII-tubulin – VDAC2 
interaction. Drawing from a study completed by Gilliam and colleagues (2013), where maximal 
H2O2 emission at 2, 24, and 72 hours following a single dose of doxorubicin chemotherapy was 
measured yielding decreased H2O2 emission over time. Similarly, a panel of microtubule targeted 
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compounds have been shown to increase OXPHOS gene expression by activating PGC-1a while 
decreasing ROS emission through upregulation of MnSOD in C2C12 cells (164). These two 
studies and the findings of the current report suggest that changes in ADP/ATP flux and ROS 
emission may be transient and depend on the time and dose of vinblastine administration.  
 Vinblastine treatment had no effect on ADP-dependent mitochondrial bioenergetics or 
maximal H2O2 production in the WG muscle. This may be explained by the reduced number of 
microtubules in a more glycolytic tissue potentially rendering further depolymerisation 
insignificant (16) when compared to the effect of paclitaxel on microtubules. Although there 
were no bioenergetic impairments in response to paclitaxel, we observed a significant decrease in 
whole gastrocnemius muscle weight which is coupled with significantly reduced voluntary 
running distance and a trend for a reduced torque frequency following vinblastine treatment. The 
functional and microscopy data gathered here would suggest that vinblastine may be effecting 
the muscle through an alternate pathway.  
 The mechanisms of cell death from microtubule targeted chemotherapies in cancer cells 
is well known (94, 102, 117, 137, 168). Vinblastine is known to induce cell cycle arrest and 
activation of c-Jun-N-terminal protein pathway, contributing to the initiation of apoptosis 
through the activation of caspase 3 (69, 137). In-vitro incubations with vinblastine in EDL PmFB 
show a reduced capacity for calcium retention suggesting an increased susceptibility to apoptosis 
(116). Interestingly, following in-vivo injections, it appears that vinblastine is inhibiting the 
induction of apoptosis through an increased calcium retention capacity and reduced activity of 
caspases 3, 8 and 9. This is particularly confusing as we expected glycolytic tissues to respond 
similarly to vinblastine. These data suggest that the route of vinblastine administration may play 
a role in its activity. 
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 In conclusion, these results suggest that short-term treatments with microtubule targeted 
chemotherapies alter mitochondrial bioenergetics but do not fully support the tubulin-VDAC 
model of mitochondrial bioenergetic regulation. Surprisingly, microtubule stabilization increased 
while destabilization decreased force production but may be occurring independently of 
bioenergetic impairments resulting from an altered tubulin-VDAC interaction. Overall, the 
current model of tubulin regulation of VDAC permeability may be more complex than initially 
proposed (127, 136). Further work is needed to completely elucidate the contribution of the 
tubulin-VDAC interaction in mediating these mitochondrial and muscle impairments, as well as 
alternative mechanisms by which these compounds alter mitochondrial bioenergetics.  
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Supplemental Figures  
 
 
Supplemental figure 6-1. Soleus PmFB mitochondrial bioenergetics following in-vivo 
muscle contraction. In the presence of 20mM creatine; A. Complex I-supported respiration 
stimulated with pyruvate (5mM) and malate (4mM) at physiological (25µM) submaximal (300 
and 500µM) and maximal (5mM and 10mM) ADP concentrations (n=9-10). B. Complex I-
stimulated H2O2 emission stimulated in the presence of pyruvate (10mM) and malate (4mM) 
(n=9-10) C. H2O2 emission at a given ADP concentration expressed as a percent of maximal 
H2O2 emission. In the absence of creatine; D. Complex I-supported respiration stimulated with 
pyruvate (5mM) and malate (4mM) at physiological (25µM) submaximal (300 and 500µM) and 
maximal (5mM and 10mM) ADP concentrations (n=9-10). E. Complex I-stimulated H2O2 
emission stimulated in the presence of pyruvate (10mM) and malate (4mM) (n=8-10) F. H2O2 
emission at a given ADP concentration expressed as a percent of maximal H2O2 emission. 
Results are represented as means ± SEM. #p<0.05 saline vs. paclitaxel, $p<0.05 saline vs. 
vinblastine and &p<0.05 paclitaxel vs. vinblastine.  
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Supplemental figure 6-2. White gastrocnemius. PmFB mitochondrial bioenergetics 
following in-vivo muscle contraction. In the presence of 20mM creatine; A. Complex I-
supported respiration stimulated with pyruvate (5mM) and malate (4mM) at physiological 
(25µM) submaximal (300 and 500µM) and maximal (5mM and 10mM) ADP concentrations 
(n=9-10). B. Complex I-stimulated H2O2 emission stimulated in the presence of pyruvate 
(10mM) and malate (4mM) (n=9) C. H2O2 emission at a given ADP concentration expressed as a 
percent of maximal H2O2 emission. In the absence of creatine; D. Complex I-supported 
respiration stimulated with pyruvate (5mM) and malate (4mM) at physiological (25µM) 
submaximal (300 and 500µM) and maximal (5mM and 10mM) ADP concentrations (n=8-10). E. 
Complex I-stimulated H2O2 emission stimulated in the presence of pyruvate (10mM) and malate 
(4mM) (n=8-9) F. H2O2 emission at a given ADP concentration expressed as a percent of 
maximal H2O2 emission. Results are represented as means ± SEM. #p<0.05 saline vs. paclitaxel, 
$p<0.05 saline vs. vinblastine and &p<0.05 paclitaxel vs. vinblastine. 
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Supplemental figure 6-3. Calcium retention capacity following in-vivo contraction. A. 
Soleus and B. white gastrocnemius calcium retention capacity following 2-days of saline, 
paclitaxel or vinblastine injections and in-vivo muscle contractions. Results are expressed as 
means ± SEM. 
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Chapter 7 
Mitochondrial bioenergetic dysfunction in Duchenne muscular dystrophy is associated with 
microtubule disorganization in skeletal muscle  
 
This chapter is currently under first round of revisions in PLOS one PONE-D-19-09897. It is 
included in this thesis in the submitted format. 
 
 
 
Author contributions: SVR and MCH designed the study and collected data. SVR, analyzed data 
and drafted manuscript. SVR, MCH and CGRP approved and finalized submitted version. 
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Abstract 
In Duchenne muscular dystrophy, a lack of dystrophin leads to extensive muscle weakness and 
atrophy that is linked to cellular metabolic dysfunction and oxidative stress. This 
dystrophinopathy results in a loss of tethering between microtubules and the sarcolemma. 
Microtubules are also believed to regulate mitochondrial bioenergetics potentially by binding the 
outer mitochondrial membrane voltage dependent anion channel (VDAC) and influencing 
permeability to ADP/ATP cycling. The objective of this investigation was to determine if a lack 
of dystrophin causes microtubule disorganization concurrent with mitochondrial dysfunction in 
skeletal muscle, and whether this relationship is linked to altered binding of tubulin to VDAC. In 
extensor digitorum longus (EDL) muscle from 4-week old D2.mdx mice, microtubule 
disorganization was observed when probing for α-tubulin. This cytoskeletal disorder was 
associated with a reduced ability of ADP to attenuate H2O2 emission during impaired oxidative 
phosphorylation relative to wildtype controls. However, this was not associated with altered a-
tubulin-VDAC2 interactions. These findings reveal that microtubule disorganization in 
dystrophin-deficient EDL is associated with impaired ADP control of mitochondrial 
bioenergetics, and suggests that mechanisms alternative to a-tubulin’s regulation of VDAC2 
should be examined to understand how cytoskeletal disruption in the absence of dystrophin may 
cause metabolic dysfunctions in skeletal muscle. 
 
Key Words: Duchenne muscular dystrophy, mitochondrial dysfunction, VDAC, tubulin, 
cytoskeleton, skeletal muscle  
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Introduction 
In Duchenne muscular dystrophy (DMD), mutations in the X-linked gene dystrophin 
leads to progressive weakness in locomotor muscles. Occurring in 1:3500-5000 males, the 
absence of this cytoskeletal-sarcolemmal linker protein results in a compromised cell membrane 
that becomes damaged after contraction (5, 18). While persistent calcium influx has been linked 
to repeated cycles of fibre degeneration and regeneration (18), the loss of dystrophin has also 
been shown to cause disorganization of microtubules, specifically measured as a-tubulin, in 
extensor digitorum longus (EDL) muscle in C57Bl/10mdx mice, given dystrophin is a 
microtubule anchor (13, 111). However, the manner by which this altered microtubule network 
contributes to metabolic dysfunction remains unclear. 
Mitochondrial dysfunctions have also been identified in skeletal muscle, diaphragm and 
heart from mouse models of Duchenne muscular dystrophy (39, 53, 107, 154, 170). A specific 
impairment in the ability of ADP to attenuate mitochondrial H2O2 emission during impaired 
oxidative phosphorylation was identified in multiple muscles at 4 weeks of age in D2.mdx mice 
(52) The cause for this mitochondrial dysfunction was not identified, although multiple stressors 
inherent in the disease could be contributors. One possibility may be that mitochondrial 
dysfunctions arise from a disorganized cytoskeletal network that was reported previously in the 
C57Bl/10.mdx model (13, 111). Specifically, as mitochondria are known to bind to tubulin, a 
component of microtubules (20, 115, 127, 145), it is possible that altering microtubule 
architecture may influence mitochondrial bioenergetics. Indeed, we have previously shown that 
inducing microtubule disorganization in EDL with microtubule-stabilizing and destabilizing 
compounds alters ADP’s control of mitochondrial bioenergetics (116). As such, it seems 
plausible that the disorganized microtubule network in EDL from C57Bl/10.mdx mice (111) are 
  140	
related to mitochondrial dysfunctions observed in other muscles (39, 53, 154, 170). However, 
this relationship has not been definitively demonstrated within the same muscle of the same 
mouse model, nor has a potential mechanism been explored for how microtubules may alter 
mitochondrial function in this disorder.  
The first objective of the present study was to determine if disorganized microtubules are 
associated with a loss of ADP’s central control of mitochondrial bioenergetics in EDL muscle of 
D2.mdx mice. We have previously used this mouse model to explore mitochondrial dysfunction 
in other muscles but it has yet to be examined for microtubule disorganization (53). The second 
objective was to explore whether this potential relationship was related to altered tubulin-VDAC 
binding stemming from disorganized microtubules. Specific attention was given to a-tubulin 
considering it binds various isotypes of β-tubulin as an a/β heterodimer with the CTT tail of both 
components having affinity for VDAC (40, 126, 127, 161). VDAC2 was selected given 1) its 
deficiency results in embryonic death thereby demonstrating its importance (112), 2) it has been 
proposed that VDAC2 may uniquely regulate the more efficient creatine-dependent phosphate 
shuttling mechanism (4, 7, 86, 165) and 3) because we have previously shown that tubulin-
VDAC2 interactions are changed when microtubule organization is altered by paclitaxel (115). 
The results demonstrate a relationship between microtubule disorganization and impaired ADP 
control of H2O2 emission during oxidative phosphorylation. Contrary to the hypothesis, this 
dysfunction was not associated with altered a-tubulin-VDAC2 binding as detected by a 
proximity ligation approach (<30nm resolution) (82).  These findings highlight the association 
between microtubule networks and mitochondrial dysfunction in DMD suggesting an important 
role of cytoskeletal architecture in mediating metabolic dysfunction in this disease. The results 
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also challenge the model of tubulin regulation of VDAC permeability to ADP, although 
alternative mechanisms for future investigation are discussed. 
Materials and Methods 
Animal Care 
Briefly, male 4-week old D2.mdx mice (29) were used from a colony at York University 
originally established with breeding pairs from Jackson Laboratories (Bar Harbor, United 
States). Due to breeding issues, separate male wildtype (WT) DBA/2J mice were purchased from 
Jackson Laboratories and were acclimated for 72 hours before experiments were performed. All 
experiments and procedures were approved by the Animal Care Committee at York University 
(AUP approval number; 2016-18). Other muscles from these mice were used for separate 
manuscripts in preparation at the time of this submission. 
Preparation of permeabilized muscle fibre bundles (PmFB)  
All experimental procedures were completed as reported previously (104, 115). Mice 
were anesthetized with isoflurane and maintained at a 3-5% flow rate for the duration of the 
tissue harvest. EDL muscles were removed and quickly placed in BIOPS buffer containing 
(mM): 50 MES, 7.23 K2EGTA, 2.77 CaK2EGTA, 20 Imidazole, 0.5 Dithiothreitol (DTT), 20 
Taurine, 5.77 ATP, 15 phosphocreatine and 6.56 MgCl2•6H2O (pH 7.1) (53, 76, 104, 115, 156) 
on ice. Tissue was trimmed of fat and connective tissue in BIOPS buffer maintained at 4°C and 
separated using antimagnetic needle-tipped forceps under magnification (Zeiss 2000, Germany). 
Each 1-3 mg bundle was permeabilized with 40µg/ml saponin in BIOPS for 30 min. PmFB 
allocated for pyruvate-induced H2O2 emission were permeabilized in the presence of 35µM 2,4-
dinitrochlorobenzene (CDNB) to remove endogenous glutathione and permit detection of H2O2 
emission supported by the pyruvate dehydrogenase complex (36). Once permeabilized, PmFB 
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were washed for 15 min at 4°C in MiRO5 buffer containing (mM): 0.5 EGTA, 10 KH2PO4, 3 
MgCL2•6 H2O, 60 K-lactobionate, 20 hepes, 20 taurine, 110 sucrose and 1 mg/ml fatty acid free 
BSA (pH 7.1) for respiration experiments, buffer Z containing (mM): 105 K-MES, 30 KCl, 10 
K2PO4, 5 MgCl2•6 H2O, 1 EGTA and 5 mg/ml BSA (pH 7.1) for H2O2 emission assays and 
buffer Y containing (mM): 250 sucrose, 10 tris-HCl, 20 tris Base, 10 KH2PO4, and 0.5mg/ml 
BSA for 10 min and then again in buffer Y with 10µM blebbistatin to determine calcium 
retention capacity. All wash steps were completed at 4°C.  
Bioenergetic assays  
 PmFB were placed into a high-resolution respirometer (Oroboros Instruments, Corp. 
Innsbruck, Austria) with two different buffer conditions designed to model in-vivo metabolic 
control conditions; in the presence of 20mM creatine to promote cytoplasmic-mitochondrial 
cycling of  creatine/phosphocreatine (“phosphate shuttling”) through mitochondrial creatine 
kinase (mtCK) in the inner membrane space (4, 86, 156) and in the absence of creatine to 
promote ADP/ATP cycling. Approximately 350µM of O2 was added to each chamber with each 
experiment completed before reaching 150µM O2. Other technical details of respirometer 
settings and conditions are described previously (53, 75, 89, 104, 115, 156). Experiments were 
performed in the presence of 5µM blebbistatin to prevent ADP-induced muscle contraction  (53, 
104, 105) and normalized to wet weight. State 3 respiration was supported by 5mM pyruvate + 
2mM malate (NADH, complex I) followed by ADP titrations at 25, 100, 500 and 5000µM ADP. 
10µM cytochrome c was added to test for intactness of the outer mitochondrial membrane, with 
all responses exhibiting <15% increase in respiration. 20mM succinate (FADH2) was then added 
for complex II-supported respiration.  
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PmFB were placed into a quartz cuvette containing 1ml of Buffer Z containing 10µM 
Amplex UltraRed, 0.5U/ml horse radish peroxidase, 40U/ml Cu/Zn-SOD1 and 5µM BLEB to 
measure H2O2 emission. Experiments were completed fluorometrically (QuantaMaster 40, 
HORIBA Scientific, Edison, NJ, USA) with continuous stirring and maintained at 37°C. 
Pyruvate (10mM)/malate (4mM) were used to stimulate H2O2 emission at complex I (NADH) 
followed by ADP titrations at 25, 100 and 500µM ADP to attenuate H2O2 emission during 
oxidative phosphorylation. Upon completion, bundles were blotted dry and lyophilized to obtain 
a dry weight for normalization as previously described (53, 89, 115). 
Calcium retention capacity (CRC) was performed fluorometrically (QuantaMaster 80, 
HORIBA Scientific, Edison, NJ, USA) with a separate batch of PmFB as previously described 
(6, 35, 53) with the addition of 5mM ADP to mimic physiological conditions.  PmFB were 
placed into a quartz cuvette containing Calcium Green-5N (Invitrogen) dissolved in Buffer Y 
(35) where an initial 8nm CaCl2 pulse was added followed by 4nm CaCl2 pulses until 
mitochondrial permeability transition pore opening was evident. Two 0.5mM pulses of CaCl2 
were then added to establish maximum fluorescence by saturating the fluorophore. Similarly to 
H2O2 bundles, PmFB were lyophilized to obtain dry weights for normalization.  
Single fibre isolation, immunofluorescent staining and proximity ligation assay 
A separate set of D2.mdx and control DBJ/2J mice (n=8-10) were used for 
immunofluorescent experiments as described previously (115). Briefly, EDL single fibres were 
isolated with 0.2% collagenase type 4 (Worthington, LLS004188, Lakewood, NJ) for 70 min 
(maintained at 37°C) and triturated until viable single fibres were released. Fibres were fixed 
with 4% paraformaldehyde for 10 min, permeabilized with 0.01% triton-X100 for 10 min and 
then blocked with 5% BSA PBS++ for 60 min, all at room temperature. Samples were then 
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incubated with α-tubulin (1:1000 Sigma, T6199) for 4 hours at room temperature followed by 
VDAC2 overnight at 4°C (1:250, Santa Cruz, 32059). Half of the fibres were used for detection 
of α-tubulin following incubation with the secondary antibody Alexa Flour 488 (Invitrogen, 
A21121).  
The remaining fibres retained following primary antibody incubations were used for 
determination of protein-protein interaction by proximity ligation assay. Fibres were probed 
according to manufacturer’s instructions with some modifications described previously (115). 
Briefly, proximity ligation assay anti-goat minus (Sigma, DUO92001) and anti-mouse plus 
(Sigma, DUO92006) probes were used to detect primary antibodies used above. Single fibres 
were incubated with anti-goat minus and anti-mouse plus probes (1:5 dilution) for 1 hour prior to 
a treatment with the detection reagents red (Sigma, DUO92008) consisting of a 30 min 
incubation with the provided ligase to splice the oligonucleotide ends of the probes together, and 
a 1 hour 40 min incubation with the provided polymerase to read and amplify the signal on the 
resulting DNA strand. All incubations were completed at 37°C. Fibres were coated in anti-fade 
mounting medium and covered with a coverslip. 
Image capture and quantitation  
A Zeiss laser scanning confocal microscope 700 (Carl Zeiss) was used to acquire images 
with a 63X oil immersion objective with the pin hole set to 1AU capturing 8-10 stacks with a z-
step of 0.32 µm at 3 different points along the fibre. To detect a-tubulin on 
immunohistochemically stained samples, fibres were excited at 488nm for α-tubulin. Samples 
were excited at 594nm to capture α-tubulin-VDAC2 interactions. Images were analyzed using 
Imaris image quantifying software (Bitplane). 
Western blotting 
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Western blotting procedures were completed as previously reported (51, 53) using rodent 
OXPHOS Cocktail, ab110411, Abcam, Cambridge, UK, 1:250 dilution), VDAC2 (Santa-Cruz, 
32059, Dallas, TX, 1:1000 dilution) and adenine nucleotide translocase 1 (ANT1, ab180715, 
Abcam, 1:1000 dilution) antibodies.  
Statistics 
The ROUT test was used to omit outliers followed by the D’Agostino-Pearson omnibus 
normality test to verify that all data followed a normal distribution. Statistical differences were 
assessed by two-way ANOVA for ADP-stimulated respiration and attenuation of H2O2 emission 
followed by Bonferroni multiple comparison post-hoc analysis when appropriate. Differences in 
glutamate and succinate stimulated respiration, H2O2 emission in the absence of ADP and CRC 
were determined through a student’s un-paired t-test (GraphPad Prism 7, La Jolla, CA). Results 
are reported as mean ± SEM with significance accepted at p< 0.05. 
Results 
Altered microtubule organization is associated with impaired ADP-control of bioenergetics in 
D2.mdx mice 
 Confocal microscopy confirmed the disorganization of microtubule architecture in EDL 
from D2.mdx compared to WT as was reported previously in C57.Bl/10mdx (Figure 7-1)(13, 
111). As microtubules have been proposed to regulate ADP permeability through VDAC, we 
next determined the ability of ADP to stimulate respiration and lower H2O2 emission during 
oxidative phosphorylation. In the presence of creatine-supported phosphate shuttling (4, 43, 86, 
165) complex I-supported respiration (NADH from pyruvate) was impaired in D2.mdx vs WT at 
500µM (-43%, p=0.0008) and 5mM ADP (-38%, p<0.0001) with a main effect observed across 
groups (p<0.0001) (Figure 7-2A), as was combined complex I and II (additional FADH2 from 
  146	
succinate) (p=0.0002) (Figure 2B). Similar results were obtained in the absence of creatine in the 
media – a condition that promotes ADP/ATP cycling without the more efficient mitochondrial 
creatine kinase-dependent phosphate shuttling (4, 42, 86, 165) - for complex I-supported 
respiration at 5mM (-31%, p<0.0001) and 30mM ADP (-30% p<0.0001) with a main effect 
observed across groups (p<0.0001) (Supplemental figure 7-1A) in addition to combined complex 
I and II respiration (-48%, p=0.001) (Supplemental Figure 7-1B).  
 
 
Figure 7-1. Microtubule organization. Confocal microscopy of a-tubulin-stained single EDL 
fibres from WT and D2.mdx mice (n=5-8). Scale bar, 10µm. 
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Figure7-2. Mitochondrial bioenergetics in EDL PmFB. ADP-stimulated respiration was 
initially supported by complex I (NADH from 5mM pyruvate/4mM malate) in the presence of 
creatine (n=12) (A) followed by complex II (FADH2 from 20mM succinate) (n=11-12) (B). 
H2O2 emission was stimulated at complex I (NADH from 10mM pyruvate/4mM malate) in the 
presence of creatine (n=12) (C) followed by an ADP titration (n=11-12) (D). Calcium retention 
capacity (n=10) (E). Results are reported as mean ± SEM, (*p<0.05).  
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Supplemental figure 7-1. Mitochondrial bioenergetics in the absence of creatine in EDL 
PmFB. ADP-stimulated respiration supported by complex I (NADH from 5mM pyruvate/4mM 
malate) (n=12) (A) followed by complex II (FADH2 from 20mM succinate) (n=12) (B). H2O2 
emission was stimulated at complex I (NADH from 10mM pyruvate/4mM malate) (n=11-12) (C) 
followed by an ADP titration (n=12) (D). Results are reported as mean ± SEM, (*p<0.05). 
 
Maximal H2O2 emission during State II/uncoupled respiration (no ADP) was similar 
between D2.mdx and WT in the presence (p=0.39) (Figure 7-2C) and absence of creatine 
(p=0.97) (Supplemental figure 7-1C). The ability of ADP to attenuate H2O2 emission during 
oxidative phosphorylation was impaired (main effect, p<0.0001) (Figure 7-2D). This impairment 
in ADP was not observed in the absence of creatine in the media (Supplemental figure 7-1D). 
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These findings demonstrate a specific impairment in the ability of creatine to improve ADP’s 
control of bioenergetics as reported previously in dystrophin-deficient muscle (51, 53). 
 We next employed a calcium retention capacity assay to determine whether dystrophic 
muscle is more susceptible to mPTP formation (which is believed to involve VDAC) (128). 
However, no differences were observed between WT and D2.mdx EDL (p=0.13) (Figure 7-2E).  
Reduced ANT1 protein content, but not a-tubulin-VDAC2 interactions, may contribute to 
mitochondrial ADP-impairments in D2.mdx mice  
 A proximity ligation assay was used to determine whether a-tubulin-VDAC2 interactions 
were different between D2.mdx and WT (115, 127, 136). However, similar protein-protein 
interactions were found in D2.mdx and WT mice (p=0.83) (Figure 7-3). No changes were 
observed in specific subunits of complexes I (p=0.54), II (p=0.12), III (p=0.70), IV (p=0.50) or V 
(p=0.48) nor their sum (p=0.45) (Figure 4A). VDAC2 (p=0.10) (Figure 7-4B) protein content 
was similar between WT and D2.mdx while the inner mitochondrial membrane transport protein 
adenine nucleotide translocase 1 (ANT1) was significantly reduced in D2.mdx compared to WT 
(-27%, p=0.03) (Figure 7-4C). 
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Figure 7-3. a-tubulin – VDAC2 interactions in single EDL fibres. Schematic representing the 
model of a-tubulin-VDAC2 interaction (A). Confocal microscopy images (B) and graphical 
depiction of the proximity ligation assay of a-tubulin-VDAC2 (n=8) (C). Scale bar, 10µm. 
Results are reported as mean ± SEM. 
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Figure 7-4. Protein content of mitochondrial proteins. Integrated densitometry for subunits of 
electron transport chain complexes I-V (OXPHOS; n=10-11), (A) VDAC2 (n=10) (B) and ANT1 
(n=9-10) (C) with representative blots. Results are reported as mean ± SEM, (*p<0.05).   
 
Discussion 
In D2.mdx mice, we demonstrate that microtubule disorganization in EDL muscle is 
associated with a reduced ability of ADP to stimulate mitochondrial oxidative phosphorylation 
and attenuate H2O2 emission. However, contrary to the hypothesis, there were no differences in 
the degree of a-tubulin-VDAC2 interactions assessed by proximity ligation assay. These 
findings demonstrate that microtubule disorganization and mitochondrial dysfunction occur 
concurrently in dystrophin-deficient muscle, but that the tubulin-VDAC model of bioenergetic 
0.00
0.05
0.10
0.15
O
XP
H
O
S 
Pr
ot
ei
n 
de
ns
ity
/
to
ta
l p
ro
te
in
 (A
.U
)
WT
D2.mdx
CI CII CIII CIV CV SUM
WT D2.mdx0.00
0.01
0.02
0.03
0.04
VD
AC
2 
Pr
ot
ei
n 
de
ns
ity
/ 
to
ta
l p
ro
te
in
 (A
.U
)
WT D2.mdx0.00
0.01
0.02
0.03
AN
T1
 
Pr
ot
ei
n 
de
ns
ity
/ 
to
ta
l P
ro
te
in
 (A
.U
) *
V-ATP5A - 55KDa
III-UQCRC2 - 48KDa
IV-MTCO1 - 40KDa
II-SDHB - 30KDa
I-NDUFB8 - 20KDa
VDAC2 - 32KDa
ANT1 - 33KDa
A
B C
D2.mdxWT
  152	
control may not represent a causal link between these two phenomena leaving the possibility that 
other mechanisms may exist. 
Model of tubulin regulation of VDAC permeability 
Impaired mitochondrial bioenergetics is thought to contribute to muscle weakness in 
Duchenne muscular dystrophy (39, 51, 53). However, the specific link between dystrophin 
deficiency and mitochondrial dysfunction has not been fully resolved. While Ca2+ stress has been 
proposed as a primary cause of swollen mitochondria and impaired oxidative phosphorylation in 
mdx mice (170), separate observations of altered microtubule networks (13, 66, 111) were also 
linked to disrupted cytosolic NADPH oxidase-induced ROS and Ca2+ signaling (66). An 
intriguing possibility of a mitochondrial link to microtubule disorganization emerges when 
considering the separate discoveries that tubulin components of microtubules can directly bind to 
VDAC on the outer mitochondrial membrane and decrease its permeability to ADP/ATP cycling 
(4, 42, 124, 126, 127). Considering that pharmacological alterations of microtubule networks 
changes tubulin-VDAC interactions and ADP-dependent bioenergetics (115), it seems plausible 
that the distinct observations of disorganized microtubules and mitochondrial dysfunctions in 
D2.mdx muscle may be due to altered microtubule-VDAC interactions. Such an observation 
would implicate microtubule disorganization in D2.mdx mice as a modulator of mitochondrial 
dysfunction in addition to the cytosolic stressors noted previously (66).   
However, the present findings demonstrate no differences in the degree of a-tubulin-
VDAC2 interactions despite the association between microtubule disorganization and 
mitochondrial dysfunction. Nevertheless, this observation does not rule out the possibility of 
other tubulin-VDAC interaction combinations. For example, while the CTT tail of a-tubulin has 
been shown to block the pore of VDAC, there is a greater affinity of the CTT tail on certain β 
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isotypes, particularly βIII and VDAC1 (126). In addition, it has been suggested that free βII 
tubulin binds VDAC in muscle – independent of heterodimeric tubulin – such that this free pool 
may be a distinct regulator of ADP/ATP cycling through VDAC (161). Lastly, the affinity of 
tubulin binding can be modulated through post translational modifications (145) such as 
phosphorylation (146) or altered mitochondrial membrane lipid composition (125) which 
highlights the complexity of the potential regulation of this pathway. The present findings 
warrant additional investigation into these alternative possibilities of how microtubule network 
dynamics may change the regulation of ADP-control of bioenergetics through VDAC. 
This study does not rule out the possibility that VDAC1 or VDAC3 are differentially 
affected by disorganized microtubule networks in D2.mdx muscle. However, it has been 
suggested that only VDAC2 regulates the effect of creatine on respiration through phosphate 
shuttling (7), as assessed in the present study, possibly by being functionally linked to 
mitochondrial creatine kinase as well as tubulin in a super-complex (42). The lethality of 
VDAC2 knockout mice also suggests its importance in regulating mitochondrial bioenergetics 
(112). Nevertheless, the lack of change in α-tubulin-VDAC2 in the present investigation 
warrants further study of VDAC1 and 3 interactions with tubulin isotypes in mdx muscle given 
their influence on respiration, particularly in the absence of creatine(112).  
Lastly, an additional relationship was found between reduced ANT1 content and 
impaired ADP-dependent mitochondrial bioenergetics. As ANT1 is found on the inner 
mitochondrial membrane, it is not thought to bind tubulin directly but may still be part of a larger 
complex with mitochondrial creatine kinase and VDAC (4). Reduced ANT1 may be a distinct 
contributor to impaired ADP-control of bioenergetics in EDL muscle similar to the reductions 
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previously reported in white gastrocnemius and quadriceps in D2.mdx mice at the same age of 4 
weeks (51, 53).  
In conclusion, the present investigation demonstrates that microtubule disorganization is 
associated with mitochondrial dysfunction within the same muscle of dystrophin-deficient mice, 
but this may not be mediated by altered α-tubulin-VDAC2 interactions. Additional research is 
warranted given the proposed model of tubulin-VDAC regulation of bioenergetics is complex 
and captures the role of phosphate exchange in the form of creatine-dependent phosphate 
shuttling through mitochondrial creatine kinase as well as creatine-independent ADP/ATP 
cycling, both of which may depend on the specific VDAC isoform interacting with specific 
tubulin isotypes. The association between microtubule organization and mitochondrial 
dysfunction reported herein serves as a foundation for extensive exploration between these 
various combinations to determine if microtubules truly ‘link’ dystrophin deficiency to 
mitochondrial bioenergetics. 
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Supplemental data – not included in publication 
 
Supplemental Figure 7-2. Mitochondrial bioenergetics in WG PmFB. ADP-stimulated respiration supported by complex I (NADH 
from 5mM pyruvate/4mM malate) presence (A) and absence (E) of creatine (n=11-12) followed by complex II (FADH2 from 20mM 
succinate) in the presence (B) and absence (F) of creatine (n=11-12). H2O2 emission was stimulated at complex I (NADH from 
10mM pyruvate/4mM malate) in the presence (C) and absence (G) of creatine (n=10-12) followed by an ADP titration (n=11-12). 
Results are reported as mean ± SEM, (*p<0.05).  
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Supplemental Figure 7-3. Calcium retention capacity. (n=10-12) Results are reported as mean 
± SEM. 
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Chapter 8 
 
8.1 General Discussion 
 
 Emerging research posits that microtubules can regulate mitochondrial bioenergetics. 
This model is intriguing given it implicates the cytoskeleton as a direct regulator of energy 
homeostasis, oxidative stress and apoptotic pathways – all of which are linked to mitochondria. 
The application of this model is potentially wide spread given many disorders demonstrate 
considerable microtubule dynamics and a range of mitochondrial dysfunctions. Given the 
importance of mitochondria in supporting the wide range of energy demands and redox-
dependent processes, this model may represent a new paradigm by which muscle function can be 
influenced through cytoskeletal-mitochondrial dynamics. The purpose of this thesis was to 
determine the degree to which manipulating microtubule networks alter mitochondrial function 
through the proposed tubulin-VDAC model of bioenergetic regulation. 
Overall, the observations of this thesis suggest that the tubulin-VDAC model does not 
consistently predict the effect of altering microtubule organization on mitochondrial 
bioenergetics. Specifically, microtubule targeted chemotherapy significantly perturbs cellular 
microtubule organization causing a host of side effects including, mitochondrial dysfunction and 
muscle weakness (65, 74, 130, 169). Similarly, the lack of dystrophin in skeletal muscles from 
the mouse model of Duchenne muscular dystrophy results with a myriad of cellular impairments 
such as, mitochondrial dysfunction and sever muscle weakness (39, 51, 52, 60). These models 
allowed the examination of the tubulin-VDAC interaction through exogenous (the administration 
of paclitaxel and vinblastine) and endogenous/genetic (D2.mdx mouse) microtubule 
manipulations; uncovering the contribution of the tubulin-VDAC interaction to muscle 
mitochondria bioenergetics and skeletal muscle function. A summary of ADP-dependent 
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mitochondrial bioenergetics in the presence (Table 8-1) and absence (Table 8-2) of creatine can 
be found below. 
Partially in line with our hypothesis, the chemotherapy model of microtubule stabilization 
with paclitaxel increased a- and bII-tubulin interaction with VDAC2 in isolated EDL single 
fibers, limiting the ability of ADP to attenuate H2O2 emission in an in-vitro model without 
limiting ADP-dependent respiration. In-vitro microtubule destabilization with vinblastine in the 
EDL does not support the tubulin-VDAC model. The amount of tubulin interacting with VDAC 
was unchanged, yet still increased respiration and impaired the ability of ADP to attenuate H2O2 
emission. In cardiac tissues, in-vitro incubations with paclitaxel and vinblastine significantly 
reduced ADP-stimulated respiration and attenuation of H2O2 emission in the absence of a change 
in tubulin-VDAC interaction. These results were mirrored in the absence of creatine but not in 
the presence of creatine when analyzed in-vivo. 2-days of paclitaxel injections increased a- and 
bII-tubulin interaction with VDAC2 in soleus muscle without altering ADP-dependent 
bioenergetics. Vinblastine impaired the ability of ADP to attenuate H2O2 emission in both 
creatine dependent and independent conditions following 2-days of in-vivo injections. WG 
PmFB also yielded controversial results where respiration was only impaired following 
paclitaxel in the absence of creatine. Lastly, the Duchene muscular dystrophy model of known 
microtubule disorganization and severe mitochondrial dysfunction yielded no change in a-
tubulin in the presence of impaired mitochondrial bioenergetics. Overall, these results do not 
fully fit the speculated model of tubulin regulation of VDAC permeability. Below, this thesis 
attempts to consolidate these findings with the current literature to broaden the understanding of 
the tubulin-VDAC model. 
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Table 8-1. Summary of changes to ADP-dependent mitochondrial bioenergetics in the presence of creatine under various 
conditions of microtubule organization. 
 
^Proximity Ligation assay could not be performed in this tissue due to technical limitations as outlined in the respective chapters. 
*Note: Refer to Chapter 3 – Methodological considerations to delineate between tissue distribution throughout studies 
 
 
  
    ADP-dependent mitochondrial dysfunction 
Chapter Approach Tissue 
Tubulin-VDAC interactions Respiration H2O2 + ADP Relationship between tubulin-VDAC and 
mitochondrial 
function 
a-tubulin- 
VDAC2 
bII-tubulin- 
VDAC2 Pac Vin Pac Vin 
4 In-vitro glycolytic EDL Ý Ý Û Ý ß ß 
ü paclitaxel 
X vinblastine 
5 
In-vitro and 
in-vivo 
oxidative  
Heart 
(in-
vitro) 
Û Û ß ß ß ß X Paclitaxel X vinblastine 
Heart 
(in-vivo) N/A
^ N/A^ Û Û Û Û N/A 
Soleus 
(in-
vitro) 
N/A^ N/A^ Û ß Û Û N/A^ 
6 
In-vivo 
glycolytic vs. 
oxidative  
Soleus Û Ý Û Û Û ß X paclitaxel X vinblastine 
WG N/A^ N/A^ Û Û Û Û N/A^ 
7 
In-vivo 
glycolytic 
(D2.mdx) 
EDL Û Û ß ß No relationship 
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Table 8-2. Summary of changes to ADP-dependent mitochondrial bioenergetics in the absence of creatine under various 
conditions of microtubule organization. 
 
^Proximity Ligation assay could not be performed in this tissue due to technical limitations as outlined in the respective chapters. 
Note: Refer to Chapter 3 – Methodological considerations to delineate between tissue distribution throughout studies 
 
 
 
 
    ADP-dependent mitochondrial dysfunction 
Chapter Approach Tissue 
Tubulin-VDAC interactions Respiration H2O2 + ADP Relationship between tubulin-VDAC and 
mitochondrial 
function 
a-tubulin- 
VDAC2 
bII-tubulin- 
VDAC2 Pac Vin Pac Vin 
4 In-vitro glycolytic EDL N/A
^ N/A^ N/A^ N/A^ N/A^ N/A^ ü paclitaxel X vinblastine 
5 
In-vitro and 
in-vivo 
oxidative  
Heart 
(in-
vitro) 
Û Û N/A^ N/A^ N/A^ N/A^ X Paclitaxel X vinblastine 
Heart 
(in-vivo) N/A
^ N/A^ ß Û ß ß N/A^ 
Soleus 
(in-
vitro) 
N/A^ N/A N/A^ N/A^ N/A^ N/A^ N/A^ 
6 
In-vivo 
glycolytic vs. 
oxidative  
Soleus Û Û Ý Ý Û ß X paclitaxel X vinblastine 
WG N/A^ N/A^ ß Û Û Û N/A^ 
7 
In-vivo 
glycolytic 
(D2.mdx) 
EDL Û Û ß Û No relationship 
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8.2 Conclusions on tubulin regulation of VDAC permeability through microtubule manipulation 
 
 The work presented in this thesis is the first to determine the interaction between both a- 
and bII-tubulin and VDAC2 in cardiac and skeletal muscles. The current literature analyzing this 
interaction has been limited through methodology, where either the addition or removal of 
tubulin from cardiomyocytes and isolated mitochondria respectively, were the means of 
manipulating this potential interaction. This thesis challenges the current model of tubulin-
VDAC interactions through in-vitro and in-vivo microtubule manipulation with microtubule 
stabilizing and destabilizing compounds, in an attempt to determine the resulting effect on ADP-
dependent mitochondrial bioenergetics. While we are able to draw some conclusions from the 
presented work, no definitive conclusions can be made. This thesis encompassed in-vivo and in-
vitro work (mimicking creatine dependent and independent conditions) in an attempt to mirror 
physiological conditions, yielding some contradictive results. As such, to speak to the current 
model of tubulin-VDAC interactions, this discussion will primarily focus on ADP-stimulated 
bioenergetics.  
 In both glycolytic EDL and oxidative soleus muscles, in-vitro and in-vivo microtubule 
stabilization with paclitaxel resulted with an increased tubulin-VDAC2 interaction. In glycolytic 
tissues, this increased interaction limits the ability of ADP to attenuate H2O2 emission while also 
reducing ADP-stimulated respiration in a creatine independent manner. In addition, the increased 
tubulin-VDAC2 interaction uncovered an increased H2O2 emission potential in the absence of 
creatine, surprisingly, not effecting any ADP-dependent bioenergetic pathways in the soleus 
muscle. These results are in partial support of the hypotheses made in chapter 3, whereby an 
increased interaction limits the ability of ADP to enter the mitochondria to either stimulate 
respiration or attenuate H2O2 emission. While these findings are intriguing, it raises the question 
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of the importance of experimental model selection and the differences in tissue types. Thus far, 
we can conclude that promoting microtubule stabilization through increased polymerization 
increases the amount of interactions between tubulin and VDAC2. This increased interaction 
may be altering ADP-dependent mitochondrial bioenergetics in EDL and soleus muscles but 
does not fully support the current model of tubulin regulation of VDAC permeability. 
Tubulin exists in a state of dynamic stability where free tubulin should be readily 
available from newly depolymerized microtubules for polymerizing microtubules. To our 
knowledge, the architectural organization of the various tubulin isoforms has not been 
confirmed. a-tubulin is known to form an orthogonal network pattern often represented as what 
microtubules should look like in the literature, but the various tubulin isoforms are not 
represented, limiting the conclusions that can be drawn from microtubule manipulations. 
Confocal microscopy images of immunohistochemically stained bII-tubulin presented in chapter 
4 show no apparent change in organization following stabilization and destabilization but 
resulted with an increased a- and bII-tubulin-VDAC2 interaction. Perhaps there is a 
conformational or structural change to the tubulin molecule in response to paclitaxel or 
vinblastine treatment that may be mediating the change in interaction observed. This work 
highlights the need to further understand the function of microtubules and tubulin in skeletal 
muscles. 
8.3 Modeling in-vivo conditions with the absence and presence of creatine 
 
The fundamental model of ADP/ATP flux through the mitochondria has been accepted to 
be through the efficient creatine dependent, and inefficient creatine independent pathways 
outlined in chapter 2 (Figure 2-3), where the transport of ADP/ATP and PCr/Cr is accepted to 
occur through VDAC. In chapter 5 and 6, the majority of ADP-dependent bioenergetic 
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impairments in response to paclitaxel and vinblastine occurred in the absence of creatine. This 
was particularly perplexing as this system is speculated to only contribute to 20% of energy 
exchange (4, 86, 165, 166). Perhaps, in an attempt to preserve efficient ADP/ATP transfer, 
muscle fibers allow the inefficient pathway to become compromised in the event of cytotoxicity 
preserving the pathway that the fiber is more reliant on. This may contribute to the measured 
impairments through the creatine independent pathway. The permeability of VDAC has been 
historically measured through reconstructed planar lipid membranes embedded with VDAC, 
where changes in membrane potential can mediate cation/anion selectivity (99, 123). This thesis 
has focused only on the physical interaction between tubulin and VDAC2 measured through the 
proximity ligation assay but does not discount the possibility that a change in the electrochemical 
gradient may have occurred as a result of microtubule stabilization and destabilization limiting 
the ability of ADP to diffuse through VDAC. An attempt was made to determine mitochondrial 
membrane potential in PmFB but our laboratory determined that the assay was not reliable when 
assessing membrane potential with the common tetraphenylophosphonium (TPP+) probe. This 
method is currently optimized for isolated mitochondria and therefore pose a limitation as our 
aims are to maintain the intracellular integrity of the cell. Future studies could consider imaging 
live cells with intact microtubule architecture using fluorescent membrane potential probes to 
contribute to the elucidation of the current results.  
8.4 Cumulative understanding of the tubulin-VDAC interaction and regulation of ADP 
permeability.  
 
 The current understanding of the tubulin-VDAC interaction has been developed by 
embedding VDAC to planar lipid membranes followed by the addition of tubulin (127, 145, 
146). While this method has proven to be very useful in uncovering the physiological functions 
of VDAC and tubulin, in-vivo conditions differ significantly. Specifically, cardiac and skeletal 
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muscle contains the entire cytoskeletal network including microtubules, intermediate filaments, 
thick and thin filaments, costamers, intercalated discs (cardiac tissue), in addition to the 
abundance of proteins and organelles which may play a role in the overall metabolism of the cell. 
These features are not captured in the reconstructed planar membrane models. In addition, 
microtubules exist in a state of dynamic stability, where tubulin is constantly polymerizing and 
depolymerizing. It is important to consider the environment cells are in, in order to make 
accurate interpretations of what in-vivo conditions may be like. 
Another limitation of the reconstructed planar membrane model is that tubulin is studied 
in the absence of MAP and EB binding proteins which may not truly capture how tubulin-VDAC 
interaction may be occurring under physiological conditions. This thesis aimed to capture the 
tubulin-VDAC interaction in its “natural environment” through paraformaldehyde fixation, 
securing all intracellular proteins and organelles in place, capturing the interaction under 
different physiological conditions (microtubule stabilization and destabilization). In addition, the 
use of PmFBs also maintains the integrity of the intracellular organelles which, in theory, should 
maintain the tubulin-VDAC interaction following microtubule stabilization and destabilization. 
This allows the accurate measurement of mitochondrial bioenergetics with the majority of the 
cell intact. Unfortunately, this method permeabilizes the cell membrane, where the cytosol is 
washed out. The cytosol may contain the free-tubulin pool, GTP/GDP, MAP and the EB family 
of proteins that would subsequently be washed out with the cytosol, placing a limitation to our 
interpretations. Concomitantly, this may be beneficial as during the incubation phase with 
paclitaxel and vinblastine, as all proteins required to maintain dynamic stability are present. The 
subsequent wash steps would then “freeze” the intracellular conditions so that when measured, 
microtubules would maintain a stabilized or destabilized condition during bioenergetic assays.  
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Another method of assessing the tubulin-VDAC interaction has been through the addition 
of tubulin to isolated mitochondria or through the removal of tubulin from cardiomyocytes to 
determine changes in ADP-stimulated respiration (40, 127, 135). While these two methods show 
a clear relationship between ADP-stimulated respiration and the presence of tubulin, some 
limitations exist. Homogenates undergo a series of differential centrifugation steps, breaking the 
microtubule network, reforming mitochondria into micelles that do not fully mimic in-vivo 
mitochondrial ultrastructure. In cardiomyocytes, the removal of bII-tubulin with trypsin does not 
discount the possibility of other tubulin isoforms from being removed in the process. The 
dynamic stability of microtubules and intricate organization of mitochondria poses 
methodological difficulties in the measurement of the tubulin-VDAC interaction. Research thus 
far has completed great strides in furthering the understanding of this novel interaction and its 
contribution to mitochondrial bioenergetics but further work is still required to fully deduce the 
mechanism.  
8.5 The effect of cytotoxic drugs on mitochondrial bioenergetics 
 
 This thesis demonstrates that paclitaxel increases both a- and bII-tubulin interaction with 
VDAC2 which correlates with impaired H2O2 kinetics when measured in-vitro in PmFB from 
EDL muscles. An increased a- and bII-tubulin interaction was also measured in rats injected 
with paclitaxel, soleus PmFB resulting with an increased voluntary running and hind-limb torque 
frequency coupled with increased calcium retention capacity and activation of caspase 3. 
Portions of these in-vitro and in-vivo studies partially support the hypothesis stating that 
increased microtubule stabilization would increase the tubulin-VDAC interaction but the effect 
on ADP-stimulated bioenergetics appears to be selective in EDL and not applicable in soleus 
muscles. Instead, in soleus PmFBs, calcium retention capacity is increased and surprisingly, 
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caspase 3 activity is also increased suggesting the induction of apoptosis. As mentioned above, 
paclitaxel has been shown to induce apoptosis through alternative mechanisms. Calcium 
retention capacity was increased which, in theory would suggest an inhibition on apoptosis but 
the increased caspase activation suggests otherwise. Perhaps paclitaxel is disrupting normal 
mitochondrial activity by preventing calcium induced mPTP formation while still initiating 
apoptosis through caspase 3 activation. Due to tissue limitations, we were not able to measure 
caspase 9 activity which may have shed light on whether caspase 3 was initiated through the 
release of cytochrome c oxidase. These divergent data indicate that paclitaxel may be inducing 
apoptosis through an alternative mechanism in oxidative skeletal muscles when compared to 
glycolytic tissues.  
Results from the glycolytic EDL and WG muscles appear follow somewhat of a similar 
response to paclitaxel treatment. This is exemplified in the ADP-dependent data collected. The 
ability of ADP to attenuate H2O2 emission in the EDL muscle was impaired while in the 
absence of creatine, there was significantly lower respiration when compared to control in the 
WG muscle. Due to time and cost of running the PLA assay, this measure was not completed in 
WG embedded tissues which limits the conclusions drawn regarding the tubulin-VDAC model. 
Both glycolytic EDL and WG PmFBs treated with paclitaxel did not elicit a response to calcium 
retention capacity or caspase activation. These data support the idea that the tubulin-VDAC 
model may illicit different responses in different skeletal muscle types.  
 In-vitro and in-vivo treatment with the microtubule destabilizer vinblastine did not elicit a 
change in both a- and bII-tubulin interaction with VDAC2. Interestingly, in the absence of a 
change in tubulin-VDAC interaction vinblastine treatment caused some mitochondrial 
bioenergetic changes. In the soleus muscles vinblastine produced divergent results when 
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comparing in-vitro and in-vivo approaches. ADP stimulated respiration was significantly 
decreased in-vitro while in-vivo this was statistically significantly increased. Similarly, H2O2 
kinetics were similar to control under in-vitro conditions but in-vivo, H2O2 kinetics were 
significantly impaired in the presence and absence of creatine. This trend was mirrored in the 
CRC data where in-vitro resulted with trends for decreased CRC while in-vivo yielded increased 
CRC. This divergent data provides further evidence that the tubulin-VDAC model may not be as 
clear cut as once speculated. Further work in an oxidative tissue is required to understand the 
role of the tubulin-VDAC model in bioenergetic regulation.  
  In EDL PmFBs, vinblastine increased respiration while also impairing H2O2 kinetics and 
decreased calcium retention capacity. This was not mirrored under in-vivo conditions in the 
glycolytic WG muscle where vinblastine had no effect on ADP-stimulated respiration and H2O2 
kinetics but appeared to limit the activation of apoptosis through increased CRC and decreased 
caspase activation. Here, we can speculate that vinblastine is preventing the induction of 
apoptosis as the mitochondrial may be attempting to “remove” its dysfunctional intracellular 
components to maintain overall functional mitochondria.  Altogether, these data demonstrate that 
although microtubule destabilization with vinblastine did not alter the a- and bII-tubulin 
interaction, it may have 1) altered another tubulin-VDAC isoform interaction not measured in the 
current thesis, 2) caused a post-translational modification to either a- or bII-tubulin not 
measured or 3) altered mitochondrial membrane potential changing the ion selectivity 
independent of any tubulin involvement.  
 Chapter 5 explores both in-vivo and in-vitro effects of microtubule stabilization and 
destabilization in cardiac tissue yielding a host of ADP-dependent bioenergetic impairments 
independent of any change in both a- and bII-tubulin interaction. Here, both paclitaxel and 
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vinblastine significantly reduced ADP-stimulated respiration, reduced H2O2 emission potential 
while also reducing the ability of ADP to attenuate H2O2 emission. Mitochondrial bioenergetic 
impairments were not related with increased susceptibility to apoptosis induction as there was no 
change in calcium retention capacity or caspase activation in both in-vitro and in-vivo models. 
Similarly to soleus PmFBs, these results suggest that there may be other isoform combinations of 
tubulin and VDAC that may be limiting ADP diffusion. Paclitaxel and vinblastine are known to 
have a dose dependent effect where lower doses have shown to have beneficial effects to injured 
cardiac tissues while higher doses can activate various apoptotic pathways (28, 117, 168, 175). 
The in-vitro concentrations used in this thesis were in line with concentrations previously 
published (74, 101). To our knowledge, this thesis is one of the first to explore changes ADP-
dependent mitochondrial bioenergetics following microtubule manipulation with cytotoxic 
compounds where this data may be capturing the initial impairments to mitochondria that may 
subsequently lead to mitochondrial dysfunction and cell death. This thesis has uncovered several 
questions which now provide the stepping stones towards designing new experimental models to 
elucidate the in-vitro and in-vivo contribution of the tubulin VDAC model to whole muscle and 
mitochondrial bioenergetic regulation. 
8.6 Utilization of the proximity ligation assay to measure tubulin-VDAC interactions 
 
 Saetersdal and colleagues (1990) were the first to measure b-tubulin in close proximity to 
isolated cardiomyocyte mitochondria using immunogold labelling (131). Since discovering that 
tubulin may in fact bind to VDAC on the OMM, different laboratories have done extensive 
research trying to understand the purpose of this interaction, but limited work has been done to 
measure the physical interaction between tubulin and VDAC. Carre and colleagues (2002) were 
successful at using immunoprecipitation methodology to isolate VDAC and probe for both a- 
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and bII-tubulin in a variety of cancer cell culture (20). No other lab, including our own 
(unpublished previous experiments), has been able to successfully co-immuoprecipitate tubulin 
or VDAC in muscle tissues suggesting the need of an alternative protein interaction 
determination method. In 2018, Rostovtseva and colleagues were the first to publish the use of 
the proximity ligation assay to measure the interaction between bIII-tubulin-VDAC1 in human 
neuroblastoma cells. In addition, data presented in this thesis also measured a- and bII-tubulin 
interaction with VDAC2 in cardiac and skeletal muscles using the proximity ligation assay (126). 
More and more labs have been utilizing the proximity ligation assay as a tool to measure protein-
protein interactions providing support for use as an adequate tool for this type of measurement. 
The proximity ligation assay is a method similar to immunohistochemistry where the 
assay is predominately reliant on the molecular distance between the tubulin and VDAC 
antibodies. Oligonucleotide probes recognize the primary antibody, which when incubated with a 
ligase and followed by a polymerase, read and amplify a signal that can then be detected at a 
particular wavelength (Figure 8-1). The strengths of the proximity ligation assay are its ability to 
detect protein-protein interactions with a 40µm resolution, providing greater accuracy when 
compared to co-localization which only determines whether proteins are in the same relative 
area. In addition, the proximity ligation assay is relatively simple to use (once optimized), 
providing clear detection of protein interactions (82). In the current work, negative control 
experiments were used to ensure the specificity of the assay (Supplemental Figure 9-1). While 
the proximity ligation assay has proven to be a useful tool in detecting protein-protein 
interactions, it does have some limitations.  
 Optimization of the proximity ligation assay is highly dependent on the strength and 
accuracy of the primary antibody used. It is also crucial to perform sufficient washing between 
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steps as incubation of primary antibodies and oligonucleotide probes can provide a false positive 
response if the access antibodies are not properly washed away. In addition, over amplification 
with the polymerase incubation may result in a saturated signal limiting quantitative 
interpretations (82). Other methods of assessing protein–protein interactions include fluorescence 
resonance energy transfer (FRET), co-immunohistochemistry/precipitation and fluorescence 
complementation. While these methods are well established and more commonly used, they 
require the use of live cells, organelle specific fluorophores, specific equipment, and/or 
combination of fluorescent tags not compatible for tubulin or VDAC2 detection in our 
laboratory. The proximity ligation assay allowed the determination of a protein-protein 
interaction in isolated cardiomyocytes, EDL single fibers and embedded soleus muscles, without 
perturbing the intracellular environment.  
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Figure 8-1. Representative schematic of the proximity ligation assay. 
 
8.7 Limitations 
 
In chapter 6 we explored an in-vivo model, injecting paclitaxel and vinblastine into 8-
week old Wistar rats for 2 days to observe changes in tubulin-VDAC interactions and 
mitochondrial bioenergetics to then relate to muscle weakness. Adhering to the guidelines of the 
animal care facility at York University, we adapted our treatment schedule based on previous 
rodent literature where 2mg/ml/body weight was commonly used over 5-10 days (14, 55, 71). 
The initial intention for this study was to administer 2mg/ml/body weight of both paclitaxel and 
vinblastine for a duration of 5 days. Unfortunately, pilot studies revealed a severe negative 
phenotype following both paclitaxel and vinblastine injections where food consumption and 
voluntary movement significantly decreased following treatment. In addition, the rat’s fur was 
constantly raised indicating pain and discomfort with the development of brown discharge 
around the mouth and nasal area. With the advice from the animal care committee and the 
campus veterinarian, the drug dose for both paclitaxel and vinblastine was reduced to 
1mg/ml/body weight with a 2-day duration. While this was sufficient to still elicit mild 
Tubulin
VD
AC
1° antibody
1° antibody
Probes
Probes
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phenotypic change in behavior and physiological change in experiments, it is not completely in 
line with previously published rodent literature.  
Another limitation faced in chapter 6 was the inability to complete the proximity ligation 
assay in both soleus and WG muscles. With the tubulin-VDAC interaction measured in both 
tissues, a direct comparison between protein interaction and bioenergetics for both tissues could 
have been made. As mentioned in chapter 2, microtubule density and organization differ in 
oxidative and glycolytic tissues and it has not been determined whether the tubulin-VDAC 
interaction would differ between the two fiber types. Inferring from the proximity ligation assay 
data collected in chapter 4 and 6, we can assume that the a- and bII-tubulin-VDAC interaction 
would yield a similar response (increased interactions) to paclitaxel in the WG muscle as well. 
The initial intention was to utilize embedded tissue as the single fiber isolation protocol used in 
chapter 4 requires the isolation of muscles from tendon to tendon rendering the soleus and WG 
unusable for these purposes. The last limitation in this chapter was the inability to determine 
whether microtubule organization was altered in response to in-vivo paclitaxel and vinblastine 
injections. Instead, we were reliant on previous literature, observations from chapter 4, and the 
rats’ phenotypic response to injections to determine the effectiveness of our drug injections.  
In chapter 7 we aimed to determine whether the tubulin-VDAC interaction contributed to 
the mitochondrial dysfunction seen in the mouse model of Duchenne muscular dystrophy. It is 
well known that microtubule organization is severely disrupted in mdx mice as dystrophin 
directly binds microtubules anchoring them to the sarcolemma providing stability throughout the 
cell (13, 66, 111). These studies explored a-tubulin as the only marker for microtubule 
organization which may be limiting as there are various tubulin isoforms that may be altered as a 
result of a lack of dystrophin. Previous literature has identified the disruption of a-tubulin in the 
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mdx model of Duchenne muscular dystrophy and therefore was the only tubulin isoform 
explored in this thesis. Secondly, microtubule density and organization differs in glycolytic and 
oxidative tissues, posing a limitation of not measuring both tissue types in the mouse model of 
Duchenne muscular dystrophy. Although the work presented in chapter 7 did not show a change 
in tubulin-VDAC interaction when comparing the mouse model of Duchenne dystrophy to 
wildtype control, a mitochondrial bioenergetic impairment were still present. Lastly, the 
contribution of other tubulin and VDAC isoforms were not explored which may be contributing 
to the ADP-dependent mitochondrial bioenergetic impairments seen.  
8.8 Future directions 
 
 Tubulin regulation of VDAC permeability poses an exciting systematic mechanism 
whereby acute changes to the physiologic environment may cause a dynamic change in the 
tubulin-VDAC interaction to allow or inhibit the diffusion of energy through the mitochondria. 
Although a substantial amount of work has been done to understand this interaction, there is still 
much to clarify. Specifically, in cardiac and skeletal muscle, where little is known about the 
activity of microtubules and tubulin, further work should be done to explore the quantity of the 
different tubulin isoforms and isotypes. Uncovering each tubulin isoform contribution to overall 
microtubule architecture may assist in determining what roles they may play in the maintenance 
of muscle metabolism (126). This is of particular importance as previous literature revealed 
microtubule targeted compounds do not change mitochondrial membrane potential and that it is 
in fact the presence of microtubule that cause changes to mitochondrial function (74). 
In addition to isoform/and isotype exploration, microtubules are known to undergo post-
translational modifications where detyrosination has been shown to enhance the tubulin-VDAC 
interaction. Uncovering any further post-translational modifications that may occur to 
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microtubules may contribute to elucidating tubulin regulation of VDAC permeability. Similarly 
to tubulin, it is important to explore the contribution of VDAC1 and 3 to the tubulin-VDAC 
model. It may be that under certain cellular conditions, specific tubulin-VDAC interactions 
respond more than others. The complete elucidation of the potential combinations of tubulin 
isoform interactions with VDAC isoforms is required to advance the understanding of this 
interaction.  
 Chapter 6 investigated the contribution of muscle contraction following in-vivo paclitaxel 
and vinblastine injection to mitochondrial bioenergetics. Exercise is a potent stimulator of 
mitochondrial biogenesis and has been shown to improve mitochondrial and whole muscle 
function. An interesting route to further elucidate the contribution of the tubulin-VDAC 
interaction to ADP-dependent bioenergetics would be to explore the effect of an acute and 
chronic muscle contraction (endurance training) to determine whether this elicits a change in the 
tubulin-VDAC interaction. If completed in a healthy, untreated animal model, an increased or 
decreased interaction, coupled with improved muscle force, and mitochondrial bioenergetic may 
indicate that increased or decreased tubulin-VDAC interaction supports improved mitochondrial 
bioenergetics. This work would address some limitations presented in this thesis. 
 As mention above, results from chapter 6 in regard to ADP-dependent mitochondria 
bioenergetics in the presence and absence of creatine has raised many questions concerning the 
efficient and inefficient “phosphate shuttling” system. One such question is whether there is an 
electro-chemical change, in addition to a physical (tubulin-VDAC interaction) change, 
perturbing the diffusion of ADP/ATP? To address this question, similarly to chapters 4 and 5, 
PmFB incubated with mitochondrial uncouplers such as oligomycin and carbonyl cyanide-p-
trifluoromethoxphenylhydrazone (FCCP) to perturb mitochondrial membrane potential in an in-
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tact fiber (preserving microtubule architecture) prior to measurements of protein-protein 
interactions and ADP-dependent bioenergetics may reveal further insight into the tubulin-VDAC 
interaction.  
8.9 Conclusions 
 
 This thesis highlights the complexity of what was initially believed to be a simple model 
of ADP/ATP regulation through VDAC. In-vitro, the model is partially met in EDL muscles with 
increased tubulin-VDAC interactions following only paclitaxel incubations relating to impaired 
H2O2 kinetics. Alternatively, the remaining findings in cardiac, EDL and soleus muscles 
(chapters 4 - 7) do not fit the model following both paclitaxel and vinblastine incubations. 
Perhaps it is the contribution of other tubulin and VDAC isoforms in these tissues that may be 
eliciting the mitochondrial bioenergetic impairments observed. Similarly, in-vivo, the tubulin-
VDAC model did not explain the changes to mitochondrial function in the absence and presence 
of creatine but instead has now challenged the fundamental phosphate shuttling model. Future 
work should explore the effect of a higher dose and longer administration of microtubule 
targeted chemotherapies, attempting to mimic what is standard dosing in humans. Lastly, the 
disorganized microtubule architecture found in the mouse model of Duchenne muscular 
dystrophy does not contribute to an altered tubulin-VDAC interaction when compared to 
wildtype. Again, this suggests that other tubulin or VDAC isoforms should be explored. In 
addition, determining whether free or polymerized tubulin contributes to the mitochondrial 
bioenergetic impairments observed requires further exploration. Overall, this thesis has 
uncovered many potential avenues to explore to further elucidate the mechanism of tubulin 
regulation of VDAC permeability. 
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Appendix 
A1. Histology preparation – single fiber isolation  
 
Equipment  
 
• 50ml falcon tubes 
• water bath (maintained at 37°C) 
• Incubator (maintained at 37°C with 5% CO2) 
• Transfer pipettes (5) of various sizes 
• Glass transfer pipette + bulb 
• Hydrophobic pen 
• Microscope slides 
• Microscope cover slips 
 
Reagents 
 
• 0.2% collagenase 
• High glucose DMEM 
• Low glucose DMEM 
• Horse serum low glucose DMEM 
• Paraformaldehyde  
• PBS 
 
Protocol 
1. Coat 6-9 60mm dishes with horse serum and fill to approximately ½ with LG DMEM. 
a. Assign 2 dishes as “good fibers” to store viable fibers 
2. Combine 2mL of horse serum and 10mL of LG DMEM in a 50mL falcon tube to coat 
pipettes of various diameters  
a. Use transfer pipettes to create a range in mouth sizes. Prepare one glass pipette by 
using a flame to smooth sharp edges 
3.  Store in an incubator at 37°C (can make all dishes for 1 week and leave in incubator). 
a. Horse Serum can be reused for coating until finished  
4. Prepare 2 50ml tubes with 0.2% collagenase solution on day of harvest. Store in a water 
bath at 37°C until tissue is collected. 
5. Harvest muscle and directly place in warmed 0.2% collagenase and keep in a water bath 
at 37°C for approximately 90 (mouse) to 120 (rats) minutes. 
a. Periodically swirl tissues to ensure maximum diffusion 
6. Ensure all pipettes are coated with HS LG DMEM solution 
7. Following collagenase digestion, using the largest pipette transfer muscle to a warmed 
HS HG DMEM dish. 
8. Triturate the muscle until viable fibers are released 
a. Transfer viable fibers into “good fibers” dish and transfer remaining muscle to a 
new dish and continue to triturate/transfer/switch to new dish until desired amount 
of fibers are collected. 
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b. Never leave fibres at room temp for more than 10 minutes, put back in incubator 
to allow them to re-equilibrate if taking longer than 10 minutes 
9. Once viable fibers have been collected, carefully replace media with fresh PBS until the 
solution is clear. 
a. Insure the dish always has fluid in it as to not dry out fibers 
10. Fixation: fill dish with ½ 4% PFA and ½ PBS and place in fridge for 5-10 minutes for 
fixation 
11.  Transfer fixed fibers into a final dish and store at °C 
a. Fibers can be used up to 1 week 
 
 
http://www.jove.com/video/50074/isolation-culture-individual-myofibers-their-satellite-cells-
from 
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A2. Histology preparation – embedded muscle and slicing 
 
Equipment 
 
• Metal bowl 
• Styrofoam container 
• String 
• Thumb tacks 
• Weigh spatula 
• Foil or 1.5mL tube 
 
Reagents 
 
• Methybutane  
• Liquid nitrogen 
• OCT embedding compound 
 
Protocol 
 
1. Use string to secure metal bowl in suspension within Styrofoam container 
2. Cool Styrofoam container and metal bowl with lipid nitrogen 
3. Add methybutane to cooled bowl and allow to cool 
a. Listen carefully, will hear a first sizzle but wait for a second sizzle to know 
methybutane is cool enough 
4. Lightly coat the flat end of the weighing spatula with OCT compound and gently place 
tissue in desired orientation. Apply another coat of OCT compound over the muscle 
covering it completely and immediately place into liquid nitrogen cooled methybutane 
5. Let tissue freeze for approximately 30-60 seconds 
6. Remove and quickly detach from spatula and cover with labelled foil or 1.5mL tube. 
7. Store at -80°C until ready for use 
a. Best to use embedded samples within 1 year of collection. 
 
Sectioning embedded muscle protocol: 
 
1. Cool cryostat to -22°C 
2. Remove stored muscle (at -80°C) to equilibrate in cryostat for ~ 1hour 
3. Adjust blade angle to 0° and folding shield to an appropriate position to prevent the 
muscle from rolling on itself (will have to slice and adjust as you go) 
4. Once at the muscle, slide 3 transverse sections (serial if possible) at a 10µm thickness 
5. Allow slices to dry for 30min before storage (-80°C) 
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A3. Histology – Immunohistochemical staining  
 
Equipment 
 
• Microscope slides 
• Microscope coverslips 
• Hydrophobic pen 
• Light blocking container 
• Glass pipettes (flamed tipped) 
 
 
Reagents 
 
• Primary and secondary antibodies of interest 
• PBS 
• Clear nail polish 
• 0.01% (single fibers) or 0.05% (muscle sections) tritonX-100 
 
Protocol – single fibers 
 
1. Using a hydrophobic pen, outline the perimeter of the microscope slide to create a barrier 
2. Place several drops of PBS on to slide and transfer desired amount of fixed single fibers 
(approximately 8-10) 
3. Remove PBS with a 200µL pipette and add approximately 2mL of 0.01% tritonX-100 
a. Incubate for 10 min to permeabilize 
4. Wash fibers with PBS by removing and then re-adding PBS until all triton has been 
removed 
5. Incubate with primary antibody for desired length of time  
a. For proximity ligation assay (PLA), both a- and bII-tubulin primary antibodies 
were incubated for 4 hours at room temperature RT) followed by a wash as 
outlined in step 4 and incubation with VDAC2 primary antibody overnight at 4°C 
b. For PLA protocol stop here and see section A3.1 – 3.3  
6. Wash fibers as indicated in step 4 
7. Incubate with secondary antibody for 1 hour RT 
a. For fluorescent secondary’s, ensure slides with fibers are kept out of the light. 
8. Wash fibers as indicated in step 4 
9. Using a 200µL pipette, remove all liquid from microscope slide and carefully use a kim 
wipe to remove remaining access liquid.  
10. Pipette 2.5-5µL of anti-fade reagent over each fiber 
11. Gently place coverslip over fibers 
12. Secure with nail polish and let dry overnight 
13. Images should be acquired within ~2weeks of staining.  
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A3.1 Histology – Immunohistochemical staining: Proximity ligation assay: Rat single fibers 
 
Reagents 
• Proximity ligation assay kit including 
o Plus, and minus probes – matching primary antibodies 
o Antibody diluent 
o Detection reagents  
o Wash buffers A and B  
 
Equipment 
• Incubator maintained at 37°C 
 
Protocol 
1. Follow protocol “A3 – immunohistochemical staining” stopping at step 5 to prepare for 
PLA 
2. Following incubations with primary antibodies, wash fibers 3x with buffer A 
3. Incubate fibers with both plus and minus probes (1:10 dilution) diluted with antibody 
diluent (provided in kit) for 1 hour in incubator 
4. Wash fibers with 3x in buffer A 
5. Prepare ligation buffer  
a. Dilute 5x ligation buffer with ddH2O) 
b. Add ligase (1:40 dilution) *vortex buffer to ensure it is well mixed 
6. Incubate with ligation buffer for 30min in cubator 
7. Wash fibers 3x 5minutes with buffer A 
8. Prepare amplification buffer 
a. Dilute 5x amplification buffer with ddH2O 
b. Add polymerase (1:80) * vortex buffer to make sure it is well mixed 
9. Incubate fibers with amplification buffer for 1 hour and 40 min in an incubator  
a. Protect fibers from light from this point 
10. Wash fibers 2x 4minutes with Buffer B 
a. Dilute a small about of Buffer B to make 0.5% Buffer B 
11. Wash fibers with 0.5% Buffer B 1x for 5 minute 
12. Using a 200µL pipette, remove all liquid from microscope slide and carefully use a kim 
wipe to remove any remaining liquid.  
13. Pipette 2.5-5µL of anti-fade reagent over each fiber 
14. Gently place coverslip over fibers 
15. Secure with nail polish and let dry overnight 
16. Images should be acquired within ~2weeks of staining.  
 
 
A3.2 Histology – Immunohistochemical staining: Proximity ligation assay: Rat sectioned 
muscle 
 
Reagents 
• Proximity ligation assay kit including 
o Plus, and minus probes – matching primary antibodies 
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o Antibody diluent 
o Detection reagents  
o Wash buffers A and B 
• 4% Paraformaldehyde 
• hydrophobic pen 
• 0.5% triton X-100 
 
Equipment 
• Incubator maintained at 37°C 
 
Protocol 
 
1. Thaw frozen muscle sections for 15 minutes RT 
2. Outline squares with a hydrophobic pen around each or all sections 
3. Pipette 4% paraformaldehyde over each section, ensuring to cover the entire fiber and let 
fix for 1 hour RT 
4. Wash fiber 3x 5min with PBS 
5. Follow protocol “A3 – immunohistochemical staining” stopping at step 5 to prepare for 
PLA 
6. Following incubations with primary antibodies, wash fibers 3x with buffer A 
7. Incubate fibers with both plus and minus probes (1:7.5 dilution) diluted with antibody 
diluent (provided in kit) for 1 hour in incubator 
8. Wash fibers with 3x 10minutes in buffer A 
9. Prepare ligation buffer  
a. Dilute 5x ligation buffer with ddH2O) 
b. Add ligase (1:40 dilution) *vortex buffer to ensure it is well mixed 
10. Incubate with ligation buffer for 1 hour in an incubator 
11. Wash fibers 3x 10 minutes with buffer A 
12. Prepare amplification buffer 
a. Dilute 5x amplification buffer with ddH2O 
b. Add polymerase (1:80) * vortex buffer to make sure it is well mixed 
13. Incubate fibers with amplification buffer for 2 hour and 30 min in an incubator  
a. Protect fibers from light from this point 
14. Wash fibers 3x 10 minutes with Buffer B 
a. Dilute a small about of Buffer B to make 0.5% Buffer B 
15. Wash fibers with 0.5% Buffer B 3x 5 minutes 
16. Using a 200µL pipette, remove all liquid from microscope slide and carefully use a kim 
wipe to remove any remaining liquid.  
17. Pipette 2.5-5µL of anti-fade reagent over each fiber 
18. Gently place coverslip over fibers 
19. Secure with nail polish and let dry overnight 
20. Images should be acquired within ~2weeks of staining.  
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A3.3 Histology – Immunohistochemical staining: Proximity ligation assay: Mouse single 
fibers 
 
Reagents 
• Proximity ligation assay kit including 
o Plus, and minus probes – matching primary antibodies 
o Antibody diluent 
o Detection reagents  
o Wash buffers A and B 
• hydrophobic pen 
• 0.5% triton X-100 
 
Equipment 
• Incubator maintained at 37°C 
 
Protocol 
 
1. Follow protocol “A3 – immunohistochemical staining” stopping at step 5 to prepare for 
PLA 
2. Following incubations with primary antibodies, wash fibers with buffer A 
3. Incubate fibers with both plus and minus probes (1:10 dilution) diluted with antibody 
diluent (provided in kit) for 1 hour in incubator 
4. Wash fibers with in buffer A 
5. Prepare ligation buffer  
a. Dilute 5x ligation buffer with ddH2O) 
b. Add ligase (1:40 dilution) *vortex buffer to ensure it is well mixed 
6. Incubate with ligation buffer for 30 minutes in an incubator 
7. Wash fibers 3x 5 minutes with buffer A 
8. Prepare amplification buffer 
a. Dilute 5x amplification buffer with ddH2O 
b. Add polymerase (1:80) * vortex buffer to make sure it is well mixed 
9. Incubate fibers with amplification buffer for 1 hour and 40 min in an incubator  
a. Protect fibers from light from this point 
10. Wash fibers 3x 5minutes with Buffer B 
a. Dilute a small about of Buffer B to make 0.5% Buffer B 
11. Wash fibers with 0.5% Buffer B 1x 1 minute 
12. Using a 200µL pipette, remove all liquid from microscope slide and carefully use a kim 
wipe to remove any remaining liquid.  
13. Pipette 2.5-5µL of anti-fade reagent over each fiber 
14. Gently place coverslip over fibers 
15. Secure with nail polish and let dry overnight 
16. Images should be acquired within ~2weeks of staining.  
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A4. Permeabilized muscle fiber bundle (PmFB) preparation 
 
Equipment 
 
• Ice blocks 
• Dissecting microscope 
• Anti-magnetic fine tipped forceps (1 large, 1 small) 
• 18mm cell culture dish 
• 1.5ml tubes  
• gel loading tips 
 
Reagents 
 
• Biops buffer 
• MIR05 buffer 
• saponin 
 
Protocol 
1. Prepare a Styrofoam container with ice and 5ml tubes filled with biops buffer (see section 
for preparation instructions) 
2. Prepare 40µg/ml saponin dissolved in biops (saponin tubes) 
a. Dilute 7µL of 10mg/mL saponin into 1.5mL of biops 
3. Prepare equal amounts of 1.5mL tubes 1) with 40µg/mL saponin + biops and 2) MIR05 
buffer (see section for preparation instructions) (wash tubes) 
4. Harvest tissue and immediately submerge into ice cold biops buffer  
5. Decant tissue with biops into a 18mm dish and place on an ice block under a dissecting 
microscope 
6. Cut all connective tissues and remove blood and fat  
7. Gently begin separating fibers ~1-3mg wet weight fiber bundles  
8. Place muscle bundles into saponin tubes and rock at 4°C for 30 minutes 
9. Transfer permeabilized muscle fiber bundles (PmFB) to wash tubes and rock at 4°C for 
15 minutes 
10. PmFB are ready for bioenergetic assays 
a. See appendix for respiration experimental protocols (A4.1) and buffer preparation 
(A4.2-A4.3) 
b. See appendix for H2O2 emission experimental protocols (A4.4) and buffer 
preparation (A4.5 – 4.8) 
c. See appendix for calcium retention capacity experimental protocols (A4.7) and 
buffer preparation (A4.8) 
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A4.1 Sample respiration protocol 
  
Sample respiration protocol 
Substrate Event Code STOCK Titration 
Volume (µl) 
Final 
Concentration in 
chamber 
Miro5 
BLEB 
Lights out  
Fibre 
 
5uM BLEB 
F10 
Fibre 
20mM Cr 
10mM 
 
 
1uL 
 
 
5uM 
 
Stop stir bar, turn on lights and verify fibre is in chamber/not stuck on side wall 
Hit F10 (Lights out) 
100% O2 O  Injection 325-350 µM 
Pyruvate 
Malate 
P 
M 
2M 
1M 
5 
4 
5 mM 
2 mM 
ADP 25 µM D 5 mM 10 25 µM D 
ADP 50 µM D 5 mM 10 50 µM D 
ADP 100 µM D 50 mM 2 100 µM D 
ADP 250 µM D 50 mM 6 250 µM D 
ADP 500 µM D 50 mM 10 500 µM D 
ADP 5 mM D 500 mM 18 5 mM D 
Cytochrome c 
oxidase Cyt C 4mM  5 10uM 
Glutamate GLU 2M 5 5mM 
Succinate Succ 2M 20 20mM 
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A4.2 Biops Buffer 
 
Chemical Stock Solution Molecular Weight Final 
Concentration 
Addition to 2 
Litre final volume 
CaK2EGTA* 100mM  2.77mM 55.4mL 
K2EGTA* 100mM  7.23mM 144.6mL 
Na2ATP  555.1 5.77mM 6.28g 
MgCl2 • 6H2O  203.3 6.56mM 2.67g 
Taurine  125.1 20mM 5.02g 
Na2Phosphocreatine  327.14 15mM 9.81g 
Imidazole  68.1 20mM 2.72g 
Dithiothreitol 
(DTT) 
 154.2 0.5mM 0.154g 
MES Hydrate  195.2 50mM 19.52g 
* prepare stock solutions (see instructions below) 
 
CaK2EGTA: Dissolve 2.002g CaCO3 in 100mM hot (80°C) solution of EGTA (7.608g of EGTA 
in 200mL ddH2O). Add 2.3g of KOH and adjust pH to 7.0 using KOH. Freeze unused portions 
 
K2EGTA: dissolve 7.608g EGTA and 2.3g KOH into 200mL ddH2O. Adjust pH to 7.0 using 
KOH. Freeze unused portions 
 
Protocol 
1. Add approximately 1500mL of ddH2O to 2000mL beaker 
2. While constantly stirring add stock solutions of CaK2EGTA and K2EGTA 
3. Weigh and add all powder chemicals 
4. Adjust pH to 7.1 using KOH pellets 
5. Using graduated cylinder, bring total volume to 2000mL 
6. Filter and then aliquot into 50mL falcon tubes 
a. Leave some room at the top of the tube to allow for expansion when buffer is 
freezing 
7. Freeze falcon tubes 
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A4.3 MiRO Buffer 
 
Chemical Stock Solution Molecular Weight Final 
Concentration 
Addition to 2 
Litre final volume 
EGTA  380.4 0.5mM 0.38g 
MgCl2 • 6H2O  203.3 3mM 1.22g 
K-Lactobionate* 0.5M 358.3 free acid 60mM 240mL 
Taurine  125.1 20mM 5.02g 
KH2PO4  136.1 10mM 2.72g 
HEPES  238.3 20mM 9.54g 
Sucrose  342.3 110mM 75.3g 
BSA  154.2 1g/L 2g 
* prepare stock solution (see instructions below) 
 
K-Lactobionate: Dissolve 71.6g lactobionic acid in 300mL ddH2O, adjust pH to 7.0, adjust final 
volume to 400mL with ddH2O 
 
Protocol 
1. Add approximately 1500mL of ddH2O to 2000mL beaker 
2. While constantly stirring add stock solution of K-Lactobionate 
3. Weigh and add all powder chemicals 
4. Adjust pH to 7.1 using KOH pellets 
5. Using graduated cylinder, bring total volume to 2000mL 
6. Filter and then aliquot into 50mL falcon tubes 
a. Leave some room at the top of the tube to allow for expansion when buffer is 
freezing 
7. Freeze falcon tubes 
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A4.4 Sample H2O2 protocol  
 
 
 
 
  
Treatment in 
Saponin 
Solution  
In Cuvette Prior 
to Experiment 
Volume to Add Substrate added to 
induce H2O2 
Volume to 
add 
NONE Amplex Red 
  
0.2U/mL HRP 
1mL 
 
2uL of 10U/ml 
10mM Succinate 5µL of 2M  
Mouse: 35µM 
CDNB 
 
Rat: 100µM 
CDNB 
Amplex Red 
  
0.2U/mL HRP  
 
 
 
0.5uM Rotenone 
1mL 
 
2uL of 10U/ml 
 
 
 
2uL of 250uM 
10mM Pyruvate 
 
5µL of 2M 
Mouse: 35µM 
CDNB 
 
Rat: 100µM 
CDNB 
Amplex Red 
  
0.2U/mL HRP  
1mL 
 
2uL of 10U/ml 
10mM Pyruvate 
 
2mM Malate 
5µL of 2M 
 
2µL of 1M 
ADP titration 
Final concentration Amount to add ADP stock 
15uM 3ul 5uM ADP 
50uM 7uL 5uM ADP 
100uM 1uL 50uM ADP 
250uM 3uL 50uM ADP 
500uM 5uL 50uM ADP 
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A4.5 Buffer Z 
 
Chemical Molecular weight Final concentration (mM) Addition to 500mL final 
volume (g) 
K-MES 233.33 105 12.26 
KCL 74.55 30 1.12 
KH2PO4 136.08 10 0.7 
MgCL2 6H2O 203.3 5 0.51 
EGTA 380.35 1 0.19 
BSA  5mg/mL 2.5 
 
Protocol 
1. Add ` 400mL of ddH2O to 1000mL beaker 
2. Weigh and add powder chemicals 
3. Adjust pH to 7.4 using KOH pellets 
4. Using graduated cylinder, bring total volume to 500mL 
5. Filter and then aliquot into 50mL falcon tubes 
a. Leave some room at the top of the tube to allow for expansion when buffer is 
freezing 
6. Freeze falcon tubes 
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A4.6 Amplex ultra Red buffer preparation 
 
Stock A = Amplex ultra red without creatine  Stock B = Amplex ultra red + 20mM 
creatine 
 
Stock A and B ingredients required:   
  Amplex Ultra-Red (Invitrogen A36006) 
  5000 IU/ml Cu/Zn Superoxide dismutase (SOD1; Sigma S9697) 
  10mM Blebbistatin (BLEB; Cayman) 
  DMSO 
  Buffer Z (0.5mg/ml BSA) 
  0.5M EGTA (aliquots in freezer) 
 
Stock B additional ingredients: 
  20mM Creatine hydrate 
 
Final concentrations for both AUR Stock A and AUR Stock B: 
  10µM AUR 
  1µM BLEB 
  25U/ml Cu/Zn SOD1 
  1mM EGTA 
 
 
Work fairly quickly given AUR and BLEB should not be stored on ice.  Best to prepare with 
lights out in lab as AUR and BLEB are light sensitive. 
 
Preparation of AUR Stock A (No Creatine): 
 
Step 1: Prepare 5mM AUR.  Add 666.6ul of DMSO to 1mg AUR.  Vortex gently.  Prepare in 
black tube but do not place on ice (DMSO will freeze). 
 
Step 2:  Prepare 10mM BLEB.  Add 1.71 mL DMSO to 5mg bottle of BLEB.  Prepare in black 
tube but do not place on ice. 
 
Step 3:  Prepare 10uM AUR stock.  Mix the following: 
- 160.6 ml of Buffer Z (0.5mg/ml BSA).  Note:  sucrose buffers lower oxidant emission. 
- 325µL of 5mM AUR 
- 812.5µL of 5000 IU/ml SOD1 
- 16.24µL of 10mM BLEB 
- 325µL of 0.5M EGTA 
 
Aliquot 1.050 µL in black tubes.  Store at -80◦C. 
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Preparation of AUR Stock B (20mM Creatine): 
 
Prepare 10µM AUR stock as in Stock A but with 20mM creatine monohydrate.  Mix the 
following: 
 
- 160.6 ml of Buffer Z (0.5mg/ml BSA) 
- 484.74 mg creatine monohydrate 
- 325µL of 5mM AUR 
- 812.5µL of 5000 IU/ml SOD1 
- 16.24µL of 10mM BLEB 
- 325µL of 0.5M EGTA 
 
Aliquot 1.050 µL in black tubes.  Store at -80◦C. 
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A4.7 Calcium retention capacity – sample protocol 
 
Substrate Stock 
Concentration 
Addition to cuvette Final Concentration in 
Cuvette 
CRC Assay Buffer  300µL  
Glutamate 2M 1.5µL 10mM 
Malate 1M 1.5µL 5mM 
      ** make sure fibre is at the bottom of cuvette attached to stir bar** 
Collect 400 second background to establish “F-Min” 
CaCl2 5mM 2.5µL 8nmol 
Wait 5 minutes or until steady state 
CaCl2 5mM 1.25µL 12nmol (4nmol pulse) 
Wait 5 minutes in between pulses and continue pulsing until pore opens 
CaCl2 50mM 3µL 0.5mM Pulse (F-Max) 
Wait 3 minutes before final addition, this should establish F-Max but last addition is to make sure 
CaCl2 50mM 3µL 0.5mM Pulse (F-Max) 
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A4.8 Buffer Y 
 
Chemical Final 
Concentration 
Addition to 500mL final 
volume 
Sucrose 250mM 42.78g 
Tris-HCl 10mM 0.788g 
Tris Base 20mM 1.21g 
KH2PO4 10mM 0.68g 
BSA 0.5mg/mL 0.25g 
**Due to high sugar content buffer may being to precipitate within 3-4 weeks, even when stored 
at 4°C. Be sure to check buffer periodically to insure clarity 
 
Protocol 
1. Add 300mL of ddH2O to 1000mL beaker 
2. Weigh and add powder chemicals 
3. Using graduated cylinder, bring total volume to 500mL 
4. Filter and store at 4°C 
 
Calcium retention capacity assay buffer 
 
Chemical Final 
Concentration 
Addition to 120mL final 
volume 
Buffer Y (freshly made)  120mL 
Creatine 20mM 0.358g 
EGTA 40uM 9.6µL of 0.5M 
2-Deoxyglucose 5mM 0.0984g 
Hexokinase 2U/mL 160µL of 1500U/mL 
BLEB 5µM 60µL of 10mM 
Calcium Green* 1µM 400µL of 0.3mM 
Tharpsigargin** 2µM 160µL of 1.5mM 
 
Protocol 
1. Dissolve 0.5mg calcium green-5N in 1.398mL water 
2. Add 100mL of ddH2O to 200mL beaker 
3. Weigh and add powder and liquid chemicals 
4. Bring to volume with ddH2O 
5. aliquot into 165µL stocks and freeze 
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A5 Western blotting – Tissue homogenization  
 
Equipment 
• 1.5mL tubes 
• motor and pestle  
• centrifuge 
 
Reagents 
• CHAPS buffer (see A8.3 for buffer ingredients) 
• Phosphatase inhibitor cocktail 2 and 3 
• Protease inhibitor cocktail 
 
Protocol 
1. Chip ~15-20mg of frozen muscle tissue (on liquid nitrogen) and weigh 
2. Prepare a 1.5mL tube with 200µL of Chaps buffer with: 
a. Phosphatase inhibitor 2 (1:100) 
b. Phosphatase inhibitor 3 (1:100) 
c. Protease inhibitor (1:200) 
3. Add weighed muscle to tube and correct volume to match (20mg of tissue:400µL buffer) 
dilution 
4. Homogenize with a motorized Teflon pestle 3x 10 seconds with 10 second rests 
a. **always maintain on ice during homogenization 
5. Centrifuge samples at 1500g for 10 minutes at 4°C 
6. Collect supernatant and store samples at -80°C 
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A5.1 Western blotting 
 
Equipment 
• Thick and thin glass plates 
• Green stands 
• Gel holder cassetts + foam 
 
Reagents 
• See appendix (A8.1) for buffer recipes  
 
Protocol 
1. Place clean plates washed in methanol in green stands on foam and make sure there is a 
tight seal 
2. Prepare running gel (1 column makes 2 gels) *DO NOT ADD TEMED UNTIL READY 
TO LOAD 
3. Using transfer pipette transfer running gel (with TEMED) until top of green door 
4. Using new transfer pipette on opposite end of plate add water to top of plate removing 
any bubbles 
5. Let set until left over running gel is hard 
6. Make Stacking Gel *DO NOT ADD TEMED UNTIL READY TO LOAD 
7. Make 1X RUNNING BUFFER (990mL dH20, 110mL 10X Running Buffer) in graduated 
cylinder 
8. Go get samples in liquid nitrogen and thaw on ice 
9. Turn on heat block to 95°C 
10. After 30 minutes, turn over gel holder to remove excess water, using square paper towel 
remove water from corner of gel and wipe plate clean 
11. Using Transfer pipette add stacking gel (with TEMED) to top of plate 
12. Insert comb starting from one end on angle, careful of splash 
13. Let set until left over stacking gel is hard  
14. Put standard on bench 
15. Vortex thawed samples 
16. In fumehood mix Laemmeli’s buffer and 2-mercaptoehtanol (100ul 2-mer: 900uL Lam) 
17. In new labeled tubes mix given quantites of water, Lam buffer mix and protein (see excel 
sheet) 
18. Boil for 5 minutes in heat block 
19. Remove combs from gels and transfer to tank 
20. Fill holders with 1X Running Buffer and then tank 
21. Load wells with given volume based on excel sheet with standard in first well always 
22. Put lid on at set volts to 160 and time to 40 min, press run 
23. Transfer Gels following steps 
24. Block for 1 hour at room temp in 15ml Odyssey Blocking Buffer (50% BB,50%TBS) 
25. Pour out blocking buffer into falcon tube and keep in fridge 
26. Cover membrane in Primary in fridge overnight 
27. Do 4x5min washes in TBST 
28. Cover membrane box in foil and wash in secondary at room temp for 1 hour 
29. 4x5min washes in TBST 
  208	
30. Rinse in TBS then pour out and put fresh TBS to detect 
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A5.2 Western blotting: Buffer preparation 
 
10 X Running Buffer: 
 
 500 ml 1 L 2 L 
Tris 15 g 30 g 60 g 
Glycine 72 g 144 g 288 g 
SDS 5 g 10 g 20 g 
 
1 X Running Buffer:  10 X Running buffer 100 ml 
    dH2O   900 ml 
 
 
10 X Western Transfer Buffer: 
 
 500 ml 1 L 
Glycine 52.5 g 105 g 
Tris Base 22.5 g 45 g 
 
1 X Western Transfer Buffer:  10 X Tranfer buffer 80 ml 
     Methanol  160 ml 
     dH2O   560 ml 
 
 
10 X TBS (Tris Buffered Saline): 
 
 500 ml 1 L 
Tris 12.1 g 24.2 g 
NaCl 40 g 80 g 
Adjust to pH 7.6 with HCl 
 
1 X TBST: 
 1 L 2 L 
10 X TBS 100 ml 200 ml 
dH2O 900 ml 1800 ml 
Tween 20 1ml 2 ml 
Note: Ensure solution is stirring when adding Tween 
 
Primary antibody preparation - Blocking Buffer - .1% Tween - .01% SDS 
 
Secondary antibody preparation - Blocking Buffer - .1% Tween 
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- .01% SDS 
 
Running and stacking gel preparation 
  
 Stacking Running 
5% 6% 8% 10% 12% 
dH2O 6.8 ml 11.4 10.6 ml 9.4 ml 8 ml 6.7 ml 
1.5M Tris-Base, pH 8.8 *** 5 ml 5 ml 5 ml 5 ml 5 ml 
1M Tris-HCl, pH 6.8 1.25 ml *** *** *** *** *** 
30 % Acrylamide 1.70 ml 3.4 ml 4 ml 5.3 ml 6.7 ml 8 ml 
10 % SDS 100 µl 200 µl 200 µl 200 µl 200 µl 200 µl 
       
10 % APS 100 µl 200 µl 200 µl 200 µl 200 µl 200 µl 
Temed 20 µl 20 µl 20 µl 20 µl 20 µl 20 µl 
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A6. Caspase activity assay 
 
Equipment 
• 1.5mL tubes 
• Motorized Teflon pestle 
• Centrifuge 
 
Reagents 
• Caspase 3: AC-DEVD-AMC (Enzo - ALX-260-031-M001) 
o 1mg into 1.48 mL DMSO for 1mM Stock 
• Caspase 3 Inhibitor: AC-DEVD-CHO (Enzo - ALX-260-030-M001) 
o 1mg into 2mL DMSO for 1mM Stock 
• Caspase 8: AC-IETD-AMC (Enzo - ALX-260-042-M001) 
o 1mg into 1.48 mL DMSO for 1mM Stock 
• Caspase 8 Inhibitor: AC-IETD-CHO (Enzo - ALX-260-043-M001) 
o 1mg into 2mL DMSO for 1mM Stock 
• Caspase 9: AC-LEHD-AMC (Enzo - ALX-260-080-M001) 
o 1mg into 1.45 mL DMSO for 1mM Stock **different MW from 3 and 8 
• Caspase 9 Inhibitor: AC-LEHD-CHO (Enzo - ALX-260-079-M001) 
o 1mg into 1.86mL DMSO for 1mM Stock 
• Caspase homogenization buffer (see A9.2 for buffer ingredients) 
• Caspase incubation buffer (see A9.2 for buffer ingredients) 
 
Protocol 
1. Homogenize ~15-20mg of frozen tissue with motorized Teflon pestil for 3x 10 seconds 
with 10 seconds rests inbetween 
a. Prepare 1.5mL tube with ~75µL of caspase homogenization buffer and then add 
weighed tissue 
b. Bring to final volume based on tissue weight (10:100) 
2. Centrifuge samples at 4°C 
a. Spin at 700x g for 10 minutes and retain supernatant  
b. Spin at 16300x g for 20 minutes and retain supernatant (**this fraction contains 
proteasomes) 
3. Aliquot samples and store at -80°C 
a. Thaw each sample only once 
4. Determine protein concentration with the reducing agent compatible kit 
5. Dilute 1mM stock of each substrate into 100µM using incubation buffer – make up total 
volume needed for all samples plus 20µL extra (see loading table in excel) 
6.  Add 30ug of protein from frozen and spun homogenate into the wells (total of 6 wells for 
each sample) 
7.  Add x µl of diluted substrate (110- amount added for 30ug protein) for Caspase 3 to 2 
wells 
8. Repeat step 3 using Caspase 8 and Caspase 9 substrate 
9. Add 3uL of Caspase 3 inhibitor to 1 of 6 wells 
10. Repeat step 5 for Caspase 8 and 9 inhibitor 
11. Read every 2 minutes for 1 hour  
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a. Excitation = 360nm, emission = 460nm at 37°C 
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A6.1 Caspase homogenization buffer 
 
Chemical Molecular Weight Concentration Amount added 
Sucrose 342.3 250 mM 42.8g 
Tris 121.14 50 mM 3.03g 
DTT 154.25 1 mM 0.077g 
EDTA 372.24 1 mM 0.186g 
MgCl2  203.3 5 mM 0.51g 
Glycerol  10% 50mL 
**total volume = 100mL 
 
 
A6.2 Caspase incubation buffer 
 
Chemical Molecular Weight Concentration Amount added 
HEPES 283.3 100 mM 2.38g 
Sucrose 342.3 10% 10g 
DTT 154.25 1 mM 0.015g 
**total volume = 100mL 
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A7. Rat In-vivo muscle function system – Plantar flexion hind-limb force production 
 
Equipment 
• Aurora scientific 1305A: 3-in-1 whole animal system – Rat  
o 305C-FP: Dual-mode footplate  
o 605A: Dynamic muscle data acquisition and analysis system 
o 608C: LCD monitor 
o 701C: Electrical stimulator and micro-electrodes 
o 806D: In-situ rat apparatus 
• Clippers 
• Medical gauze 
 
Reagents 
• Iodine solution (Providone-iodine) 
• Saline 
• Isoflurane  
 
Protocol 
1. Anaesthetize rat with 5% isoflurane and maintain at 3% 
a. Throughout entire procedure ensure body temperature is maintained at 37° 
2. Shave entire hind-limb with clippers and sterilize with iodine solution (3x washes with 
saline) 
3. Secure foot to footplate with tape, adjust and secure knee at 90°  
a. Ensure heel is flush to the bottom of the footplate and the foot is extremely 
secured. Monitor foot/heel and knee placement during protocol. 
4. Place electrodes as shown in image below 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
** electrode placement requires optimization to ensure user consistency. Recommend 
practicing entire protocol for minimum 1 week to determine whether consistent results 
are obtained.  
5. Determine twitch and length 
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a. Run twitch stimulation and adjust amperage and length to ensure all muscle fibers 
are recruited  
b. Should obtain 3 consecutive maximal twitches  
6. Run Torque frequency protocol 
a. 25, 50, 75, 100, 125, 150, 175, 200, 225, and 250 Hz 
b. Rest for 10 minutes 
7. Determine maximum torque 
8. Run fatigue protocol 
a. Rest for 15 minutes total: measure max torque at 5, 10 and 15 minutes 
 
**Torque protocol 
• Pulse width: 0.2ms, train duration: 300ms, delay: 200ms 
**Fatigue protocol 
• Frequency: 60Hz/second for 120 seconds, stimulation: 300ms with 700ms rest at 119 
repeats 
 
 
